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PREFACE
The National Agricultural Biotechnology Council (NABC) was founded in
1988 to provide an open forum to consider timely issues of agricultural
biotechnology. The ultimate objective was the safe and efficacious development
of products and processes based on agricultural biotechnology; to the original
objective one might add equitable. Since its inception, the NABC has provided
a unique, necessary and educational opportunity to discuss emerging issues of
agricultural biotechnology worldwide since agricultural biotechnology, even
more so than other technology, is global.
The NABC has a record of early identification and broad consideration of the
major issues: sustainable agriculture in 1989; food safety and nutritional quality
in 1990; social issues in 1991; animal biotechnology in 1992; risk in 1993;
public good in 1994; and discovery, access, and ownership of genes in 1995.
The issue of access and ownership of genes is of growing concern to not-for-
profit research institutions, and NABC Report 7 has served as a primary source
of useful background, issue identification, and recommendations.
The NABC 8th annual meeting—Novel Products and New Partnerships—was
hosted June 5–7, 1996 by NABC member institution Rutgers, the State
University of New Jersey. This report summarizes the presentations and
workshop dialog at the meeting. Novel products of agricultural biotechnology
represent a tremendous opportunity for agriculture, and discussion and
identification of emerging issues were initiated in an open forum with broad
representation. Agriculture could play a major role in substantially replacing
fossil-based materials, such as energy and chemicals. NABC8 initiated
discussion on these novel products and the attendant novel partnerships, as
well as continuing the dialogue on novel foods.
The NABC Council is composed of senior management of most of the major
not-for-profit agricultural biotechnology research and/or teaching institutions
in Canada and the United States. In 1996, the NABC membership grew to
25 with the addition of the University of Illinois at Urbana-Champaign. Future
plans include additional members from academic and private not-for-profit
research institutions, and governmental research agencies without regulatory
responsibilities from the United States and Canada, Mexico, and Central
America. Initial financial support for NABC was provided by the Joyce
Foundation and the U.S. Department of Agriculture. Today, member institutions
provide support.
The annual meeting is the major NABC activity. The NABC member institutions
propose meeting topics to the Council, which then selects the subject and pro-
vides guidance to assure that speakers and workshop co-chairs represent the
full spectrum of viewpoints. Host institutions make special efforts to have broad
representation at the meeting, including those from academia, government,
industry, the public, farming, and others. There is not only an opportunity, but
an expectation, that each attendee will speak, listen, and learn through
participation at plenary sessions, in the workshops, and in the workshop
summary presentations.
The workshop reports are the most important outcome of a NABC meeting,
and are placed at the beginning of the report, followed by the presentations of
plenary and other speakers. Each year, 7,000 NABC Reports are printed and
distributed worldwide to individuals working in industry, government,
academia, public interest groups, and other fields.
In addition to the NABC Reports, the NABC produces a newsletter, NABCnews.
In 1996, the NABC initiated Agricultural Biotechnology in the News, a timely
two-page summary of significant reports related to agricultural biotechnology.
Biotechnology, and especially agricultural biotechnology, had its most dynamic
year ever in 1996: transgenic crops entered the marketplace; genome mapping
and sequencing expanded the database so that a biological equivalent to the
chemical periodic table is being suggested; and multinational chemical and
pharmaceutical companies have acquired or purchased substantial equity in
almost all of the "established" agricultural biotechnology companies.
Although some still believe that human safety and environmental risk is a
continuing issue in agricultural biotechnology, others see equitableness,
including access, as a significant emerging concern. Candid forums such as
NABC8 help promote understanding of the multitude of diverse viewpoints,
and provide an opportunity for addressing concerns about agricultural
biotechnology.
Ralph W.F. Hardy Jane Baker Segelken
NABC President NABC Executive Coordinator
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A major attraction of biotechnology for investors has been the allure of new
market opportunities and the prospect of revolutionary medical, food, and
other products that will change our lives. However, biotechnology’s critics have
long expressed concern that the unpredictability of the effects of such changes
are reasons for prudence and caution. In spite of some false starts, unrealistic
expectations, and unfulfilled promises, recombinant DNA biotechnology is now
maturing as an important discipline that will underpin much of our biological
research and development during the next century. Surprising to some is the
important role of agricultural biotechnology to not only the food and feed
industry, but also to the chemical, pharmaceutical, environmental, and energy
industries, as new products are emerging in these marketplaces.
Agricultural biotechnology is beginning to act as a matchmaker for some
unexpected marriages between sectors. The National Agricultural Biotech-
nology Council’s (NABC) eighth annual meeting — Agricultural Biotechnology:
Novel Products and New Partnerships — held at Rutgers, The State University
of New Jersey, New Brunswick, New Jersey on June 4–7, 1996, debated the
social, ethical, economic, research, development, and commercialization issues
and opportunities that the new products of biotechnology pose for consumers,
farmers, industry, public interest groups, government, and universities. Asked
to be provocative and to speculate, 14 plenary speakers from the public and the
food, pharmaceutical, and environmental and energy sectors set the stage for
intensive workshop discussions of the social and ethical issues raised by new
products and the opportunities for structural and economic changes.
Following the plenary sessions, participants in three workshops tackled a set
of tough questions from the viewpoints of the food industry, the pharmaceutical
industry, and the environmental and energy sector.
NABC 8: An Overview
PETER R. DAY AND LAURA MEAGHER
Co-Chairs, NABC 8 Planning Committee
Rutgers, The State University of New Jersey
New Brunswick, N.J.
PLENARY SESSION HIGHLIGHTS
PLENARY SESSION I: NOVEL PRODUCTS AND NEW PARTNERSHIPS
Kenneth Barton, Vice President for Research, Agracetus, was one of the two
keynote speakers. His talk, “Biotechnology: Catalyst for Change in Agricul-
ture,” set the stage by pointing out how the application of biotechnology will
help to sustain population growth and food production on the earth’s finite area
of cultivable land. The increased speed and great breadth of current change,
along with the relevance of biotechnology to industries other than agriculture,
will significantly impact progress in this field. He pointed to the current ac-
celeration of the transition from biotechnology development to product and
market development and the unprecedented scope of recent introductions to
the marketplace. Barton went on to review the important role that intellectual
property protection will continue to have in shaping the biotechnology industry
in years to come. The speed of developments in biotechnology was illustrated
by the progress made in improving the strength of cotton fibers, with a single
genetic engineering step responsible for a strength increase equivalent to that
achieved in 30 years of classical plant breeding.
As a counterpoint to the brave new world of biotechnology, the other key-
note speaker, Rebecca Goldburg, Senior Scientist, Environmental Defense Fund,
spoke of the unknown environmental impacts of biotechnology. She explained
the skepticism of the environmental community over promises that fertilizers
and pesticides would be replaced by crops that fix their own nitrogen and
protect themselves from pests and diseases and benefit the environment. The
first have not materialized and engineered resistance has yet to have a signifi-
cant effect in reducing pesticide applications. She described those claims as
greenwashing. In her view, bioremediation has been oversold and pollution
prevention will be far more effective in dealing with the problems caused by
chemical wastes. Goldburg also expressed continuing concern over the hazards
that might result from gene transfer between the growing range of engineered
plants and animals and their wild and cultivated relatives. She cited the many
examples of escapes from aquaculture facilities, pointing to added risk of trans-
genic fish to wild populations. And she stressed the importance of conditions
attached to recent permits issued by the EPA that can lead to the cancellation
of permits. Those conditional registrations represent a step toward the kind of
innovative regulations the environmental community seeks to have in place.
Together, the keynote speakers demonstrated the open sharing of diverse
views that has become the hallmark of the NABC conferences.
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PLENARY SESSION II: CREATING NEW MARKET OPPORTUNITIES FOR
AGRICULTURAL BIOTECHNOLOGY
David Evans, Executive Vice-President, DNA Plant Technology Corporation,
described the commercial opportunities for tomatoes that stay firm and fresh
longer (ethylene-regulated tomatoes, for example, now have a shelf-life of
somewhere between 40 and 90 days.) He reviewed the seven different tech-
nologies that must be used to achieve this result, noting that all of them are
governed by various intellectual property claims that limit a company’s ability
to commercialize new developments. He underscored the potential impact upon
the industry of this increasingly complex and interwoven state of intellectual
property rights, citing the challenge of balancing possible obstacles to inno-
vation with companies’ need to exert control over intellectual property.
From the pharmaceutical industry, Dianne Defuria, Director of Commercial
Development, Bristol Myers-Squibb, discussed the role of industrial-scale plant
cell culture technology in relieving her company of its dependence on extract-
ing the anti-cancer drug paclitaxel from the bark of Pacific Yew, which at first
was peeled by hand from the trunk and major limbs in natural stands. Interest-
ing issues of high technology facilitating conservation of trees arise from this
sort of situation.
Jeff Gain, Chair of the Board of the Alternative Agricultural Research and
Commercialization (AARC) Corporation of the USDA, represented the Environ-
mental and Energy sector and discussed industrial uses of agricultural products.
He stressed the difficulties in growing industrial hemp without cyclone fences,
guard towers, and search lights!
Caron Chess, Director of the Center for Environmental Communications,
Rutgers University, discussed the public’s interest in agricultural biotechnology
and their perceptions of risk. She reviewed the importance of how information
is supplied, pointing to the fallacy of the overly simplistic idea that if you give
people information it will change their attitude and, in turn, their behavior.
Information does not make people agree with what scientific experts might call
“rational.” An array of additional factors enter into their formation of opinions.
PLENARY SESSION III: SOCIAL ISSUES, REGULATIONS, AND ETHICS
The first speaker, Sister Miriam MacGillis, Director of Genesis Farm, presented
a point of view completely opposed to biotechnology as well as other inter-
ventions by humans in natural processes. She voiced her concern about world
hunger, presenting a view that the lawlessness of the global market system is
responsible for the crises of modern society. Her thesis is that an obsession with
genetic engineering may bring about a total undermining of the life that bio-
technology is committed to redesigning.
In a provocative juxtaposition of presentations, Charles Arntzen, President/
CEO, Boyce Thompson Institute, devoted his presentation to the utilization
of biotechnology for fighting disease among children in lesser developed
countries. He gave an account of some successful research on the expression
of antigenic proteins in transgenic plants that may make it possible to raise
vaccines in plants against hepatitis B, bacterial and viral diarrheal disease, and
other infections. The objective of this work is to create an oral vaccine that is
delivered when the transgenic food plant that expresses it is consumed. The
plant of choice is the banana because its fruit is eaten raw and it is a widely
accessible and acceptable food in many lesser developed countries.
Ken Evans, President of the Arizona Farm Bureau, described the application
of other modern technologies and spoke of his own use of a 300 horsepower
sludge injection tractor remotely controlled by a portable computer. Using
sensitive biotechnology-based tests to detect and reject loads contaminated
with toxic materials and disease organisms, he has applied over three million
metric tons of uncontaminated municipal biosolids during the last 18 years,
raising the elevation of his 22 square-mile ranch by over three inches! Clearly
a believer in the proactive adoption of suitable technologies, Evans predicted
that industrial and chemical feedstock production will be a major source of
revenue for future farmers, who will be as comfortable on the Internet as
yesterday’s farmers were using a shovel. He stressed, however, that innovative
farming must be done with provision for recreational land use and improved
environmental management.
Martine Kraus of the Center for the Study of Law and Society, University
of California, Berkeley, described the importance of regulation that assists
the development of the biotechnology industry without stifling innovation.
A comparison of the experience of United States and German biotechnology
companies was revealing as shown by Germany’s 20-fold higher regulatory
costs. Whereas regulation creates a known climate for companies and assures
consumer confidence, it was reassuring to note her conclusion that innovation
thrives independent of the regulatory framework.
PLENARY SESSION IV: ECONOMIC AND STRUCTURAL ISSUES
The session began with a talk by Brewster Kneen, an agricultural journalist
from British Columbia, who discussed the biases and assumptions implied
in the expression “food industry.” Stripped of its hyperbole, Kneen reduced
biotechnology to a monoculture modeled on the production line. Drawing an
analogy between the safety of automobiles and of biotechnology, he highlighted
our ability to ignore or eliminate what doesn’t fit or what is unknown, and our
preoccupation with speed and precision.
Julian Cooper, of PPL Therapeutics, spoke of the value to the pharmaceutical
industry of proteins produced in transgenic animals. He used as an example the
attachment of a milk gene promoter to a gene encoding a therapeutic protein.
The latter is expressed in the mammary gland of the animal so that the trans-
genic protein can be harvested and purified from its milk with no adverse
effects on the animal. Many therapeutic proteins are modified after translation
from DNA in order to be therapeutically active in ways that bacterial expression
systems, for example, cannot handle. A case in point is the inability of bacterial
systems to add sugar residues to proteins (glycosylation). The yields of trans-
genic proteins from mammalian tissue culture systems are low, and the costs
of establishing them are high, making production by farm animals an attractive
mechanism for providing some important pharmaceuticals.
In his talk about the use of plants to remove heavy metals from contaminated
soil, Burt Ensley, CEO of Phtyotech Inc., spoke about the novel blending of
agriculture with the environmental industry. The best results have been ob-
tained with selected forms of an agronomic crop, Indian Mustard, that take up
and concentrate toxic metals from contaminated soils. When the plants with
high concentrations of metal are harvested, the biomass of plant debris from
a contaminated site is only about two percent of the original mass of contami-
nated soil, decreasing disposal costs while leaving cleaned topsoil in place. The
harvested plants can be composted or incinerated to further concentrate the
toxic metals. He showed experiments in progress on lead contaminated land in
the inner city of Trenton, N.J., where the objective was to render the site safe
for other uses in a way that can be perceived by the community as “natural”
and “environmentally friendly.”
The final plenary paper, by Marylou Garr of the Ontario Federation of Agri-
culture, presented biotechnology from a farmer’s perspective. She described the
evolution over the last three years of the Ontario Agricultural Biotechnology
Committee. This group was designed to promote knowledge and understanding
within the agricultural industry, to improve communication within the agri-
cultural community and between it and society at large, to influence future re-
search and commercialization, and to encourage assessment of and access
to biotechnology products for Ontario. Because the rate of discovery of new
products is far more rapid than our ability to address the issues that each raises,
the committee is already performing a valuable function at the intersection of
research and development with farming and the public.
In between the plenary sessions, participants joined one of three workshops.
While the plenary sessions described here were designed to stimulate contro-
versy, the real heart of the meeting lay in the dialogues arising in the work-
shops. In those breakout sessions, participants explored implications of
Creating New Market Opportunities; Social Issues, Regulations, and Ethics;
and Economic, and Structural Issues for a particular industry sector. Lively
debate coupled with mutual respect ran throughout those sessions. The
workshop reports begin on page 23.
Those attending the Food Industry Workshop discussed the pathways to
be taken by new food products, issues of communication, regulation, and
consumer concern over food, and the ways in which the production of new
food crops might impact the structure of the agricultural and food industries.
Day/Meagher
FOOD INDUSTRY WORKSHOP RECOMMENDATIONS
Recommendations to help create new market opportunities for agricultural
biotechnology products include:
• Increased Public Input and Awareness: It was agreed that most impor-
tantly, increased public input and awareness must occur. Consumers must
be kept informed and provide input in areas such as directions for public
research for biotechnology products and processes, regulatory progress
and issues, and methods for prevention of unintended consequences
resulting from use of these products.
 • Ensure That Industry Take Clear Responsibility for Risk: Participants also
recommended that some mechanism be established for industry to better
internalize the risk and establish improved accountability should negative
consequences occur, such as the medical device industry in the case of
breast implants.
 • Establish Competitive Research Consortia: Establishment of competitive
research consortia to share and leverage knowledge and expertise was felt
to be a recommendation that would be successful for the industrial devel-
opment of new products and processes.
• Allocate Monies to Examine Social, Ethical, and Legal Issues: Several
participants felt that public and private research and development should
include an allocation of monies to examine the social, ethical, and legal
issues surrounding the topic, as is being done in the Human Genome
Project.
In preparing for a new model of agriculture and food production, the question
of what the farming model will look like in 15-20 years needs to be considered.
Will it be more highly industrialized with a small number of multinational
conglomerates controlling agriculture and producing the bulk of the food
supply? Will the small-to medium-size farming operation survive and thrive?
Participants expressed the view that farmers can best prepare for the future by:
• Staying Informed: Farmers must educate themselves on the technologies
available as well as the political and regulatory climate that exists, and
keep up to date on current and anticipated impacts and opportunities.
• Get Involved: The voice of the farming community is becoming unified
and will gain effectiveness as the numbers of those involved increases.
Participation in the political and developmental process is a necessity.
• Consider Alternatives: If vertical integration does occur, farmers must be
prepared to seek alternative ways to survive and thrive. These include
teaming up to form co-ops or other partnership operations that can
compete with large industry, and developing production and distribution
alternatives such as community shared agriculture (CSA) and organic
farming.
The Pharmaceutical Industry Workshop explored similar issues but con-
centrated on the newly emerging relationship between agriculture and the
industry and the special problems of dealing with emerging markets, possible
consumer concerns over agriculturally based pharmaceuticals, and the eco-
nomic implications of bridging the gap that has existed between agriculture
and pharmaceuticals.
PHARMACEUTICAL INDUSTRY WORKSHOP
RECOMMENDATIONS
The group’s recommendations include:
• Develop educational instruments to improve the level of awareness in the
public, the media, the farming community, and the pharmaceutical, food
processing, and retailing industries.
• Information materials must describe the intent, benefits, risks, and risk
management mechanisms.
• Regulatory change should be considered to meet increasing consumer
demands for access to the functional food category.
• NABC member institutions should promote workshops and other related
activities for dialogue between the agri-food and health care communities,
academics, and the public.
• Participation of industry representatives at NABC meetings should be
encouraged.
• NABC member institutions should encourage graduate students and post
docs to attend NABC meetings by covering their costs.
Participants in the Environmental and Energy Workshop discussed the ramifi-
cations of both immediate and long-term examples of harnessing agricultural
biotechnology to new environmental and energy-efficiency objectives. They
also explored the public’s willingness to change lifestyles to improve the
environment and the numerous economic issues that will affect the expanded
connections between agriculture and this rapidly growing sector.
Workshop Recommendations
ENVIRONMENT AND ENERGY INDUSTRY RECOMMENDATIONS
Recommendations to help create new market opportunities for agricultural
biotechnology products that are beneficial to society include:
• Develop strategies that represent a balance of broad perspectives based
on inputs from the major stakeholders (public interest groups, industry,
government, scientific community, farmers).
• Encourage government to take the lead in framing an approach to
developing novel products (e.g. alternative fuels to replace petroleum-
based fuels) that reflects long-term considerations, taking into account
implications for the economy, the environment, national security, and
other relevant issues.
• Develop educational programs at all levels from K-12 to professional
schools and continuing education — emphasizing critical thinking,
systems frameworks, full cost accounting and life cycle analysis, societal
trade-offs (both current and intergenerational), and communication of
complex issues in science and technology.
Recommendations to use public opinion most effectively to shape decisions
about new products via biotechnology include:
• Develop a two-way system of education and communication on public
issues, involving citizens’ advisory groups early in the process, and giving
the public a greater sense of control over the decision-making process.
• Devise new mechanisms to convene together diverse sectors (e.g. farmers,
environmentalists, consumers, etc.) with a neutral convener in a
community-based setting
• Document success stories and highlight positive benefits to society on
environmental and energy-related products, and organize a balanced
presentation of facts and societal trade-offs.
• Conduct more research on how to communicate with the public and how
to bridge the gap between information and attitudes and behavior.
• Prioritize what products should come on-line first.
A number of measures can be taken to better prepare farmers for new
opportunities in this time of transition.
• They can better inform themselves by taking advantage of educational
opportunities and by becoming computer literate to be in a position to
receive electronically transmitted information and use computer-based
technology.
• The extension system needs to be broadened to encompass an expanded
client base and to include new technology and production and marketing
opportunities.
• Farmers should join with industrialists, financial institutions, environ-
mentalists, consumer groups, universities and government — to develop
a vision for the new agriculture and set a national agenda that takes into
account broad views of benefits and costs to the industry and to society.
• Farmers should develop cooperatives for investment in new technologies
and to create new products (e.g. Ocean Spray, Ontario Federation of
Agriculture); such cooperatives may have a greater chance than large
corporations with consumer acceptance of new and novel products.
Finally, the Group identified new partnerships that need to forged.
• Agricultural cooperatives need to be formed, facilitated by government
and universities, and focused on new visions and common goals.
• Alliances need to be formed among farmers, industry, environmentalists,
and consumer groups in neutral settings provided by universities and the
nonprofit sector.
• Universities and farmers need to develop new relationships for research
and extension based on new realities and market-driven strategies.
• New industry/government partnerships need to be formed that are
incentive-driven, that facilitate technology assessment and transfer, and
that maintain access to technology and capital by small/independent
farmers as well as large corporations.
In summing up the conference, Paul Thompson, of Texas A&M University,
stressed the importance of trust in achieving a positive synergy between
industry and public interest organizations. For this to work, both parties
must accept the fact that they each have power but that it can only be exercised
with constraint. Paul underlined the role of NABC conferences in facilitating
“reflection over science and its impact on our future.” He projected a hopeful
future for this meeting’s novel products.
For readers unable to benefit directly through participation in the give-and-
take of these workshops, the reports, on pages (23–44), provide an overview
of the multiple facets of the issues that were discussed. In the best of worlds,
these reports will serve as a springboard for wider dialogues about exciting yet
challenging Novel Products and New Partnerships.
Workshop Recommendations
Thompson
Tying It All Together
PAUL B. THOMPSON
Texas A&M University
College Station, Texas
The Rutgers conference of the National Agricultural Biotechnology Council
represents a potential turning point in public debates over the future of plant
and animal applications of recombinant DNA manipulation and other
techniques of biotechnology. Prior to the conference, debate over food and
agricultural biotechnology was focused on three product groups: herbicide
tolerant crops, animal drugs (especially BST), and crops engineered with the Bt
gene. Although there are a few important exceptions, most products approved
for use in the United States fall into one of those three groups. Debate over
those products created an alignment of interests where agricultural input
suppliers, the food industry, and commodity organizations opposed a coalition
of interest groups representing food consumers, environmental and animal
protectionists, and small scale farmers. Universities and government were
caught in the middle. Only a few products (notably recombinant chymosin,
the enzyme used in the production of cheese) escaped.
The Rutgers meeting provided an overview of the products that may come
on-line from agricultural biotechnology early in the next century. The papers
in this conference report describe new food products that will do far more
to enhance the dimensions of quality that are important to consumers: taste,
purity, and visual appeal. If the food industry can ensure the safety of bio-
technology foods (arguably in place now at the Food and Drug Administration
(FDA)) and protect the principle of individual consent and control (labels are
arguably the answer), these new products will enjoy consumer support, rather
than opposition. What is more, new food crops that emphasize disease
resistance or that utilize less toxic forms of pest control (such as Bt crops)
should garner support from the environmental community.
Authors for this NABC 8 report also note the potential for using crops and
animals in the production of pharmaceutical and industrial products. If past
history is any guide, the public will find the case for new or less expensive
forms of human medicine a compelling one. New industrial products are among
the most exciting possibilities, as applications of both plant and microbial bio-
technology permit the production of fiber and cellulose crops that can relieve
pressure on the worlds forests. The potential for liquid fuels holds out the
promise of transferring a significant part of global energy consumption from a
non-renewable to a renewable basis. Granted, the potential for such products
must not be allowed to substitute for the strides that society has made in
conservation, but there is every reason to hope that they may become a new
approach as we strive for a sustainable society.
What constraints pose challenges to the emergence of these new uses for plant and
animal biotechnology, and what new opportunities do these novel products portend?
The papers in this report provide some insight into this two pronged question.
One way of tying them all together is to recognize a synergy in both the chal-
lenges and the opportunities. A negative synergy of constraints places serious
roadblocks in the path of developing these novel products, but with a few key
changes that synergy could become strongly positive. Those key changes
revolve around two points: trust and vision.
CHALLENGES
The novel products discussed in the chapters of this report range from new
foods that are entering the regulatory process (needing “only” regulatory
approval and commercialization before becoming available on grocery shelves)
to liquid fuels derived from plant biomass (that are, at present, largely a gleam
in the eye of bench scientists conducting basic research). Yet, in every case, new
technology will be needed to make the product a reality. In the former cases, it
is scale-up technology needed for commercial production, or “soft” technology
in the form of better marketing and consumer information. In the latter cases,
basic problems in biochemistry, molecular biology, and process engineering are
yet to be solved. The current state of knowledge is therefore a constraint that
must be removed before the novel products described herein can become
widely available.
Removing knowledge-based constraints will require research in biology,
engineering, and social science. Research will require both human and financial
capital. Although a lack of either could retard development of novel products,
it seems reasonable to think that lack of money is a more serious constraint at
the present time. Public sector funding for all forms of scientific research has
been declining, and venture or investment capital for speculative biotechnology
projects outside the area of human health has become scarce. The major
agricultural biotechnology companies have herbicide tolerant or Bt crops
and animal drugs to develop. It is questionable whether they will have the
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additional resources, or be willing to invest in the research needed, to bring
novel products to market.
One reason why investors may be reluctant to fund research in these novel
products is that commercialization will require infrastructure and institutions
that do not exist. Think for a moment about what will be required to get
industrial fiber grown in Iowa or Illinois to the pulp mills that are now located
near the pine forests of Alabama or South Carolina. Note that there are no
commodity organizations for growers of hemp, or for producers of pharma-
ceuticals utilizing plants or farm animals. Do petroleum buyers or oil company
executives traverse the Dakotas in search of new sources of supply? Novel
products presuppose new and untried linkages between farm-based suppliers
and the eventual buyers and users of their products; these linkages will have
to be invented. It is reasonable to think that in the case of pharmaceutical
products, vertically integrated firms will round-up the growers or husbandry-
men they need, but even so, these contracting activities represent costs that
must be included in the commercialization of such novel products.
The regulatory framework is also a crucial dimension of infrastructure for
novel products. The FDA evaluates food safety, as well as the safety and effec-
tiveness of new drugs. The direct environmental risks of new crops are also
reviewed by the Environmental Protection Agency (EPA) and the Animal
and Plant Health Inspection Service (APHIS) at the USDA. This much of the
regulatory framework is in place. But do pharmaceutical or industrial crops
and animals pose new risks to the food system? Is there any chance that milk
from cows genetically engineered to lactate pharmaceutical products could
contaminate the milk supply? Could crops engineered for fiber or ethanol
production back cross into varieties produced for food, and if so, what are the
risks? These do not seem to be insurmountable problems, yet they will require
forms of regulatory oversight that do not currently exist.
Developing institutions and infrastructure will be very difficult if there is
public opposition to the products themselves. Vertical organization of produc-
tion may be the most cost effective method for coordinating suppliers or for
maintaining the quality control needed for new food, pharmaceutical, and
industrial products, but such changes in the structural organization of agri-
culture may be opposed by consumers and farm groups alike. Because it is
unclear whether people will oppose the integration and industrialization of
agriculture, the uncertainty itself comes to constrain efforts to build infra-
structure or to design institutions, as well as being a disincentive for investing
the money needed to support additional research. If there is a residue of public
resistance to agricultural biotechnology—as a result of acrimony over BST or
as a reaction against “playing God,” perhaps—the uncertainties are heightened,
and the risks of undertaking the research and development of these novel
(hence speculative) products begins to seem formidable indeed.
There is thus a synergy that binds the knowledge constraints, the funding
constraints, the infrastructure constraints, and the public acceptance con-
straints. Each constraint tends to reinforce the other three. How could the
public be anything but skeptical of products descended from the heritage
of controversy over herbicide tolerant crops and BST, especially when even
their boosters acknowledge that too little is known at present to make those
products a reality, and when even venture capitalists are reluctant to invest
in them? Yet public skepticism retards the development of infrastructure
(including regulatory frameworks) and undermines the support for funding
that would ultimately address public concerns. One might conclude that the
likelihood of seeing any of those novel products in our lifetimes is slim.
OPPORTUNITIES
But, on the other hand, those products are more attractive to consumers, to
environmental interests, and, if fears of vertical integration can be assuaged,
perhaps even to small-scale producers. It is certainly the case that high quality
fruit and vegetable production is already a mainstay of family farmers in the
Northeast. New pharmaceutical products may well be produced on scales quite
commensurate with small farms, and if drug companies do not insist on con-
trolling the entire process, those products, too, may provide opportunities for
small-scale producers to maintain a way of life. As such, it need not be a fore-
gone conclusion that the public will oppose these products. A new coalition
of interest groups might provide impressive support for them.
If a new coalition forms, it will have the capacity to address problems of
infrastructure and funding in novel ways. Perhaps it will be possible for
environmentalists to work with producers and industry to restructure the
regulatory process for novel products. Perhaps regulatory functions can even
be incorporated into organizations that reflect multiple constituencies, on the
model of the Underwriters Laboratory. Small- and large-scale producers may
wish to form new kinds of cooperative organizations to ensure that they main-
tain control over the market structure for those new products, and they may
find themselves in partnership with industry giants as well as public interest
groups that have a stake in seeing those technologies develop. Clearly such
coalitions will have advantages in attracting investment funding, if only because
they reduce uncertainty. The possibility of co-ops, working with consumer and
public interest groups, in partnerships with industry for development of novel
products produces a mind-bending alteration of what we might mean by
“community supported agriculture” in the 21st century.
The potential for such new social amalgamations is no less innovative and
radical than the biological amalgamations discussed throughout this volume.
Tomorrow might look very different, and not only because we will have
genetically engineered foods, fuels, and pharmaceuticals! This, of course,
implies greater involvement of more people in setting the agenda for research
on agricultural biotechnology, and it probably means that more kinds of
Thompson
research will need to be done. The fact that such research will be popular
bodes well for getting it supported not only by government but by private
foundations, too. There is potential for a positive synergy, for research progress
to beget public enthusiasm and cooperation, and for this enthusiasm to beget
new institutions and new approaches to infrastructure. And these new insti-
tutions may provide both new sources of capital and renewed vigor in the old
sources of government, foundation, and Wall Street fundraising.
This is an admittedly sketchy picture of the new positive synergy. A lot of
problems will need to be solved along the way, and many of the real concerns
about the novel products themselves, as well as residual problems from existing
products of agricultural biotechnology, still need to be addressed. Nevertheless,
there is reason to think that new coalitions will have enthusiasm for such tasks
to the extent that they see themselves engaged in activities that are truly aimed
at improving the human condition, including, of course, the environment on
which that condition depends. Will it happen? Who knows, but at least two
“big picture” items are key. One is trust, the other is vision.
KEYS TO POSITIVE SYNERGY: TRUST
A world in which the food industry, small and large food and fiber producers,
and public interest organizations representing environmental, animal, and
consumer interests work with each other (as well as with other industries) will
require new levels of trust. It would be naive to suggest that such collaborations
will come easily, and it is important to think carefully about what is meant by
trust. Philosopher Annette Baier offers some guideposts in her recent book
Moral Prejudices: Essays on Ethics. Writing from a feminist perspective, she
encourages us to resist an interpretation of trust that confuses trust with power.
It is an unavoidable fact of human society that some of us depend upon others
for our jobs, our food, our health care, and for other aspects of our well-being.
These relationships define relative positions of power and dependence. In
democratic societies, we often speak of the rules for constraining or using
power in terms of a social contract. Contractually specified power relations
are “minimal moral traffic rules, designed to restrict close encounters between
autonomous persons to self-chosen ones” (Baier 1994). Baier believes that
while the social contract is indispensable to democracy, it is a poor model for
trust. A better model emerges out of women’s experiences raising children,
caring for families, and maintaining networks of care in the community.
Trust applies in situations where explicitly specified rules and contractual
requirements are inadequate or inappropriate. To trust another person is to
expect that there will be situations in which the trustee must exercise judgment
and discernment of a sort that cannot be anticipated and spelled out in terms
ofcontractual provisions. Trust requires that trustees make such decisions based
upon a genuine and comprehensive concern for the interests, the well-being,
and the whole person of those who have placed their trust in them. Yet it is also
true that relationships of trust are bounded, that they come with limits and
with opportunities to monitor, revise, or revoke the trusting relationship. To
put this as Baier does, children do not trust their parents; their dependency
upon them is too great. Parents do trust their children to teachers, to baby-
sitters, or to friends, however, and in doing so they expect something more
subtle and responsive than letter-perfect adherence to the terms of an explicit
contract. They expect situations that have not been anticipated by the contract,
and that the trusted party will maintain trust by acting on behalf of the child,
rather than interpreting the ambiguity or unexpectedness of the situation as
an opportunity to revert to self-interest.
This means that some of the things Rebecca Goldberg and Caron Chess
discuss—regulations that utilize conditional approval or site licenses that give
citizens the power to revoke approval—may not be forms of trust in Baier’s
sense. Those measures seem to be negotiations of power, and our experience
with such negotiations tells us that where there is ambiguity in the terms of
the rule or the contract, we can expect each party to adopt the interpretation
that is most favorable to themselves. Make no mistake, I am not arguing against
institutions that spread power and that frame power relationships within ex-
plicit statements of rules and responsibilities. But let us not deceive ourselves
into thinking that these are relationships of trust. As Baier writes, “Trust is
rational in the absence of any reason to suspect in the trusted strong and
operative motives which conflict with the demands of trustworthiness as the
truster sees them. But trusting can continue to be rational, even when there
are such unwelcome suspicions, as long as the truster is confident that in the
conflict within the trusted the subversive motives will lose to the conformist
motives” (Baier, 1994).
I take this to mean that each of the parties who must collaborate in order to
create positive synergism for new products in biotechnology must share and
remain true to a common vision, even when there are substantial individual
incentives to defect from it. Perhaps an example will make this point more
clearly. Many members of the National Agricultural Biotechnology Council
have built a trust relationship with farmers, ranchers, and rural communities.
Farmers, ranchers, and rural communities represent diverse interests, and there
has always been difficulty when the knowledge produced in agricultural uni-
versities has benefited some representatives of agriculture at the expense of
others. Agricultural research is also justified in terms of benefit to the larger
non-agricultural public, but the trust relationship between agriculture colleges
and their clientele continues to imply that the scientists, administrators, and
faculty of agriculture colleges and research stations are making judgments
on behalf of agriculture. Yet, though there can be little doubt that many of
the novel products described in these pages are intended for public benefit,
it is questionable for some (at least) as to whether they are truly agricultural
biotechnology.
Novel products are exciting applications of the plant and animal sciences to
the creation of products for human medicine or industrial processes, and they
are in this sense good for the scientists, administrators, and faculty of agricul-
tural colleges. But it is not obvious that such products will ever be produced by
people who today recognize themselves as farmers or ranchers, or on the terms
that characterize the traditional economic structure of agriculturally based
communities. Are we being entirely honest, are we maintaining our trust, when
we describe these as novel products of agricultural biotechnology? Will small-
scale niche producers ever produce pigs for pharmaceutical production or
xenografts, or will those pigs be cared for in facilities that are wholly owned
and operated by medical supply or drug companies? Is it fair to say that we are
helping agriculture, when in fact the most we are doing is creating wage labor
opportunities to care for pigs in the employ of large multi-national corporations?
None of this is to say that such innovations should not be pursued, nor is it
to say that scientists currently employed in agricultural universities should not
do the work. Yet here, I think, is a way in which members of the research world
can defect from the common vision of agriculture that underlies rural com-
munity support for research and education. Researchers may not mean to betray
a trust. They may think, with some justification, that they are acting within
their rights, but that is only to underscore Baier’s point. Relationships of trust
are not simply a matter of following the rules and obeying the law. Trust re-
quires judicious thought about whether what is done is truly done for the sake
of those who trust, or whether personal motives and opportunities may have
colored the common vision. Since the point has now come to turn to vision,
let us take up the second key.
KEYS TO SYNERGY: VISION
Many of the institutional members of the National Agricultural Biotechnology
Council have been engaged in processes of “visioning” during 1995 and 1996,
so much so that the term may have lost whatever appeal it once had. Perhaps
we would be better off to use Sister Miriam MacGillis’ term, “cosmology.”
Whatever the terminology, the idea is to recognize that we tell one another
stories about where we have come from and where we are going. Although
these stories (visions) are seldom made explicit, they serve as underlying
assumptions about what is real and what is worth doing. One of those stories
that was told for centuries goes by the name of The Enlightenment Project.
This intimidating phrase signifies the vision of science and technology relieving
the many dimensions of human misery: hunger, disease, and deprivation. The
individuals who conceived this vision, Francis Bacon, Thomas Hobbes, Robert
Boyle, and Rene Descartes among them, lived during the sixteenth century,
almost five hundred years ago. Although in some respects their vision has come
true, they also thought that unleashing the forces of scientific inquiry would
just automatically, naturally redress the social problems of injustice, of cruelty,
of jealousies, and of corruption.
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No one believes that science will automatically redress those moral problems
anymore. What is more, we have learned that our technological solutions to
problems of resource scarcity can create new problems of their own, problems
in the form of pollution, health risk, and environmental degradation. There is
no doubt that we must move beyond The Enlightenment Project, that we must
find a vision (a cosmology if you will) that does not leave the resolution of
moral problems facing us to a blind and inexorable notion of technical progress.
However it has succeeded in other dimensions, that vision of progress has failed
to create a state of bliss at the end of history. We have many problems that have
always been with us, and more than a few new ones, to boot.
The mechanistic vision of nature and humanity that emerged from The
Enlightenment Project has proved an inadequate basis for understanding social
problems, environmental impacts, and the moral significance of technology’s
unexpected and unwanted effects. That much is clear. The Enlightenment
Project may also have encouraged habits of mind that fixated on patterns of
domination: domination of women, domination by race, domination of nature.
The Enlightenment Project may have made us less sensitive to the potential
for adapting to and living with our limitations, rather than trying to overcome
them. It does not follow, however, that we would have been better off never to
have undertaken The Enlightenment Project, nor does it follow from any of
this that we should abandon all use of biotechnology. There is a huge inferential
leap being made by biotechnology’s critics in this regard. We should indeed
devote serious and critical attention to the implicit vision that we may be
working with. Formulating this vision is more important than any specific
application of biotechnology, but only petty jealousy would permit us to blame
biotechnology for our collective failure to address the fundamental spiritual
issues of our time. The practitioners of biotechnology have been spectacularly
successful in acquiring the rewards of new buildings, financial success, and
public attention. It is easy (perhaps inevitable) that those who call for moral
reflection over our pursuit of technological advance should feel neglected and
cast aside. It is only too human to wish ill upon an industry that sometimes
seems willing to exploit the state of disarray and dissolution in our collective
moral vision by making fantastic promises, but the simple fact is that we will
need biotechnology in any adequate response to the ecological and moral crises
of our time.
Our new vision will almost certainly be meliorist. This forty dollar bit of
philosophical jargon means that we will abandon the view that any scientific,
technological, or political project will just automatically solve all our problems.
We will abandon the view that progress is either inevitable or automatic. This
means that we abandon both The Enlightenment Project of dominating nature’s
mechanisms and the conceit that there ever was a truly harmonious nature
(disrupted by human activity) to which we must return. In place of this, we
will recognize the ecologists dictum: everything is connected to everything else.
When we “solve” one problem, we must be prepared to find and fix whatever
breaks next. Life is indeed an evolutionary process, but not one that is tending
toward a state of perfection or bliss. Instead, each adjustment (whether human
caused or not) adumbrates through the global ecosystem, producing myriad
changes, and opening niches for novel life activities (both human and not).
The evolutionary process goes on and on. It is never finished.
The vision for human action is one of ameliorating intolerable situations, one
after another, and using whatever tools are at our disposal to do so. Plant and
animal biotechnology will be among them. Our use of those tools should be
evolutionary, rather than revolutionary. We should use biotechnology as wisely
as we possibly can, and we should be vigilant in monitoring and learning from
our mistakes. We can be sure that there will be some unintended consequences
from using biotechnology, but there will be unintended consequences from not
using biotechnology, too. We should not expect magic bullets from biotech-
nology or from not using it. We should do what we can humbly and reflectively.
That is what meliorism means.
Yet, I would like to say a few words on behalf of Francis Bacon, Thomas
Hobbes, and the other gentlemen of the Enlightenment. Their mechanistic
vision of nature indeed lead to the revolutions in health care, agriculture, and
engineering that brought about the modern world. Would that we could formu-
late a vision half so productive! And while we cannot believe that exclusive
attention to mechanisms will solve our moral and environmental problems,
we should be reminded that thinkers like Bacon and Hobbes fully expected to
spend two hours engaged in debates over philosophy and theology for every
hour spent at the laboratory bench. Who knows what vision and what synergy
we would discover if we were to collectively spend a similar proportion of our
research effort on philosophy, history, and literature.
Reproducing a vision is even more important than the initial discovery of
vision. The time that Enlightenment thinkers spent in debate over moral sub-
jects not only honed their vision of nature and human possibility, it spread that
vision to the clientele who would utilize scientific knowledge. The challenge of
disseminating a vision is altogether different today. For one thing, we have tools
of mass media at our disposal that were unavailable to Bacon and Hobbes, and
we have the advantage of a generally literate society. But we also have a much
larger client base; one that spans a much larger proportion of the population.
It is far from clear whether we can afford to invest less in forming, articulating,
defending, and disseminating a vision than could the founders of the Enlighten-
ment, though it is evident that invest less we do.
The National Agricultural Biotechnology Council and its national confer-
ences are for that reason all the more precious. They represent one of the few
forums in which reflection over science and its impact on our future can take
place. The novel products discussed in this meeting provoke a new reflection
on what that future might entail. It is, for me, a more hopeful future than we
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have hitherto seen. It will not come about without more work in both the
laboratory and in reasoned public debates. To that end, let us dedicate our
hearts and minds.
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The Environmental and Energy Workshop Group considered a number of
issues in the light of precedents being set by specific new products and services,
as well as possible long term ramifications of new markets being opened up
through partnerships between agriculture and these sectors. Participants had
limited experience directly in these sectors, but perceived several generic
opportunities and concerns.
The Group identified numerous opportunities for non-traditional products.
High among these is the opportunity to replace non-renewable petroleum-based
products with products derived from renewable plant or microbial products.
The public is likely to view environmentally friendly products in a positive
light, particularly when they bring about a corresponding decrease in the use
of chemicals and are more sustainable than traditional crops, and if they bring
about new economic growth.
However, participants perceived that the lack of a consensus vision on the
future of agriculture is impeding both producer adoption and public acceptance
of new products from biotechnology. A better understanding is needed of
economic and societal trade-offs based on full-cost accounting of benefits
and costs. Strategies were suggested to involve the public at an early stage in
the decision-making process through more comprehensive communication
and education initiatives.
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CREATING NEW MARKET OPPORTUNITIES
The Environment and Energy Group identified the most promising opportu-
nities for non-traditional products from agricultural biotechnology. These
included:
• Petroleum alternatives based on renewable resources including
ethanol, industrial oils from plants, rubber alternatives (guayule),
plastics based on starch or microbial products, industrial chemicals
replacing ethylene, starch based compostable containers for the food
industry.
• A variety of products resulting from linking pharmaceuticals with
plant and animal molecular biology.
• Stress tolerant and pest-resistant plants for agriculture and forestry
production, and agricultural animals with more efficient metabolisms.
• Industrial fiber alternatives for the paper industry.
• Plant and microbial bioremediation techniques.
• Nonfood products developed from sludge and sludge-using crops.
A number of factors were recognized as barriers to creating new market
opportunities:
• Lack of consumer understanding of science-based issues and the diffi-
culty of communicating to non-science publics who are skeptical and
fear the unknown consequences associated with new technologies.
• Reluctance of producers to move into new ventures because of an
insufficient consensus vision on the future of agriculture and the role
of producers in the new agriculture, uncertainty about the potential
risks assumed by first adopters, and lack of understanding of the
economics of the new agriculture and the potential profit in value-
added products.
• Lack of an appropriate basic marketing infrastructure for non-
traditional products including handling, transportation and
processing through alternative marketing channels; and inadequate
performance data on the marketing of new products.
• An insufficient understanding of economic and societal trade-offs
based on full-cost accounting of internal and external benefits and
costs such as waste disposal vs. reuse, energy inputs vs. energy
outputs, land required for food vs. nonfood products etc.
• A public policy framework that may stifle rather than provide
incentives to engender marketing opportunities for nontraditional,
nonfood products.
• Lack of venture capital and funding for starting up some new ventures
and for the commercialization and marketing of new technologies.
Environment and Energy Industry
• Inadequate technologies and facilities to manage wastes associated with
phytoremediation and to remove potential contaminants in sludge.
Key actions need to be taken to overcome barriers and to seize opportunities:
• Formation of producer and marketing cooperatives based on a con-
sensus vision for the new agriculture, with better assurances that
producers have significant decision making roles in vertically inte-
grated enterprises with most power and profit residing elsewhere;
and the development of new marketing channels for nontraditional
products.
• Formation of research and development teams and technology
transfer at universities with cross-cutting multidisciplinary and
systems frameworks, providing assured sources of genetic materials,
technical assistance, and providing neutral environments to convene
stakeholder partners.
• Development of new models for funding based on equitable invest-
ments in research and development and providing funding partnership
roles for institutions in the public, private and nonprofit sectors.
• Formulation of models for life cycle analysis and full cost accounting
to better assure that the development and commercialization of new
technologies solve existing problems without creating new ones
such as potentially polluting by-products of new technologies and
processes, the excessive use of prime farmland for crops used to
produce new nonfood products (e.g. corn to produce ethanol)
• Identification of the key stakeholders and their common interests to
facilitate the formation of partnerships.
A number of measures can best assure that the public will play an appropriate
role in the creation of new market opportunities:
• Explore ways to stimulate public interest and involve publics early in
the process of product development.
• Encourage the formation of community-based interest groups to
advise the biotech industry.
• Encourage the nonprofit sector to develop visions for the future and to
facilitate joint initiatives (such as the Turner and Kellogg Foundations
are doing).
• Develop educational programs at all levels to encourage thinking in
a systems framework, the identification of societal trade-offs, and full
cost accounting — in the development and marketing of products
based on new technologies and processes.
Recommendations were made by the Environment and Energy Group to help create
new market opportunities for agricultural biotechnology products that are beneficial
to society:
• Develop strategies that represent a balance of broad perspectives based on
inputs from the major stakeholders (public interest groups, industry,
government, scientific community, farmers).
• Encourage government to take the lead in framing an approach to
developing novel products (e.g. alternative fuels to replace petroleum-
based fuels) that reflects long-term considerations, taking into account
implications for the economy, the environment, national security, and
other relevant issues.
• Develop educational programs at all levels from K-12 to professional
schools and continuing education — emphasizing critical thinking,
systems frameworks, full cost accounting and life cycle analysis, societal
trade-offs (both current and intergenerational), and communication of
complex issues in science and technology.
SOCIAL ISSUES, REGULATIONS AND ETHICS
The Environment and Energy Group considered what the public is most likely
to be concerned about with new agricultural biotechnology products in this
sector. The most widely cited concern is:
• Unanticipated and potentially adverse impacts on environmental quality.
Additional concerns are:
• Potential negative impacts on food, human health, and costs to
consumers,
• Doubts about the trustworthiness and reliability of the biotechnology
industry, particularly with respect to food products, and
• Loss of biodiversity
Features of new agricultural biotechnology products most likely to be viewed
positively by the public in this sector are:
• Replacement of products based on non-renewable resources with
those based on renewable resources.
• Potential for environmentally friendly products and processes, with a
corresponding decrease in the use of chemicals and pesticides.
• Potential for new classes of products that would be more sustainable
than traditional crops and would generate new economic growth.
• Optimism that biotechnology can provide better solutions to difficult
problems.
A number of ethical issues that might arise from the introduction of new
products include:
• Equity issues relating to proprietary rights and access of small farmers
to new technologies and markets.
• Effects of new technologies on established social and economic
structures, such as the displacement of traditional products (e.g.
vanilla), or the use of land for non-food crops and the effect of this
nonfood use on the global food supply.
• Intergenerational responsibility for conserving non-renewable
resources.
Participants debated whether there are unnecessary obstacles posed to new
agricultural products by regulation. They concluded that:
• Regulatory levels seem appropriate (and less of an obstacle than in
the food and pharmaceutical industries), although paperwork can
be burdensome and rules are sometimes applied too rigidly (e.g.
academic labs governed by industry regulations).
There also was some concurrence in concerns about troublesome gaps in
the regulatory coverage of new agricultural products:
• Lack of consistent international standards leading to unfair trade
advantages,
• Uncertainty about which agencies will regulate new non-food
products,
• Growing weaknesses in the regulatory staffs (cutbacks and inadequate
training), and loss of objectivity of the review process with abolition
of entire agencies such as OTA.
• Inability to deal with specific “bad actors” without penalizing an
entire industry,
• Need for better understanding and balance between regulation/
enforcement and incentives.
• Lack of information on gene escape when engineered plants are
released for large- scale production.
Several recommendations were suggested to use public opinion most effectively
to shape decisions about new products via biotechnology:
• Develop a two-way system of education and communication on public
issues, involving citizens’ advisory groups early in the process, and giving
the public a greater sense of control over the decision-making process.
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• Devise new mechanisms to convene together diverse sectors (e.g. farmers,
environmentalists, consumers, etc.) with a neutral convener in a
community-based setting.
• Document success stories and highlight positive benefits to society on
environmental and energy-related products, and organize a balanced
presentation of facts and societal trade-offs.
• Conduct more research on how to communicate with the public and how
to bridge the gap between information and attitudes and behavior.
• Prioritize what products should come on-line first.
ECONOMIC AND STRUCTURAL ISSUES
The Group identified both potentially positive and negative impacts for
agriculture of new products being adopted by the marketplace in this industry.
Among the most positive impacts are:
• Reduction of external costs to the environment and loss of non-
renewable natural resources while offering the potential to increase
productivity by lowering input costs of production.
• Expanding markets for traditional agricultural products e.g. stress
tolerant agricultural plants, crops produced with reduced use of
chemical fertilizers and pesticides.
• Opening new markets for alternative products to replace those which
are petroleum based or which consume non-renewable natural
resources e.g. industrial fibers, liquid fuels etc.
• Creating new markets for agricultural plants (e.g. phytoremediation)
and creating income opportunities for farmers in sludge management
(e.g. tipping fees, and marketable by-products from clean sludge).
In considering potential negative impacts on agriculture of new products,
there was consensus that whether or not the impacts are positive or negative
will depend on how technologies are brought forward and on whether new
organizational structures are developed.
• There could be a negative impact on small, independent farms if
farmers lose decision-making control in vertically integrated
enterprises, if there is excessive concentration of power in large
corporations, or if there is unequal access to new technologies.
• Unless the full consequences of initially introduced products are
carefully thought out and publicly discussed, the increased suspicion
of consumers will depress the potential marketability of new products.
• Some believe that unless land use issues are addressed in timely
fashion, emphasis on nonfood/nonfeed products could decrease
acreage for food agriculture or further deplete forest areas; others
believe that market pricing could prove to be a sufficient counter
weight to any drastic changes.
A number of measures can be taken to better prepare farmers for new opportunities
in this time of transition:
• They can better inform themselves by taking advantage of educational
opportunities and by becoming computer literate to be in a position to
receive electronically transmitted information and use computer-based
technology.
• The extension system needs to be broadened to encompass an expanded
client base and to include new technology and production and marketing
opportunities.
• Farmers should join with industrialists, financial institutions,
environmentalists, consumer groups, universitiesn and government — to
develop a vision for the new agriculture and set a national agenda that
takes into account broad views of benefits and costs to the industry and to
society.
• Farmers should develop cooperatives for investment in new technologies
and to create new products (e.g. Ocean Spray, Ontario Federation of
Agriculture); such cooperatives may have a greater chance than large
corporations with consumer acceptance of new and novel products.
Finally, the Group identified new partnerships that need to forged.
• Agricultural cooperatives need to be formed, facilitated by government
and universities, and focused on new visions and common goals.
• Alliances need to be formed among farmers, industry, environmentalists,
and consumer groups in neutral settings provided by universities and the
nonprofit sector.
• Universities and farmers need to develop new relationships for research
and extension based on new realities and market-driven strategies.
• New industry/government partnerships need to be formed that are
incentive-driven, that facilitate technology assessment and transfer, and
that maintain access to technology and capital by small/independent
farmers as well as large corporations.
Environment and Energy Industry
Biotechnology-based products and processes will likely have a significant
impact on the agricultural and food industries over the next several years.
The nature of that impact is as yet unclear, and has the potential for both
positive and negative outcomes. Topics discussed as part of the workshops
at this year’s NABC meeting attempted to provide the basis for beginning to
understand the impact of increased use of biotechnology in food production.
The objective of the food industry workshop was to:
• evaluate new market opportunities for biotechnology in the food
industry,
• examine social issues, regulations, and ethics as they relate to
biotechnology in the food industry, and
• highlight the economic and structural impacts of new products on
agriculture.
CREATING NEW MARKET OPPORTUNITIES
Participants were asked to identify the most promising opportunities for new
nontraditional products from agricultural biotechnology. Not all participants
were in agreement that biotechnology-based products presented new market
opportunities, but rather some considered that they presented a threat to tra-
ditional products and methods. This concern was primarily based upon the
unknown impacts of nontraditional products on the ecosystem, health & safety,
and existing markets for traditional products.
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Areas of opportunity were identified as (in random order):
• Increased Food Quality and Safety: Increased nutritional value, better
taste, longer life, and food safety through developments such as
packaging indicators. Development of the area of nutraceuticals for
added nutritional/health value as well as removal of nutrient
absorption properties and natural toxicants.
• Vaccine Production and Delivery: Development of agricultural strains
for vaccine production and agricultural/food products for vaccine
delivery.
• Increased Producer Productivity: Increasing producer productivity
through higher yield crops, new geographic locations for crops (such
as arid areas or marginal soils), and “pharming”. Increased produc-
tivity will result in a net increase in the available food supply.
• Processing for Increased Efficiency: New and improved methods for
food harvesting and processing, as well as the use of food processing
by-products for other applications. This area provides great potential
for improvement, given that current worldwide post harvest loss is
significant.
• Environmentally Benign/Beneficial Food Products and Processes:
New agricultural crop strains that will not adversely impact the
environment and biodegradable/by-product packaging.
Considerable discussion about the drivers of these new areas of opportunity
took place. Participants felt that past and present drivers were primarily eco-
nomically motivated, e.g. producer and corporate profits. Some participants
believe that food quality and nutritional value are becoming more important,
while others maintained that economics will continue to be the major influence
in the development of new areas of opportunity.
Numerous barriers exist in developing new market opportunities, primarily
due to:
• Consumer Acceptance: The issue of trust and education repeatedly
surfaced in workshop discussions. Trust represents the comfort level
of the consumer with the expectation that nontraditional food prod-
ucts will or will not be beneficial to them. Consumers are skeptical
that government and industry truly have their best interests at heart,
and require concrete proof that this is the case. Education is an issue
because the majority of consumers are likely not educated about
biotechnology-based agricultural and food products. Because of the
lack of trust and education, consumers tend not to trust nontradi-
tional food products. Many participants felt that an effort to learn
what consumers really think and their key concerns is critical to
gaining acceptance of alternate food products.
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• Intellectual Property Rights: Intellectual property issues create barriers
to developing new market opportunities because patents are too
broad, inhibiting innovation and entry of other similar developments.
In addition, areas that cannot be protected are not as readily devel-
oped, such as nutraceuticals, where many substances are widely
available. Industry does not want to expend dollars or human re-
sources on development of products that cannot be effectively
protected from competition, regardless of the benefit to the public.
• Complicated/Unpredictable Standards and Regulations: Lack of
definition (in some areas) and cohesiveness of national and inter-
national standards and regulations governing biotechnology-based
agricultural and food products creates a significant barrier to entry of
new products. This lack of international agreement on standards and
regulations affects the public trust, in turn slowing the market entry
of nontraditional products.
Other barriers to entry include the capital costs associated with changes in
infrastructure necessary for new products and processes, the shortage and
lack of integration of resources available to develop and market these products
and processes worldwide (especially developing countries), and the lack of a
comprehensive management/integration system for transferring technologies to
the field.
The ability of the industry to overcome these barriers will dictate the future
success of biotechnology related food products and processes.
Key roles to be played in overcoming barriers and seizing opportunities
include:
• Open discussions and involvement with consumers regarding the
positive and negative implications of the use of these alternative
products and processes. The availability of information and education
on the topic will frame these discussions effectively. Mechanisms for
assuring that industry will appropriately manage the introduction and
control of these products and will deal responsibly with unintended
consequences such as creating environmental imbalances. Full dis-
closure labeling of agricultural and food products produced using
biotechnology.
• Worldwide harmonization and streamlining of regulations and stan-
dards to increase public trust and create an environment for more
efficient introduction of new products and processes.
• Carefully cultivating and maintaining a proper balance between
development of patentable and freely available products and
processes.
Participants agreed that consumers need to recognize their own responsibility
in this issue, educate themselves, and become actively involved in open dia-
logue and discussion. The public can best play a role if they are educated and
aware of the research and development, regulatory, and political issues.
The group’s recommendations include:
• Increased Public Input and Awareness: It was agreed that most impor-
tantly, increased public input and awareness must occur. Consumers must
be kept informed and provide input in areas such as directions for public
research in biotechnology products and processes, regulatory progress and
issues, and methods for prevention of unintended consequences resulting
from use of these products.
• Ensure That Industry Take Clear Responsibility for Risk: Participants also
recommended that some mechanism be established for industry to better
internalize the risk and establish improved accountability should negative
consequences occur, such as the medical device industry in the case of
breast implants.
• Establish Competitive Research Consortia: Establishment of competitive
research consortia to share and leverage knowledge and expertise was felt
to be a recommendation that would be successful to the development of
new products and processes.
• Allocate Monies to Examine Social, Ethical, and Legal Issues: Several
participants felt that public and private research and development should
include a component for allocation of monies to examine the social,
ethical, and legal issues surrounding the topic as is being done in the
Human Genome Project.
SOCIAL ISSUES, REGULATIONS AND ETHICS
Participants were asked to identify the most important public concerns with
new agricultural biotechnology products. The following were identified as most
important:
• Safety and Health: Concerns over the safety of biotechnology-based
food products, the potential for allergens, and the potential for
decreased nutritional value contribute to the general public concern
over these products.
• Lack of Control/ Fear of the Unknown: Considerable discussion took
place on this topic, and included concerns over the irreversibility of
introducing genetically engineered materials into the environment,
the lack of control over such a release, and the potential disruption
and impact on the ecosystem.
• Structural Changes in Agriculture: This concern is centered around
the structural changes that will likely occur as a result of increased
agricultural engineering, and include the evolution of monopolies
and consolidation of the food supply through vertical integration,
the impact on small to medium sized farming operations, the political
implications resulting from a consolidation, and the potential for
“new use” agriculture to compromise our ability to feed the world.
Conversely, those features most likely to be viewed as positive by the public
include;
• Increased Food Quality: Genetic engineering will provide products
with increased nutritional value, longer shelf life, and more cosmetic
appeal.
• Improved Food Safety: Advances in technology will decrease the use
of pesticides through development of disease resistant strains and
improve food safety through longer shelf life and the inclusion of
contaminant indicators in food packaging.
• Maintain a Low Cost Food Supply: Higher yielding, disease resistant
crops, more efficient processing methods, and longer shelf lives will
help to maintain a low cost food supply.
The use or intended use of alternative products raises ethical issues that
need to be addressed before acceptance can be achieved. Our responsibilities
in addressing the ethical issues in biotechnology have dramatically increased
due to the speed of change and the potential for much greater consequences
than in other areas. Among the ethical issues to be considered are:
• Playing God: Considerable concern was expressed regarding the issue
of the sacredness of life and the right of scientists to alter traditional
life forms. Should we cross natural barriers in creating or modifying
life forms? Greater concern was expressed over altering animal life
forms than plants, but each present significant ethical issues.
• Ownership of Life Forms: Who owns the genes and germplasm result-
ing from biotech research? Are these life forms patentable?
• Technology for Technology’s Sake: Should we use a technology simply
because we can? Should we not return to traditional methods? We
have a greater understanding of traditional methods, why not use
that understanding to achieve our objectives rather than pursuing a
controversial technology area?
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• Research Funding: Given the controversial nature of this area, should
public monies be used to fund research in biotechnology?
• New Product Decisions: Who really decides which products are devel-
oped and introduced in the market? Are negative social and ethical
issues overlooked in the rush to profits? Should the economic/profit
motive be the sole driver, or should social issues factor much more
strongly in the equation?
Can regulation provide some level of control over the types of products
developed and introduced, and will it help to ease some of the ethical concerns?
The public has the right to know the origin of the products they are consuming,
whether they are genetically-engineered or contain other additives and by-
products. Consumers are asking questions such as “Why are genetically-
engineered products not labeled?” and “Does the industry have something
to hide?” Legislation requiring explanatory labeling of genetically-engineered
food products will have a positive impact on how the industry is viewed. Public
opinion plays a key role in acceptance or rejection of nontraditional food prod-
ucts, and can help determine the ultimate outcome through public interest
groups, the media, and other public forums.
ECONOMIC AND STRUCTURAL ISSUES
The introduction of new products and processes in the food industry will pose
economic and structural issues to all facets of the industry. Discussions on this
topic centered around the impacts of new products on agriculture and food
processing, how farmers can best prepare for changes, and what partnerships
can be developed to take advantage of opportunities. Economic and structural
issues are difficult to address, however, due to the broad underlying issues of
markets, societal developments, and politics. In addition, dealing with a multi-
national/global industry on a national level presents tremendous difficulties.
Potential impacts of new products on agriculture being adopted by the
marketplace include:
• Horizontal Integration: New classes of agricultural products will
provide linkages and involvements with other sectors, including
pharmaceutical, energy, and environmental. This will potentially
provide additional or modified income sources for producers. This
expansion into other industrial areas could also impact negatively our
ability to feed populations, should land use be increasingly diverted to
nonfood agriculture.
• Vertical integration: Control of food production is likely to lead to
consolidation in the industry, which may lead to greater control over
the food supply by the industry and reduced availability in the types
and varieties of products. Because of agricultural production
exclusively for export use, large multinational farming organizations
will likely have less interest in maintaining the overall quality of the
land and those communities producing agricultural products, leading
to displacement of native populations. Industry, by nature of market
forces, tends to take a short-term, profit-oriented approach and does
not place significant value on the long-term, public good aspects of
their actions.
• More dependable food sources with increased nutritional value and
safety will likely result through new agricultural and production
processes.
• Resistant Strains: Increased use of biotoxins will likely cause very
strong selective pressure for insect and disease resistance, potentially
resulting in super strains, and devastating impact on agricultural
production.
• “Quick Fix “ approaches may distract attention from the broader
social and ethical issues, such as more effective distribution of food
products to starving populations.
In preparing for this new model of agriculture and food production, the
question of what the farming model will look like in 15-20 years needs to
be considered. Will it be more highly industrialized with a small number
of multinational conglomerates controlling agriculture and producing the
bulk of the food supply? Will the small to medium size farming operation
survive and thrive? Participants expressed the view that farmers can best
prepare for the future by:
• Staying Informed: Farmers must educate themselves on the technologies
available, as well as the political and regulatory climate that exists, and
keep up to date on current and anticipated impacts and opportunities.
• Get Involved: The voice of the farming community is becoming unified,
and will gain effectiveness as the numbers of those involved increases.
Participation in the political and developmental process is a necessity.
• Consider Alternatives: If vertical integration does occur, farmers must be
prepared to seek alternative ways to survive and thrive. These include
teaming up to form co-ops or other partnership operations which can
compete with large industry, and developing production and distribution
alternatives such as community shared agriculture (CSA) and organic
farming.
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Biotechnology-based agricultural and food products and processes have the
potential for tremendous impact on our society. The question of whether that
impact is positive or negative is cause for considerable debate in all sectors. Our
society has evolved to the point where we tend to focus on those short-term
solutions to the detriment of the potential long-term, global impacts of our
actions. We cannot afford to take that approach in the biotechnology sector, as
the stakes are too high. A holistic, balanced approach is necessary by all parties
involved to assure a proper balance for the future. It is our responsibility to
consider the fundamentals first, and continuously maintain a focus on the
global issues and impacts in order to assure a successful future. In the area of
biotechnology, the definition of a successful future is still open.
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The purpose of the workshop was to discuss each of the issue areas, determine
what impact they may have on the successful development of pharmaceutical
applications of agricultural biotechnology, and suggest mechanisms to over-
come any identified obstacles. Although most of the participants had little
pharmaceutical industry background or direct experience with the applications
for human health care through agricultural biotechnology, there were a few
participants with direct pharmaceutical industry experience. The participants
provided “top of mind” contributions to each of the questions and issues raised.
NEW MARKET OPPORTUNITIES
The workshop explored potential applications of agricultural biotechnology to
areas such as health care products, test models, nutraceuticals and functional
foods, organs and tissues for transplant, high value proteins and complex
molecules.
While it was expected that pharmaceutical applications of agricultural bio-
technology may provide biotechnology with an improved reputation, a number
of serious barriers to development could be forecast. These include the high
cost of development and long lead times, multiple regulatory oversight for the
products and processes, poor international regulatory standardization, overly
broad patent claims (in the US, Japan and Europe), and the genetic source
material being located off-shore.
Pharmaceutical Industry
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In order to seize the opportunities, it was generally agreed that the educa-
tional system and media must be encouraged to raise the level of awareness
in the public. Partnerships will have to be created between the marketing and
scientific communities as well as between the numerous groups involved in
the research, development, production and sales of the products. The North
American public is both poorly informed and skeptical about biotechnology,
presenting problems and opportunities. Low levels of trust continue to plague
the biotechnology industry; however it was felt that a skeptical public will force
the industrial and research communities to improve communications skills and
develop more suitable messages.
To create successful market opportunities, it was felt that the initial focus
should be on preventative versus curative products. The university research
community should consider establishing multidisciplinary teams, as is done in
industry, to ensure cross-fertilization of ideas and the development of nontra-
ditional solutions to barriers. Information provision was seen as a priority, with
a need for immediate development of education programs to raise the level of
public awareness.
SOCIETAL ISSUES, REGULATIONS, AND ETHICS
Much of the workshop discussion revolved around the public concerns of
biotechnology such as the safety of products for the environment and human
health, the perceived lack of public/individual control over product develop-
ment and consumer choice. It was noted that pharmaceutical applications of
agricultural biotechnology will likely be seen as beneficial for human health
but, at the same time, may be seen as detrimental for animal welfare or envi-
ronmental impact. The public was seen as supportive of crop and income
diversification for the primary producers yet concerned about multinationals
controlling both the genetic material and farmers growing the proprietary
strains under contract.
While there were only minor regulatory gaps recognized by the workshop,
such as the premarket regulation for foods, additives, and supplements in the
US, several important regulatory issues were identified. The regulatory scene
lacks international harmonization and approval times appear excessive. Since
health claims cannot be made on food products (except physiological claims
such as dietary fiber), North American regulations are not as supportive of
functional foods as other jurisdictions in Europe or Asia. Regulatory change
should be considered to meet the increasing consumer demands for access to
the functional food category.
Ethical considerations raised related mainly to special-interest groups in-
volved in animal welfare. Animals used as factories for production of complex
proteins as well as organ donors for transplant were considered the most likely
targets for activist concern. The farmers involved will probably be subjected to
increased interest from media as such products become more widely known.
Access to and compensation for countries that own useful genetic resources
(mostly the developing nations) was seen to be an issue; however, no specific
recommendations were tabled. The Convention on Biological Diversity
addresses this issue. The existing agreement between Merck and Costa Rica
was considered one possible approach.
ECONOMIC AND STRUCTURAL ISSUES
Pharmaceutical applications of agricultural biotechnology are expected to
increase rural job creation, diversify farm incomes with high value crops, and
introduce new domestic and export market opportunities. However, in com-
parison with other applications of agricultural biotechnology, only a small
segment of the farm community will be affected by the development of phar-
maceutical applications. Relatively few farmers will be required to supply the
worldwide market for such pharmaceutical products. Those farmers who are
involved will be subject to increased tracking, monitoring and evaluation, and
may become closely aligned with, if not employees of, large multinationals.
The development of unusual alliances will result as the traditional lines
between agriculture and health care begin to erode. Pharmaceutical, seed, food
distribution and food processing companies will work together with health care
professionals and farmers. Also, health care funding may begin to be accessed
by the agricultural research community. New partnerships will develop for
research, education, communications, and marketing. The structure of farms
will change with vertically integrated “high tech” small farms. The farming
profession will become management intensive with unusual market regulations
for farm products such as vaccines and nutraceuticals. The main challenge will
arise from quality control product issues.
Information provision was seen as a fundamental requirement to ensure the
eventual success of agricultural biotechnology applications. The entire bio-
technology community must become communicators by developing concise
messages in lay terms, delivering these messages at every opportunity and,
where possible, through credible organizations. Mass and electronic media,
local government representatives and the educational establishment should be
utilized to get the message out. The development of a continuous educational
system with credits, similar to the one existing for physicians, should be estab-
lished for pharmaceutical farmers. Additionally, a group called “Brokers for
Communication” should evolve to distribute information not only to the
public, but also to the pharmaceutical farmers, educators and others. And,
finally, the information materials must include details on the intent of the
application or product, how it will benefit the user, the risks associated with
its use and the mechanisms in place to manage the risks.
Pharmaceutical Industry
The group’s recommendations include:
• Develop educational instruments to improve the level of awareness in the
public, the media, the farming community, and the pharmaceutical, food
processing, and retailing industries.
• Information materials must describe the intent, benefits, risks, and risk
management mechanisms.
• Regulatory change should be considered to meet increasing consumer
demands for access to the functional food category.
• NABC member institutions should promote workshops and other related
activities for dialogue between the agri-food and health care communities,
academics, and the public.
• Participation of industry representatives at NABC meetings should be
encouraged.
• NABC member institutions should encourage graduate students and post
docs to attend NABC meetings by covering their costs.
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The modern agricultural industry has been highly effective in the implemen-
tation of productive new technologies that provide more food, shelter, and
industrial materials for an expanding world population. Agricultural output
needed to produce an abundant food supply for nations where economies and
distribution systems are adequate is currently achieved on approximately six
million square miles of cultivated land, the same land use as in 1950, despite
a doubling in world population throughout this period. Such expanding pro-
ductivity, on constant or even diminishing agricultural land, is an essential
component of the sustainable agricultural system we all hope to develop. It can
only be achieved through continued scientific discovery to improve germplasm
and production practices throughout the world. There is no greater opportunity
today to accomplish this than through the application of biotechnology.
Increased global information exchange, international trade, and rapid inno-
vation in many areas of technology — especially biotechnology — are now
contributing to an evolution in the world agricultural industry, through which
substantial enhancement in our industry will occur much faster than ever
before. We will see more rapid improvement and global distribution of germ-
plasm and production practices, and we must prepare to deal with entirely
novel applications for agricultural land use. More so than any previous agri-
cultural technology infusion, biotechnology will impact all elements of the
industry, all associated industries, and all of interfacing society. The increased
speed and the extreme breadth of current change make this a particularly
unsettling time. Now, as never before, there is need for industry, academia, and
consumer interests to cooperate in the identification and management of issues
generated by this new technology. We must deal with new laws and regulations,
new products and industry practices, and entirely new agricultural uses that
will emerge as the potential of biotechnology is realized.
Biotechnology: Catalyst for Change in
Agriculture
KENNETH A. BARTON
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Two circumstances are important in considering the magnitude of the situa-
tion we now face. First is the exceptional power of biotechnology to enable
rapid and precise manipulation of plant and animal genetics in ways that were
never previously feasible. Second, the application of biotechnology to other
industries beyond agriculture ensures that a massive level of research and
development expenditure will continue to fuel improvement in biotechnical
skills for the foreseeable future. Available resources for continued research
and technology development will be well above the historically low levels of
funding that have been targeted solely toward agriculture, and advances in
other industries will significantly contribute toward the rate of progress in our
own industry.
In this presentation I will discuss the breadth of the enabling technology,
its management through the intellectual property system, and the effects we
should anticipate as our industry adjusts to a more rapid pace in new product
development.
THE TECHNOLOGY
Biotechnology enables the precise alteration of metabolic processes of living
organisms to achieve novel outcomes. Advances in this field have relied upon
broad innovation in our understanding and manipulation of living materials,
which is achieved through the sciences of molecular and cellular biology.
Molecular biology is the study and manipulation of DNA, which is the common
“blueprint” of all living organisms. Such strong similarities exist in the char-
acter of DNA from all life forms that a common technology base is broadly
applicable toward gene discovery, gene mapping and tracking, and even the
genetic engineering of diverse microbial, plant, and animal systems. Cell
biology, also an integral aspect of biotechnology, is essentially the study of
structure and function of living cells. Like molecular biology, many principles
of cell biology can be generalized across species.
The necessary laboratory equipment and intellectual skills needed for
research in molecular and cellular biology have evolved dramatically over the
past two decades, and essential capabilities are already in place in most of the
world’s major academic and industrial centers worldwide, including not only
those which focus solely on agriculture, but other industries as well. Because
of the common interest in the application of molecular and cellular biology to
the health care, chemical, and other high-value industries, research and devel-
opment advances toward agricultural objectives will be furthered by discoveries
from outside our field. For example, molecular breeding technology, now
widely used to facilitate new crop development, continues to benefit greatly
from human genome mapping efforts. In addition, the refinement of gene map-
ping technology will contribute to our increased understanding of the existing
mechanisms by which plants and animals adapt to, and deal with, their envi-
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ronments, leading to new opportunities to engineer crop improvements in years
ahead. However, it is the transfer of genetic information from one organism to
another, even across species boundaries, that represents the most powerful new
opportunity for the improvement of plants and animals.
Many schemes have been developed for gene transfer to live organisms
and much of the technology is applicable toward any living cell, regardless of
species. While plant sciences have often followed the advancement of other
industries due to greater financial resources being directed toward fields such
as health care, the engineering of plants has progressed considerably faster than
comparable efforts in animals or humans because of practical and social con-
siderations. Gene delivery to all major plant species has already been achieved,
and the rate of continuing progress in refining crop gene delivery technology is
dramatic. With such powerful enabling technology in hand, our industry is now
turning to issues of new product development.
EVOLUTION OF THE AGRICULTURAL INDUSTRY
We are currently in the midst of an evolution in agriculture, provoked by the
maturation of biotechnology from the stage of concept development to appli-
cation. It is practical to view this evolution in three phases, each spanning
approximately a decade. The process began in earnest with a period of concept
evaluation and enabling technology development during the 1980s. This was
followed by a transition from technology development to early product devel-
opment, which is now underway. The evolution will continue, following the
turn of the next century, with more extensive product development, which will
lead to new agricultural applications and dramatic industry expansion.
The 1980s was an extraordinary period of technology enablement during
which biotechnical methods were generated for gene identification, gene
cloning and characterization, and for the delivery of genes to plants and
animals. Hundreds of millions of new dollars were infused into agricultural
research — much of it from the private sector — without any immediate
financial return through sale of products. It was indeed fortunate for our
progress in this emerging field that private sector funding was available, since
the early technology development was very costly and occurred as federal
research support began to decline. With many of the new technologies now
on line, the industry is increasing its focus on product-oriented research, while
continuing to refine essential aspects of enabling technology for the future.
Although marketable products were not generated during the 1980s, a signifi-
cant outcome from that period of discovery was intellectual property. The past
decade was not unlike the land rush of the past century, and many claims were
staked — large and small — that will shape the development of the industry
through the ongoing transition.
The agricultural industry in the 1990s will be dominated by a transition from
biotechnology development toward product and market development. We are
now in the midst of this change, with the first of the new products reaching the
marketplace in launches of unprecedented scope. Insect resistant cotton and
corn, herbicide resistant crops, and other early products have all been released
to a very receptive marketplace. Continued product success will ultimately
depend on the level of consistent value delivered to the consumer, but all
current indications show that new and faster product development will be a
major benefit to our industry. Years of research and product testing have gone
into each of the products now reaching the market, and the first revenues from
actual product sales are being welcomed by industry investors. However, the
development of those new products has further revealed peripheral industry
issues that result from the use of biotechnology. The creative revision of market
paradigms to enable sufficient value capture from novel products must now be
undertaken.
Following the turn of the century, the third decade of this evolution will be
characterized by more complex product development and significant com-
mercial expansion. We will watch value shift away from classical agricultural
chemical inputs toward more versatile crop and animal genetics. Industry
consolidation will continue through alliances and acquisitions, and the trend
toward vertical integration will escalate to enable more effective product
management and value capture. Many of the small companies that pursued
technology development in the past will have insufficient resources to move
products to market in a timely way, and many will close or be acquired by
larger firms. Companies of greater size and resources will adapt to the changing
environment, new production and marketing strategies will be established, and
entirely new business areas will be opened to exploit agricultural technology.
Among the key elements shaping these industry adaptations to the new tech-
nology will be ownership and control of new technologies and resulting prod-
ucts. While various commercial practices will contribute to such control, there
will be a strong influence from the patent system.
INTELLECTUAL PROPERTY IN AGRICULTURE
The generation of biotechnology skill has been very costly, and the application
of the new technology will entail higher costs in shorter research and develop-
ment cycles than historically practiced in agriculture. Government and foun-
dation support to finance this technology over the past decade has been very
limited. Increasing budget pressures in the federal government will make basic
and discovery research dollars increasingly scarce. The situation is ironic: time
frames in the enhancement of agricultural productivity are long, which is a
detraction to industry, but benefits are seen across society. Government expen-
ditures toward the enhancement of agricultural productivity have also his-
torically provided an exceptionally strong societal return. However, we are
facing a period where the continued development of agricultural productivity
will fall increasingly on private industry. For effective implementation of bio-
technology, product value must be more reliably captured to reimburse even
early stage researchers, or the product development pipeline will be diminished.
As has been demonstrated in all other technology-dependent industries, patent
law provides a mechanism to capture value when products are delivered to
consumers. That value is then distributed to contributors along the
development path.
A “patent” is a legal provision that provides an exclusive right to inventors
for a limited period of time to “make, use, or sell” their discovery in return for
releasing the knowledge of their invention to the general public. The patent
system has served many other industries well in stimulating research, encourag-
ing product development, and enabling the controlled distribution of products
to consumers. Patents are neither new or untested in agriculture, yet their
increased application to agricultural products must receive a much greater
emphasis in years ahead. Acceptance of a stronger intellectual property system
in agriculture has been slow.
Plant “certificate” protection was first offered with the Plant Patent Act
(PPA) of 1930, when breeders were given the opportunity to protect asexually
propagated crops developed through their breeding programs. Certificate pro-
tection was further extended in 1970 with the Plant Variety Protection Act
(PVPA), which covered sexually propagated crops. However, an intriguing
exclusion of a small class of crops — known as the “soup vegetables,” which
included okra, carrots, celery, tomatoes, peppers, and cucumbers — provides a
useful lesson for our current transition. The soup vegetable exclusion from the
PVPA resulted from a concerted lobbying effort by an industry sector that feared
proprietary protection would inhibit research and lead to increased vegetable
costs. In practice over the following decade, however, the protected crops
were the subject of increased research and development, with resulting yield
and quality enhancement without unacceptable price increases. In 1980, an
amendment to the PVPA was passed in which certificate protection was ex-
tended to cover the previously excluded soup vegetables. The lesson learned
through a decade of practical experience was one that had already been learned
in other industries: effective proprietary protection serves both the agricultural
industry and consumers by enabling equitable value distribution for product
innovations.
Proprietary protection for crops and animals was further extended when it
was determined that utility patent law, which is distinct from the PVPA, can be
applied to living organisms. Utility patents address products or processes that
are novel, non-obvious, have a defined utility, and are clearly described to the
general public, rather than maintained as trade secrets. The extension of utility
patent law to engineered plants and animals came about through two landmark
court rulings. In Chakrabarty v. Diamond (1980) it was determined that specific
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claims covering engineered oil-degrading bacteria were allowable under utility
patent law, because significant human intervention was required to generate
the product. This case first clarified that newly created living materials were to
be considered patentable products under utility patent law. The relevance to
agriculture was further extended in a second case, ex parte Hibberd (1985),
where it was determined that corn varieties with enhanced amino acid profiles
were patentable under utility patent law in addition to what PVPA protection
otherwise afforded. The effect of those two rulings was a dramatic escalation of
patent filings addressing all aspects of biotechnology. The applications cover
many now routine processes such as the use of DNA markers to streamline
breeding programs, technologies to make and transfer genes, and the resulting
engineered plants, seeds, and transgenic animal products from biotechnology.
Many early biotechnology patents have been issued, but still more remain
under prosecution. Concerns have been raised by various parties over the
number of new patents and the nature of claims that have emerged, based on
fears that agricultural biotechnology patents might impede research and delay
future product development. The current concerns are not unlike those which
led to the soup vegetable exclusion from the PVPA of 1970. Once again, we
can expect to find those fears to be unfounded. Research is proceeding in
both academia and industry at a rapid pace, and there has been no effort from
industry to extract value from research licenses to academia for the new tech-
nology. Indeed, many of the dominant patents in biotechnology are controlled
by academic institutions, and license revenues are contributing support for
academic research programs. Industry is effectively adjusting to the requirement
for patent licenses, and launches of valuable new products have been initiated
without inappropriate deterrence from licensing or litigation. The global
management of patents is far more unsettled, and it will be many years before
consistency emerges, particularly in nations that have not historically protected
intellectual property.
The experience from other technology arenas is being followed in biotech-
nology — early patents addressed broad enabling concepts; later inventions are
considerably more limited in scope. This is due to the requirement for novelty
in inventions, and as technologies mature it becomes more difficult to achieve
substantial advances that previously have not been disclosed to the public. The
outcome of this maturation process is that broad patents influence industry
development in the early years, while the more limited patents sustain long-
term product advancement of the industry. What is unusual in agricultural
biotechnology is that many of the most powerful patent applications, filed
early in the last decade, still remain under prosecution due to lengthy delays
imposed by prosecution backlogs and patent interference proceedings. These
dominating patents will have strong influence on the shaping of our industry
over the next two decades.
CAPTURING VALUE FROM BIOTECHNOLOGY
Genetic engineering of plants and animals is now well underway, with the
essential technology components in hand to develop real products. Gene design
and delivery technologies continue to be refined, useful genes for agronomic
and production traits are being unveiled in increasing numbers, and product
development is now the primary goal of our industry. However, the emergence
of the first new products presents a series of complex issues to the industry
regarding marketing and value capture.
The agricultural industry has historically been comprised of distinct seg-
ments including seed providers, growers, processors, distributors, and
consumer outlets. We have generally relied on the passage of commodity
materials from the farm, through processors, and on to consumers in distinct
steps that capture increasing incremental value as the refined agricultural
materials approach the end-user. A modern trend toward larger farming
operations and vertical integration, combining processing and distribution,
has been driven to date by economies of scale and other efficiencies provided
by channeled flow of materials through a controlled development pathway.
However, as biotechnology adds increasing value directly to germplasm, it will
catalyze a series of changes in industry value-capture paradigms, which will
lead to a more comprehensive transition toward identity preservation of crops
from seed to consumer.
For agriculture to be successful, products and services must have both a tan-
gible value and a mechanism to capture and return that value to product and
service providers. It is common to exchange value at the farm gate through sale
of germplasm and chemicals to growers at the processor level, where growers
receive compensation for their agricultural produce in return for deliverables to
the processor, and at the level of end-users, where processors and distributors
receive monetary value from consumers. Biotechnology is now promoting the
shift of a substantial component of crop value directly into the germplasm, but
this comes at a substantial development expense. Herbicide resistance, pest and
pathogen resistance, and various other traits of value to growers, processors, or
consumers are already entering the marketplace in the form of new germplasm.
These first product examples each involve genes encoding relatively simple,
single-gene traits. The traits now being delivered are conceptually consistent
with traits which have current market value. However, new mechanisms must
be devised to allow payment to be equitably captured and diverted from grow-
ers, processors, distributors, and consumers to compensate developers of the
novel germplasm.
Herbicide-resistant crops should enable growers to use more effective,
ecologically sound and economical herbicides than are currently at their
disposal. However, for such products to be effective in the marketplace, the
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grower must receive a tangible advantage through enhanced productivity and
decreased chemical expenditures. It is then reasonable to expect that a portion
of the financial savings seen by the grower would be shared with the provider
of the novel germplasm. This issue takes on still greater significance when
insect-resistant crops are considered. Herbicide resistance shifts farm input
expenditures from one chemical product to another, but insect resistance very
substantially reduces overall expenditures for purchased chemicals and thereby
generates much higher potential savings to the grower. The sharing of this
savings with germplasm developers can be accomplished through either pay-
ment of a premium on seed sales, or as a direct licensing payment to the
developer of the novel trait. However, such equitable value sharing is incon-
sistent with past industry practices that permit growers to save their own seed
for planting in subsequent years, a practice that would naturally limit compen-
sation delivered to those who initially created the novel germplasm. There are
now legal restrictions against the reuse of saved seed where the materials are
covered by utility patent claims, but industry acceptance must still be achieved.
If such compensation cannot be reliably returned to germplasm developers,
new cost-saving products will less likely become available to growers in the
years ahead.
FASTER PRODUCT DEVELOPMENT
Biotechnology will contribute to the streamlining of product development
cycles, or “cycle time,” in an industry where advancement has been generally
slow and methodical. Plant and animal traits, which in the past were objectives
of classical breeding programs, are already being generated in considerably
shorter time frames through the use of gene mapping and tracking. Where
formerly it may have been necessary to visually observe phenotypic traits in
populations of progeny following genetic crosses, it is becoming routine to
employ linked DNA markers to screen large numbers of progeny at an early
stage of development — even in seed prior to planting — thereby limiting
grow out to only the desired progeny. Analysis of the content of donor genome,
relative to the recipient, and selection of the most advanced progeny, enables a
more rapid introgression in far fewer breeding cycles. Thus, the rate of progress
in development of new germplasm has already accelerated, and commercial
products will become outdated more rapidly as replacements reach the market
in shorter time frames. The shortened product-life will necessitate more effec-
tive value-capture mechanisms than in the past.
The physical transfer of genes encoding new traits provides a very powerful
tool to further shorten the product development cycle. For example, in pro-
grams at Agracetus we have refined “gene gun” DNA delivery technology to
achieve delivery of genes directly into seed of commercial crop varieties. This
enables the direct germination of transgenic plants without the need for tissue
culture, thereby avoiding a process that both delays initial plant development
and limits gene transfer to only those varieties which can be managed in cul-
ture. Our first transgenic plants, in elite commercial varieties, reach maturity
within five months of project initiation and do not require time-consuming
back crossing. Because genes encoding new and desirable traits can readily be
moved across species boundaries, exceptionally diverse crop characteristics can
now be generated in a single growing season.
There are many potential advantages of such rapid product development,
but industry adaptation necessary to successfully manage these new capabilities
will be complex. This is exemplified in a second example, in which Agracetus
scientists have undertaken gene transfer programs to genetically engineer a
stronger cotton fiber, a trait that has historically been subject to premium pric-
ing and has been a long-term breeding target. The advantages of increased fiber
strength are found at various levels of the fiber industry, from processing steps
to consumer satisfaction. Stronger fiber is able to undergo more rapid pro-
cessing without breakage as the thread, yarn, and cloth are mechanically con-
structed, and the faster product through-put enabled by stronger fiber converts
to immediate savings on expensive capital equipment. In later processing steps,
where the chemical and mechanical processes used to “finish” fabrics weaken
fiber, a stronger fiber helps retain the durability characteristics that are valued
by consumers.
Through classical breeding, the average strength of cotton fiber across the
industry has been increasing at a relatively constant rate of 1.5 percent per year,
with a cumulative strength increase of 16 percent achieved from 1980 to 1991.
However, we are now able to use genetic engineering to dramatically increase
the strength of cotton fiber with the addition of genes from other organisms.
In our recent research project, the strength of the major upland cotton variety
was increased by more than 60 percent with a single transferred gene. This
represents a strength enhancement equivalent to 30 years of classical plant
breeding in a fraction of that time, and the fiber strength achieved now exceeds
the current premium system for fiber strength. Identity preservation of such
specialty fibers or an altered premium structure will therefore be needed if
exceptional value is to be captured. The industry has effectively adjusted to
incremental improvements in many characteristics such as fiber strength and
length, but must now consider the economic implications of more dramatic
quality changes in shorter time frames. In the fiber industry, and in many other
areas where crops are utilized, this will entail a more frequent evaluation of
processing technology to efficiently take advantage of new inputs. The capital
infrastructure for utilization of agriculture will need to become more flexible in
order to accept radically new and varied materials enabled by biotechnology.
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NEW PRODUCTS, NEW MARKETS
The ability to bring in new genes from different organisms further enables de-
velopment of novel agricultural products, including products that will extend
existing markets and those that will lead to entirely new business opportunities
for agriculture. A second cotton fiber concept from Agracetus offers one ex-
ample of a product that extends an existing agricultural product line. Our
intent in this program is to improve, beyond the capacity of existing cotton
germplasm, the dye-ability, chemical reactivity, absorbency, and structural
dynamics of fiber (such as shrinkage and wrinkle resistance). Already de-
veloped through this program are fibers that contain polyester in the fiber
core, and we have found that some of the more desirable characteristics of
petroleum-based synthetic fibers are imparted to the “natural” cotton fiber.
Similar programs to extend the current limits of materials derived from other
crops are underway in many other laboratories where oil, starch, and protein
alterations are being advanced beyond the capacity of existing germplasm. The
revision of plant products in this manner, by bringing in genetic information
from one organism to another, thus represents a broad opportunity to expand
current plant product markets. However, such new products will require sig-
nificant adjustment in processing practices and market structure to enable value
capture from traits not routinely monitored by the industry today. Sale of trans-
genic seed to growers at a premium price will not be sufficient, even as pro-
prietary protection becomes accepted, because the grower has no means to pass
on costs downstream to processors. The outcome will be an additional push
toward vertical integration, which will facilitate the channeling of identity-
preserved products from the field to dedicated processors, and then on to the
consumer.
The use of gene transfer between organisms also enables development of en-
tirely new agricultural uses, such as the Plant Bioreactor Program of Agracetus.
In this project, crops are used as production vessels to economically produce
large quantities of new biological materials. It has long been recognized that
plants provide the world’s most economical supply of proteins and complex
secondary metabolites, but historically the diversity and concentrations of
these materials were limited to what was found in nature or developed by man
through classical plant breeding. Gene transfer now enables the engineering
of crops to produce more of the valuable chemicals that are already found in
some species, and also new materials currently derived from other sources.
Targets of Plant Bioreactor Production include many high value biological
products destined for industrial, food, feed, and even pharmaceutical appli-
cation. Genetically engineered crops for each of those markets are currently
in development in a number of laboratories worldwide, and early product
candidates are already in field trials. Because the crops will require special
handling in the field, dedicated processing, and delivery to specific end-users,
vertical integration will clearly be a favored trend.
SUMMARY
Biotechnology represents a powerful new tool for plant and animal breeding,
and the application of this technology will lead to new products and new uses
for agriculture. This technology enables very rapid product development. The
increased speed of accomplishing genetic improvements also condenses product
development expense into much shorter time frames. These issues will neces-
sitate changes in industry practice to ensure that appropriate value can be
captured for the increased contribution of genetics as a component of final
product value. Historically, high quality genetics have been critical to agricul-
tural progress but have not fared well in capturing a significant portion of final
product value. Paper packaging now captures greater value than the grain in a
box of breakfast cereal. New paradigms for value capture will therefore evolve
to more equitably distribute value from consumers to those participants earlier
in the development path. The key industry changes to achieve this will be clari-
fication and enforcement of a strong system for intellectual property protection,
and vertical integration of the industry to coordinate value exchange from
germplasm provider to consumer. While the most exciting aspect of bio-
technology application to agriculture will be novel products and new uses
for crops, even commodity agriculture will be affected by broad changes in
industry management of crop value.
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As biotechnology develops, we could see the advent of biological pollution,
which could be more dangerous than nuclear or chemical pollution.1
Monsanto’s agricultural biotechnology provides improvements in quality and
yield of crops, and benefits the environment where crops are grown.2
Agricultural and environmental applications of modern biotechnology have
spurred considerable controversy about their environmental risks and potential
to alter the environmental impacts of other technologies and practices, such
as pesticide use. The range of biotechnology products under development is
expanding rapidly, and thus the potential for controversy over the environ-
mental effects of biotechnology products is also increasing.
The purpose of this paper is to examine environmental issues associated
with novel genetically engineered organisms being developed for agricultural,
pharmaceutical, and environmental applications. First, I will consider the pur-
poses of these novel biotechnology products and whether environmentalists
view these products as environmentally beneficial. Second, I will consider
the environmental risks of these novel biotechnology products. Third, I will
examine one novel regulatory approach to managing environmental impacts
of one category of biotechnology products.
REBECCA GOLDBURG
Environmental Defense Fund
New York, N.Y.
Novel Crops and Other Transgenics: How
Green Are They?
1Martin Khor. 1994. Why we need a Biosafety Protocol urgently. Third World Resurgence 48:20.
2Monsanto press release. Monsanto receives final regulatory approval for commercialization of insect-
protected cotton. October 31, 1995.
ARE NOVEL BIOTECHNOLOGY PRODUCTS GOOD FOR THE ENVIRONMENT?
Biotechnology products frequently are touted as environmentally beneficial.
Even in the face of such claims, however, it is unclear to many environmen-
talists whether biotechnology products will be good for the environment. In
part, this is simply because of the increasingly varied nature of biotechnology
products, which range from industrial chemicals to transgenic animals. It is
unreasonable to expect that as a class, biotechnology products will be “good”
or “bad” for the environment. But even individual biotechnology products or
types of biotechnology products face skepticism from the environmental
community, for at least two reasons.
The first reason is that the environmental community has grown wary of
environmental claims in general. As public support for environmental pro-
tection has grown, corporate environmental claims for products have become
more common. Unfortunately, these claims are not always legitimate. Plastic
supermarket bags, for example, sometimes are touted as “ecological,” even
though the bags are not made from recycled materials and customers frequently
dispose of the bags after one use. The practice of telling consumers that par-
ticular products are good for the environment, even when their environmental
benefits are dubious, has become so common that the environmental com-
munity has given this practice a special name: greenwashing. As greenwashing
has become common, so has legitimate skepticism of environmental claims —
including claims for biotechnology products.
Second, skepticism about environmental claims for novel biotechnology
products is also based on past experience with hype concerning the potential
of biotechnology. In the past, for example, biotechnology’s promoters have
promised that fertilizers will become unnecessary as crops are engineered to
fix their own nitrogen, and that pesticides will become obsolete as crops are
engineered to resist insects and other pests. Those unrealistic claims have
spurred general caution about environmental promises for biotechnology
products.
As a specific illustration of the environmental community’s response to
biotechnology products, consider bioremediation, a technology that has been
promoted heavily as one way in which biotechnology will aid environmental
protection. Most environmentalists support the concept of bioremediation —
harnessing natural processes to degrade hazardous chemicals. Nevertheless, the
environmental community has not rushed to embrace bioremediation as the
solution to problems with hazardous wastes.
In part, this response is based on the potential of environmental “snake oil”
to be disguised as a legitimate bioremediation product. Following the oil spill
from the tanker Mega Borg off the coast of Texas in 1990, for example, one
Texas company promoted heavily the success of its bioremediation product —
bacteria that supposedly “eat” oil on the surface of the ocean. According to a
report published by the Texas General Land Office, these bacteria largely
dissipated an oil slick from the Mega Borg in just seven hours, with portions of
the slick breaking up in just 30 minutes. The speed of this degradation is diffi-
cult to believe, especially given that the experimental design had no replication
of treatment and control areas, and because the oil in the treatment area simply
may have been dispersed by wind and water. The relatively low cost of such
bioremediation techniques makes them attractive to government agencies and
companies that must remediate waste, but also signals caution to many envi-
ronmentalists. Reliance on inexpensive but unproved bioremediation products
could cause considerable environmental harm if the result is that more effica-
cious cleanup methods are not used.
Not just skepticism, however, has caused bioremediation’s relatively low
profile in the environmental community. Many environmentalists are now
focused on pollution prevention rather than remediation of wastes. Changing
industrial processes to minimize the amount of waste produced is regarded as
the best way to end the problems caused by chemical wastes. Over the long-
term, biotechnologists may do more for the environment by developing novel
enzymes and other tools that allow the redesign of industrial processes, than by
developing bioremediation methods.
DO NOVEL BIOTECHNOLOGY PRODUCTS POSE NOVEL RISKS?
As of May 1996, government records indicated that in the United States there
had been about 3,500 field tests of genetically engineered plants, 50-100
field-tests of genetically engineered microorganisms, and two field-tests of
genetically engineered fish. These numbers continue to grow, involving an
ever greater diversity of genetically engineered organisms. I will examine
the environmental risks associated with genetically engineered products, as
these risks apply to species or taxa that only recently have been genetically
engineered.
Crop plants: Within the predominant group of engineered organisms —
plants — the range of species being field-tested until recently has been rela-
tively narrow. As of March 1993, about 85 percent of field-tests of genetically
engineered crops were of six species: corn, cotton, tomatoes, potatoes,
soybeans, and tobacco. However, the diversity of crops being genetically
engineered has increased substantially: transgenic varieties of more than 40
different crop plants have now been field-tested in the United States. These
include fruits and vegetables such as cranberries, papayas, raspberries, and
radicchio; ornamentals and turf plants such as chrysanthemums, gladioli,
petunias, and creeping bentgrass; and trees such as poplars, spruce, and
sweetgum. Moreover, the range of traits being introduced to crop plants is also
increasing. Along with insect, disease, and herbicide resistance — the traits
most commonly introduced to crops — a number of crops are now being
engineered to produce pharmaceuticals, polymers, and industrial enzymes,
and to alter oil, starch, and protein contents.
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The prominent ecological risk associated with crop plants is that they will
transfer, via pollination, their acquired genes to related wild or weedy plants,
or to other cultivated non-transgenic varieties of the same crop. How will these
gene transfer risks apply to the wider range of crop varieties now under
development?
The answer to this question is not straightforward. Gene transfer to wild
or weedy-related plants may pose both lower and higher risks. The primary
concern about such gene transfer is that the transferred genes may encode a
trait that confers a selective advantage. Populations of wild or weedy plants
that acquire the trait may increase to the extent that they become an ecological
or agricultural nuisance. Acquired traits for insect, disease, and herbicide
resistance — the traits that have long dominated genetic engineering of crop
plants — realistically could confer a selective advantage to a wild plant. How-
ever, it is difficult to envision many other traits now being engineered into
crops, such as production of pharmaceuticals, polymers, and industrial
enzymes, and altered oil, starch, and protein content, as conferring a selective
advantage to a wild plant. Therefore, transfer of such traits to wild or weedy
plants generally should pose low risks.
On the other hand, the wider diversity of plant species now being engineered
could increase the likelihood of gene transfer to wild or weedy plants. Concerns
about gene transfer by most of our major crops — the traditional focus of
genetic engineering efforts — are minimal in the United States. Most of these
crops originated in other areas of the world and do not have wild relatives in
the United States. Genetic engineers, however, now are focusing increasing
attention on plants such as forest trees and ornamentals that have wild popu-
lations in the United States. Many of these plants readily can transfer their
acquired traits to wild relatives, and thus have the potential to pose significant
gene transfer risks.
Gene transfer from transgenic varieties to cultivated non-transgenic varieties
of the same crop on average may pose higher risks than in the past. Gene trans-
fer to cultivated, non-transgenic varieties to date has not been a focus of great
concern, because most introduced genes are intended for use in food crops and
are intended to be safe for consumers. For example, consumers likely would
not be exposed to significant health hazards if a small percentage of a corn crop
acquired a herbicide-resistance gene from a transgenic corn growing nearby.
(One important exception to this generalization would be the transfer of
genes encoding substances that are safe for most consumers, but allergenic
for a minority of consumers, which would pose a serious risk for the allergic
minority.)
In contrast, genes encoding pharmaceuticals or industrial chemicals are not
intended to be used in foods, and expression products of such genes could pose
health hazards to consumers. Transfer of such genes from transgenic to non-
transgenic varieties could contaminate food derived from the non-transgenic
varieties, posing health risks to consumers.
Fish: Sharp declines in wild fish stocks and new technologies have created
strong economic incentives for aquaculture (fish farming). In the United States,
aquaculture production more than doubled between 1984 and 1993, and
aquaculture is now the fastest growing segment of agriculture. Worldwide,
aquaculture is growing by about 10 percent each year. Farmed shrimp, for
example, now are more than 30 percent of the world shrimp supply.
Interest in engineering aquatic organisms for aquaculture is growing rapidly,
potentially creating new environmental risks. One United States company, AF
Protein of Newton, Mass., has approached the United States Food and Drug
Administration for approval to commercialize Atlantic salmon engineered to
produce a growth hormone from chinook salmon. According to AF Protein,
their transgenic salmon fry grow 400-600 percent faster than their non-
engineered kin.
Such transgenic fish arguably pose some of the greatest risks of any type of
transgenic organisms. Aquaculture facilities are notoriously leaky. Data from
waters off Scotland’s Faroe Islands, for example, indicate that as many as 48
percent of the salmon caught by commercial fishermen have escaped from
salmon farms. In general, fish escaped from aquaculture facilities are reasonably
likely to survive and breed with natural fish populations, because most fish
have not been debilitated significantly by domestication. Therefore, transgenic
fish readily may transfer their engineered traits to wild fish populations, where
these traits might spread via natural selection. Having acquired an advan-
tageous trait, fish then could affect populations of other aquatic organisms —
for example, by competing for food. These sorts of ecological effects are of
concern particularly because considerable experience with introductions of
“exotic” fish from other geographic areas suggests that aquatic ecosystems are
highly vulnerable to ecological disruptions.
Invertebrates: Recently, a number of invertebrate species have been engi-
neered for the first time. In 1996, the USDA received the first applications for
field tests of transgenic mites and nematodes. In aquaculture, shrimp and
mollusks were first reported as transformed. Ecological risks posed by intro-
ductions of transgenic invertebrates have only begun to be examined. Those
risks especially merit scrutiny because many invertebrates are highly mobile
at certain life stages and have extremely high reproductive rates, and because
transgenic invertebrates readily may interbreed with wild conspecifics.
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NOVEL REGULATORY APPROACHES TO MANAGING ENVIRONMENTAL
IMPACTS OF AGRICULTURAL BIOTECHNOLOGY
Innovative new regulatory approaches may help our society better manage the
environmental risks and controversies associated with an expanding universe of
biotechnology products. One potentially helpful regulatory tool is conditional
registration of pesticides. For some products, conditional registrations may
strengthen environmental protection while providing significant advantages
for regulators and manufacturers.
In order to market a pesticide in the United States, the substance must be
registered by the U.S. Environmental Protection Agency (EPA) under the
Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). In general, a
company submits considerable data to the EPA concerning the human health
and environmental impacts of their product. Based on these data, the EPA
decides whether to register the pesticide. If the EPA chooses to conditionally
register a pesticide, the agency continues to require the submission of data over
a certain time period after the pesticide is commercialized.
FIFRA was originally amended to allow conditional registrations in order to
eliminate a double standard that arose as a result of increased data requirements
under the statute. Conditional registrations enabled the EPA to allow manu-
facturers to start selling a pesticide while working to fill data gaps, as long as
the EPA determined that the conditional registration would not increase sig-
nificantly the risk of any unreasonable adverse effect on the environment.
The EPA’s use of conditional registrations took an unprecedented turn
in March 1994, when the agency granted a landmark registration to two
agrochemical companies — Monsanto Company and Zeneca AG — for the
herbicide acetochlor. The EPA conditionally registered acetochlor on the basis
of arguments by the herbicide’s manufacturers that the availability of acetochlor
would greatly reduce overall herbicide use on midwestern corn crops. Amid
considerable controversy, the EPA weighed the manufacturer’s arguments for
environmental benefits against other evidence that acetochlor is carcinogenic
and may leach into ground water. Taking an unprecedented step, the EPA
registered acetochlor, but established a number of conditions for continuing the
registration beyond an initial five year period. Monsanto and Zeneca must
document promised decreases in herbicide use and must fund programs to
monitor ground water and surface water for acetochlor contamination. If the
companies do not meet these conditions, the EPA will cancel the pesticide’s
registration.
The EPA subsequently issued several conditional registrations involving
genetically engineered crops. In May 1995, the agency conditionally registered
bromoxynil for use on cotton that was genetically engineered to tolerate this
herbicide. This registration was highly controversial because bromoxynil is
absorbed through the skin and is a reproductive toxin, thus posing health risks
to farm workers. However, bromoxynil’s manufacturer argued that use of
bromoxynil-tolerant cotton would lead to a decrease in overall use of more
hazardous herbicides on cotton. Similar to acetochlor, the EPA conditioned
bromoxynil’s registration on the requirement that the manufacture substantiate
its claims of a net environmental benefit.
Later in 1995 and in 1996, the EPA conditioned registrations of corn and
cotton genetically engineered to express insecticidal Bt toxins from bacteria.
Preparations of naturally occurring Bt bacteria already are used as a safe
insecticide on relatively limited acreage by both conventional and organic
farmers. Many scientists are concerned that genetically engineered Bt crops
will be planted widely, leading insect pests rapidly to evolve resistance to Bt
toxins, and rendering Bt useless in both genetically engineered crops and as a
natural insecticide. The EPA conditionally registered Bt corn and Bt cotton to
require that the crops’ manufacturers establish programs to prevent or slow the
evolution of insect pests’ resistant to Bt.
Recent conditional registrations are distinct from previous conditional regis-
trations in the scope and kind of data they require. They are not appropriate
for all products, because they involve some extra time and effort on the part
of agency and company staff. However, they can be a “win-win” regulatory
solution in certain situations. Conditional registrations have at least four
compelling advantages:
1. Conditional registrations build into EPA’s regulatory program for
pesticides powerful new incentives for companies to evaluate
carefully and honestly the environmental implications of their
products. If a company cannot document within a specific time
period the performance it promises for a pesticide — e.g. that
Bt-resistance will not evolve — the company’s registration may
be canceled.
2. The fact that companies must document their claims, which other-
wise are easy to exaggerate, should give regulators considerable
new confidence in the information companies provide and should
boost shaky public confidence in regulatory decisions concerning
pesticides.
3. Manufacturers should gain from the EPA’s formal consideration of
a company ‘s environmental performance predictions that now are
not generally considered as part of the registration process.
4. Manufacturers gain orderly decisions allowing the commercial-
ization of controversial products that otherwise might be tied up
in lengthy regulatory debates.
In short, conditional registrations are not a panacea. They have the potential,
however, to enable the EPA to establish strong incentives for companies to
develop pesticides that provide net environmental benefits and to practice
environmental stewardship in the management of pesticide products.
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CONCLUSION
The expanding universe of biotechnology products will broaden the range of
environmental risks and controversies associated with biotechnology products.
However, the diversity of new products means that while some will become
the focus of new concern and debate, others may arouse little interest from
environmentalists. Innovative new regulatory approaches are one way in
which our society may manage better those products that spur environmental
controversies.
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Twenty years ago, consumers only ate fruit that was “in season.” Fruit was not
shipped long distances and supply was dependent on local production areas.
Demand for year-round, inexpensive produce has led to consolidation of pro-
duction where temperatures are warm, sunshine is plentiful, and labor is cheap.
In most cases, produce is now shipped long distances before being consumed.
Tomatoes grown in Mexico are trucked 3,500 miles, bananas grown in Ecuador
travel 6,000 miles on a boat, bell peppers from Holland greenhouses are flown
5,000 miles to market. Unfortunately, fruit was not designed to be shipped long
distances. In order to make it to market, fruit is picked before it is ripe (and
before it has any taste). Despite harvesting immature fruits, post-harvest losses
of fruits and vegetables still exceed 25 percent of crop production and the fruit
that makes it to market has often been described as tasteless.
STRATEGIES FOR FLAVOR AND SHELF-LIFE IMPROVEMENT
Flavor can be addressed by increasing intensity (concentration) of an impor-
tant chemical component of flavor. This can be accomplished by increasing
production of a specific compound (e.g., sucrose), by shifting the balance of
compounds (glucose versus sucrose), or by blocking production of undesirable
compounds (such as starch). Genes have been isolated to explore increased
sweetness. These include sucrose phosphate synthase (increased sucrose),
invertase (interconversion of sugars), and ADPG-pyrophosphorylase (sugar
to starch conversion).
Genetic Engineering of Flavor and Shelf Life
in Fruits and Vegetables
DAVID A. EVANS
DNA Plant Technology Corp.
Oakland, Calif.
Alternatively, flavor can be improved by delaying harvest until the fruit is
ripe. Greater firmness or reduction in ethylene production can permit fruit to
be retained on the vine until ripe, when it has achieved full flavor potential.
Increased firmness through regulation to decrease fruit softening enzymes has
met with limited success to date. Control of ethylene content appears to be
more promising. Ethylene controls ripening and rotting in many fruits and
vegetables. By reducing ethylene concentration in fruit, it is possible to arrest
development of the fruit and permit the fruit to remain on the vine until ripe.
CASE STUDY: ETHYLENE REGULATED TOMATOES
Technology
Tomato fruits produce ethylene in high concentrations during ripening. There
is a burst of ethylene production, called the climacteric, that occurs when the
tomato fruit begins to turn from green to red (Grierson and Covey, 1988). The
increased concentration of ethylene in tomato fruit is associated with color
development, fruit softening, increased respiration, and sugar accumulation.
Ethylene is a simple chemical. Its biosynthesis is understood well and the genes
that are required for biosynthesis have been identified. In addition, genes have
been identified that degrade intermediates in ethylene biosynthesis.
Ethylene formation is the result of a three-step biosynthetic pathway
(Imaseki, 1991): Methionine is converted to S-adenosyl-L-methionine (SAM)
by the enzyme methionine adenosyltransferase. SAM is converted to 1-amino-
cyclopropane-1-carboxylic acid (ACC) by the enzyme ACC synthase (ACC-S).
ACC is converted to ethylene by the enzyme ACC oxidase. Genes encoding
the enzymes involved in biosynthesis (ACC synthase and ACC oxidase) have
been identified, isolated, and cloned. It is possible to use techniques to block
expression of those genes, thereby blocking or reducing biosynthesis of ethy-
lene. Alternatively, enzymes have been identified in microorganisms or viruses
that metabolize the intermediates in ethylene biosynthesis. These include ACC
deaminase, an enzyme capable of degrading ACC, and SAM hydrolase, an
enzyme capable of degrading SAM.
The process for developing genetically engineered plants with reduced
concentrations of ethylene in the fruit is complicated and requires several
technologies that have been developed over the past twenty years. These
technologies include gene introduction into plants, selection of transformed
cells, regeneration of plants from genetically transformed cells, and gene
expression.
Commercial Opportunity
The principle commercial benefit of ethylene-regulated tomatoes is long shelf-
life. Tomatoes blocked for ACC-synthase can survive in laboratory conditions
for 90 days. At DNA Plant Technology Corp., we completed commercial tests
on a hybrid tomato variety that was blocked for ACC-S using Transwitch™
technology. In commercial tests, these ethylene-regulated tomatoes have a 40
day shelf-life. This includes harvest, five to seven days ethylene treatment to
complete color development, five to seven days to ship to market, five to seven
days storage in the local market at a repacker, seven days in the supermarket,
and 10 days with the consumer prior to consumption. This contrasts with the
maximum of 20 days for current commercial tomato varieties.
The current commercial system works as follows (How, 1991):
1. Growers harvest a tomato field two or three times during a season.
All tomatoes (unless red ripe) are harvested.
2. Tomatoes are brought from the field to a packing shed where they are
sorted by size and color. Tomatoes with some red color are usually sold
at a discount price in the local market because they are already beginning
to soften and will not survive trucking over long distances. The 90+ per-
cent green tomatoes are placed in 25 pound boxes and treated for one to
three days with 100-150 ppm ethylene, then trucked to a repacker at a
local market.
3. Upon receipt, the repacker sorts tomatoes for color. Tomatoes that
developed color in transit are shipped to supermarkets (or food service
outlets) immediately. The remaining tomatoes receive an additional two
to seven days of ethylene treatment and then are shipped to market.
Extended shelf life provides a distinct advantage throughout the chain of
commercialization.
Grower: The ACC-S regulated tomato reaches full size and flavor potential,
begins to degrade chlorophyll, but does not turn red in the field. At this stage,
the tomato can remain in the field for several weeks without rotting or soften-
ing. This attribute affords the grower two benefits. First, all the tomatoes are
harvested, i.e., no over ripe tomatoes are left in the field. This increases field
yield per acre. Second, harvest costs per pound are lower because fewer total
harvests are required.
Packer: Over-ripe tomatoes are sold at a discount in local markets (Florida,
California, and Mexico). Because all the ACC-S regulated tomatoes that are
harvested can be shipped to remote markets, revenue per pound is increased.
In addition, tomatoes left on the vine generally increase in size. Large tomatoes
command an average premium price of four to six cents per pound.
Repacker: When tomatoes arrive at a repacker they are sorted based on stage
of ripeness. Losses at the repacker range from six to ten percent of tomatoes
shipped from production areas. These are discarded tomatoes that have rotted
in route or are showing signs of impending deterioration. Ethylene-regulated
tomatoes are superior, with decreased losses.
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Retailer: Because current tomatoes rot in two to three days at retail, orders
and shipments are made daily by most large supermarkets. Loss due to rotting
can reach 20 percent of product at the retail store level. Both issues are ad-
dressed by a long shelf-life tomato. Moreover, better tasting tomatoes can be
sold at a premium price, resulting in increased revenue and profit per square
foot in the produce section of the supermarket.
Consumers: Because ethylene-regulated tomatoes are left on the vine until
they reach full maturity, the consumer purchases a better tasting tomato.
Moreover, there should be a significant reduction in the number of rotten
tomatoes in consumer homes.
The commercial potential of a better tasting, longer shelf-life tomato that is
sold at a premium price can be quantified as follows:
INTELLECTUAL PROPERTY
The technology that is required to make an ethylene-regulated tomato is the
subject of several patents and represents a mine field that must be successfully
navigated prior to introducing a product to market. The present intellectual
property situation is as follows:
Germplasm: Nearly all commercial acreage of fresh market tomatoes is
grown using proprietary seed developed by a seed company. The open polli-
nated, publicly available varieties (e.g., Rutgers, Floradade) cannot compete
with current hybrid varieties in yield and disease resistance, hence genetically
engineered open pollinated varieties are not commercially viable. As proprietary
seed is controlled by seed companies, relationships must be negotiated with
seed companies to obtain access to parental seed for genetic engineering. The
largest tomato seed companies are Seminis, Ferry Morse, and Sun Seeds. Other
companies with breeding capability have developed proprietary tomato germ-
plasm using breeding or cellular genetics (Morrison and Evans, 1996). In
addition to hybrids and the protection inherent in segregation of hybrid seeds,
most companies also seek Plant Variety Protection Certificates on one or both
of the hybrid’s parents. Those layers of protection, along with seed production
capability, assure seed company involvement in commercialization of geneti-
cally engineered tomatoes.
per 100 lbs. harvested standard ethylene controlled
Revenue $20.00 $60.00
Costs $16.00 $38.00
Margin $ 4.00 $22.00
Margin % 20% 37%
Gene Introduction: There are two methods available for gene introduction
in tomatoes. Agrobacterium tumefaciens-mediated gene transfer is the preferred
method. Agrobacterium plasmids are modified to incorporate desired promoters
and genes and the natural infection behavior of the bacterium is used to deliver
the DNA into plant cells. Broad claims have not been issued on this technology.
However, several components of this technology, such as the use of binary
vectors, are the subject of patents. A secondary gene introduction method is
ballistics. Ballistics uses some method to shoot DNA into plant cells. Variations
on the type of microprojectile and the acceleration device have been optimized
during experimentation for different crop plants and likely would need to be
optimized for tomatoes. DuPont Corp. has claims in a U.S. patent that are
directed to the ballistics technology. Other patents are issued or pending on
various modifications of the ballistics approach for specific plant species.
Plant regeneration: Regeneration using standard tissue culture methods is
routine in tomato. The method using leaf pieces of tomatoes as explant material
has been used in several laboratories since the early 1980’s. No broad patents
cover the commonly used techniques for tomato regeneration.
Promoters: A wide range of promoters have been identified that will express
DNA in plants. Some of these, including 35S, derived from cauliflower mosaic
virus, are the subject of issued or pending patents (Fraley, et al., 1994). Much
effort has been directed to isolation of tissue-specific promoters. Fruit-specific
promoters in tomato would be ideal to ensure that ethylene regulation is
directed to the tomato fruit and to ensure that ethylene production (involved
in disease resistance) is not blocked in leaf and other tissue.
Selectable markers: Markers are foreign genes that are inserted into target
plant cells at the same time as a segment of DNA that can modify ethylene.
Because ethylene regulation cannot be selected in a test tube, the selectable
marker permits transformed cells to proliferate while non-transformed cells die.
Resistance to kanamycin (conferred by the nptII gene) is a preferred selectable
marker that has received both EPA and FDA approval for use in tomatoes and
other crop plants. Kanamycin resistance is the subject of an issued patent in the
United States and a pending patent in Europe (Rogers and Fraley, 1991).
Genes: Segments of DNA can be patented in the United States. For ethylene,
patents are issued or pending on each gene that has been identified in ethylene
biosynthesis or degradation. For example, the USDA has a pending patent on
the ACC-S gene that we have used. The gene isolation work was completed at
the USDA in Albany, California (Oeller, et al., 1991). The USDA has licensed
the gene to multiple companies within different fields to ensure broad com-
mercialization of the government funded technology. Other genes have been
isolated including ACC-oxidase (Hamilton, et al. 1990), ACC-deaminase
(Klee, 1994), and SAM hydrolase (Good, et al., 1993).
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Gene expression: In order to block ethylene biosynthesis using ACC-
synthase or ACC-oxidase, the endogenous genes must be regulated to decrease
their expression. Two methods have been used in tomatoes: Transwitch®
and antisense. Transwitch® is a unique phenomenon in which some plants
resulting from transformation with a homologous gene are suppressed for the
target gene (Jorgensen, 1995). Antisense achieves a similar result, i.e., gene
suppression, by inserting a gene sequence that is complementary to the target
gene (Shewmaker, et al., 1992). Each technique is the subject of issued patents
in the United States and Europe.
COMMERCIALIZATION IMPLICATIONS
Despite the demonstrated value of ethylene-regulated tomatoes, no one is
presently in the market with such a product. This product has extremely high
barriers to entry due to the intellectual property situation. The companies
closest to market are DNA Plant Technology, Monsanto/Calgene, and Zeneca
Plant Sciences. It is likely that each party will need licenses to intellectual
property from other companies in order to successfully commercialize an
ethylene-regulated tomato. While the current patent situation presents an
additional commercialization hurdle to the three companies, it also tends
to eliminate the prospect of future new entrants developing and marketing
an ethylene-regulated tomato.
RESEARCH AND PLANNING IMPLICATIONS
Several general lessons have been learned from attempts to commercialize
ethylene-regulated tomatoes that apply to all commercial projects using plant
genetic engineering.
1. Many patents are still pending. Work initiated today using technology
developed by others may never be commercialized in the absence of
licenses. Many of the basic agricultural biotechnology patents have
not been resolved, with broad patents still possible or likely for gene
introduction and gene regulation technology.
2. In commercial or academic genetic engineering research, genes need to
be inserted into the best existing germplasm. This affords an appropriate
benchmark to value the technology and eases adoption of new varieties.
Seed company and technology-provider alliances involving universities
and research laboratories are more likely in the future.
3. The earliest product developed is not always the first to be commercial-
ized. The complex business system of fresh market tomatoes and the
complex patent situation have delayed commercialization. If a new
genetically engineered variety requires modification of growing or
handling practices, adoption is slow.
4. In a complex business system a novel trait may have multiple benefits.
The ethylene-regulated tomato provides benefits to growers, packers,
repackers, retailers, and consumers while originally targeted to increase
shelf-life.
SUMMARY
The initial hurdles for commercialization of products of plant genetic engineer-
ing included technical, regulatory, and consumer acceptance. As the first prod-
ucts are now ready for market introduction, it is obvious that an additional
major hurdle exists: intellectual property. Patents have been granted that cover
a number of basic biotechnology methods and the use of specific genes for
genetic engineering. For some technologies and genes, patents already have
been issued and represent barriers to commercialization. For other technol-
ogies, the patents are still pending and represent an uncertainty. Indications
from the first products being commercialized in cotton, corn, and soybean
suggest that patents are being aggressively enforced and are being used to
establish competitive advantage in the marketplace. Clearly, if broad patents
are upheld by the patent office and the courts, alliances and cross licenses will
be necessary for commercialization.
The modification of consumer-preferences traits could have implications
for several, perhaps unintended, steps in the chain of commercialization. For
example, ethylene regulation in tomato will primarily result in a tomato with
longer shelf-life. However, the tomato will not be red when it reaches full
maturity, can stay in the field for a longer period of time prior to harvest,
requires post-harvest ethylene treatment, and results in delivery of a better
tasting tomato to consumers. These features of the ethylene-regulated tomato
require modification of harvest practices and modification of handling and
packing procedures. Moreover, production trials and operation tests may
suggest modification of pesticide practices, staking, and handling in the field;
sorting, ethylene treatment, and shipping from the field; as well as packaging
and pricing for the retailer. Ultimately, successful commercialization of new
consumer-preference traits in fruits and vegetables requires more than simple
insertion of a gene into a plant.
D. Evans
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The rationale for utilizing plant cell culture for production in the pharmaceuti-
cal industry can be exemplified by the realities faced in TAXOL® development.
Such a case study provides the justification for Bristol-Myers Squibb’s (BMS)
investment of well over $10 million to develop this technology to the scale of
commercial production. BMS believes that other products will follow for plant
cell culture and that other new production technologies will be developed as
the need and opportunity are identified for high value products.
Plant Cell Culture Technology
M. DIANNE DEFURIA
Bristol-Myers Squibb Company
Princeton, N.J.
Why Plant Cell Culture for Pharmaceuticals?
¥ Historical success and future promise of natural products as
therapeutics
¥ Increasing constraints on bioprospecting and wild biomass
collection
¥ Emerging technologies increase utility as research tool and
feasibility for commercial use
¥ IdentiÞcation of high-value products with supply problems
Why plant cell culture in the pharmaceutical industry? You are familiar with
the historical successes and what we hope is the future promise of natural prod-
ucts with therapeutic applications. The pharmaceutical industry realizes that
there are increasing constraints on bioprospecting, as well as the collection of
wild biomass for production of natural product-based therapeutics. There are
many emerging technologies, some of which David Evans described earlier, that
have inspired people to use plant cell cultures as a research tool for drug dis-
covery, whether from direct isolation, biotransformation, or directed fermenta-
tions. BMS is the first to look at cell culture for commercial production of a
large, complex therapeutic molecule because of its high value and supply prob-
lem. The compound is paclitaxel; the active ingredient in the product, TAXOL®.
This product alone motivated a large pharmaceutical company with massive
investments in all kinds of production facilities to turn to plant cell culture —
a recent scientific development with little practical application.
A more in-depth look at the four reasons for using cell culture in the
pharmaceutical industry reveals that the full potential of natural products
in medicine has not been realized.
Seventy-five percent of the world’s population depends almost entirely on
plants to treat illness and disease. Historically, 25 percent, and now somewhat
less, of the U.S. pharmaceutical market has been based on plant-derived com-
pounds. There are the older remedies such as digitalis, but also state-of-the-art
drugs like TAXOL®. Very few of the two or three hundred species of plants have
been specifically evaluated for their therapeutic benefit, and the compounds
that have been derived are very novel, diverse, and complex. There are, un-
doubtedly, many more plant-derived compounds of medicinal value to be
identified. However, one important question arises: “Can the continued tradi-
tional screening of plant materials economically compete with new combinatorial
chemistry approaches?” The answer is not yet in, but many are betting on a
combination of the two technologies.
Success and Promise of Natural Products
¥ 75% of world population relies on plants for treating illness/
disease
¥ 25% of U.S. pharmaceutical market from plant-derived
compounds, including state-of-the-art drugs, e.g. TAXOL¤
¥ Only 2% of the >250,000 plant species have been extensively
evaluated as therapeutics
¥ Unparalleled diversity of complex, novel molecular structures
Constraints on Bioprospecting
¥ Geo-political impediments to access
¥ DifÞculty of reliable resupply
¥ Unrealistic expectations of many source countries
¥ Development vs. preservation of biodiversity, disappearance
of rainforest, extinction of many species
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The constraints on bioprospecting are many, (see Figure 3). BMS and many
other companies have screened natural products for many years. We have all
experienced the increasing geopolitical impediments to accessing new biomass
for screening. This is because of the difficulties of prospecting in countries with
underdeveloped scientific infrastructure, less stable governments, or other
constraints. The need for resupply after an interesting compound is identified
may follow years after acquisition of the original plant material. Scientific or
government personnel changes may have occurred, and access for resupply is
sometimes denied or impossible to accomplish. Many source countries have
unrealistic expectations. Plants and their genetic material have been viewed
as “green gold.” Many countries believe bioprospecting within their borders
offers a rare opportunity for economic development in a context of limited
possibilities. This view is unrealistic based on the potential discovery of a single
pharmaceutical product after 3-5 years of screening and another 10 years of
high risk development by the pharmaceutical company. In addition, there is the
need to balance the problem of disappearing rain forests and extinction of many
plant species with the need for development in source countries. As seen in
Figure 4, many technologies, from emerging genetic-engineering possibilities
to evolutionary improvements in standard research techniques, have been used
to increase the utility of cell culture at any scale.
Emerging Technologies
¥ Transgenic plants proteins (Abs, insulin)
Ñ Agrobacterium spp vectors
Ñ ÒGene GunÓ technology
¥ Improvements in analytical chemistry, robotics, and Òmicro
researchÓ
¥ Improvements in bioreactor design for enhanced mass
transfer
The last underlying reason for cell culture in the pharmaceutical industry is
identification of a high value product with limited options for facile commercial
production. TAXOL® clearly fits into this category.
High Value Products/Supply Problem
¥ SkikoninÑnaphthoquinone for skin ailments and as a dye in
cosmetic and silk industry
¥ Paclitaxel (TAXOL¤)
Ñditerpenoid for cancer therapy
TAXOL® was identified over 30 years ago by the National Cancer Institute
(NCI). They found the compound to be a drug with exciting potential for
cancer therapy, but sufficient quantities for development hindered its progress
for decades.
In the early 1960’s, an extract of Pacific yew bark was found to contain very
low concentrations of the active material. In addition, supply of the bark was
extremely limited. It wasn’t until 1971, prompted by this limited supply, that
Dr. Monroe Wall isolated and determined the structure of TAXOL®. In 1979,
Susan Horovitz identified that paclitaxel killed cancer cells in a unique way, by
binding to tubulin. Paclitaxel’s novel structure and unique mechanism of action
made it a high priority for clinical trials by the NCI.
The progress of the clinical trials was extremely slow because only 0.5
kilogram was produced over two years. Although trials were started in 1983,
it took until 1989 to demonstrate clinical activity in solid tumors. The first
success was with refractory ovarian cancer. The NCI wanted to proceed, but
needed a partner to further develop the drug. A competition was held to
determine who in the private sector could best develop the drug. Bristol-Myers
Squibb won the competition and then established cooperative agreements with
multiple government agencies, not a trivial task, to continue development.
The USDA’s Forest Service and the Interior Department’s Bureau of Land
Management assisted in an extensive bark collection program in the Pacific
Northwest — mostly in large areas of Washington, Oregon, and Idaho. The
government agencies developed plans to harvest the bark in a responsible way,
to transfer the bark to BMS, and to minimize the impact on the environment
of this huge collection to assure that the yew tree was not threatened. Bristol-
Myers Squibb paid for all those activities, bought the bark, and managed
the bark collection contract with Hauser Chemical Company. No one had
experience with such a large collection effort, but it was well worth the effort
since the drug was made available to the NCI for vastly expanded clinical trials
within a few months.
TAXOL¤
Pre-CRADA TAXOL® Development
1964 Anticancer activity of PaciÞc yew bark extract noted
1971 Isolation and purification reported
1979 Unique mechanism of action described
1983 Clinical trials initiated
1989 Activity in refractory ovarian cancer reported
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The Pacific yew tree, Taxus brevifolia, is a small, scrubby-looking, extremely
slow-growing tree. Very little was known about it — whether it existed and
how many there were. The tree was considered a nuisance shrub by timber
companies harvesting high-value timber like Douglas Fir. Fortunately, from
spring to fall the bark of the Pacific yew was easily peeled by hand from the
trunk and major limbs of the tree. Up to 1,000 people were in the woods
harvesting bark from 1991- 1993. The Forest Service issued a permit for each
collection bag and policed the effort closely. There was quite a bureaucracy
associated with this collection and the prevention of theft. The bark was taken
to collection centers where it was ground to a workable size, further milled,
either dried in the sun or in low temperature tumblers, and then packed in
large wooden boxes and trucked to Colorado to be chemically extracted. This
process was a low-tech but high brute-force effort. It was an inefficient process,
with uncontrollable quality of the raw materials, but at the time it was the only
possible production process and it worked to the benefit of U.S. public health.
An alternative source was needed as quickly as possible, so BMS immediately
established the multifaceted research program outlined in the following figure.
TAXOL¤
Cooperative Agreements
¥ Government AgenciesÑto develop annual plans, oversee
bark transfer, and ecosystem research/conservation studies
¥ BSMÑpay all government expenses, buy bark, and administer
bark collection contract
Bristol-Myers Squibb
for NCI/DHHS
Forest Service Bureau of Land
for USDA Management
for USDI
Together with the Weyerhauser Paper Products Company, several yew tree
plantations were established that served two purposes — research for
determination of the best cultivar for future plantations, and development of
the best methods to cultivate the huge amounts of biomass that would be
necessary for commercial supply. Prior to reaching these objectives, BMS had 12
million yew trees planted as a commercial source of biomass. The research
effort with Weyerhauser used tens of thousands of clippings collected from
ornamental nurseries all over the United States. They were hand-planted and
cultivated for months in huge greenhouses built specifically for this purpose so
that all growing conditions could be completely controlled. The plants were
transferred to nurseries to acclimate them to the outdoors and then grown in
commercial-scale nurseries. They were grown for three to five years before
harvest. The initial idea was to harvest the entire plant and process it to extract
either the core of the paclitaxel molecule or the intact product. But, it turned
out that the important precursor 10 deacetyl baccatin III (10 DAB) was much
more readily and economically available from Taxus baccata, which grows in
Europe and Asia, than from the North American Taxus species. Therefore,
commercial supplies of 10 DAB were produced in Europe for use by BMS.
Years earlier the company had licensed a process to attach the precursor 10
DAB to the active side chain, and semisynthesis proved to be a commercially
viable option. The renewable biomass, originally gathered in the wild in Europe
and Asia, but now cultivated in Italy, is extracted and the purified 10 DAB is
shipped to Ireland where the side chain addition occurs. The purified bulk
paclitaxel is then shipped to Puerto Rico for formulation and the product,
TAXOL®, is shipped to our distribution centers worldwide.
TAXOL¤
Alternative Sourcing Research
¥ Yew plantations
Ñ R&D to determine best cultivar and conditions
Ñ Cultivation of biomass for commercial supply
¥ Renewable biomass (clippings)
Ñ Precursor isolation/semi-synthesis
Ñ Direct isolation of paclitaxel
¥ Plant cell culture
¥ Total synthesis ?
¥ Other ??
DeFuria
While the above process is much more efficient and controllable than bark
extraction, the vagaries of weather can still have a significant impact on total
production and quality of the raw materials.
The plant cell culture option was brought to the attention of BMS by a small
company, Phyton Catalytic. This company had been interested in developing
plant cell culture specifically for the production of paclitaxel for several years.
BMS agreed to sponsor their research and licensed the technology as a possible
method of production.
Might the BMS collaboration with Phyton on plant culture provide an even
better process? We believe the answer will be yes. Although a great deal of
research has been accomplished, much development remains. Tens of thou-
sands of yew tree explants were grown on solid nutrient media until calluses
were developed. Small flask suspension cultures were used to select and deter-
mine optional growth parameters for high producing cell lines. Further research
was done in the bench top scale bioreactor where it was determined quickly
that paclitaxel produced in cell culture had fewer impurities than that isolated
from bark and needle extracts. In addition, cell lines could be selected to
produce a specific Taxane of interest.
The potential advantages of cell culture production of paclitaxel emerged
quickly and can be generalized to other fermentations as well.
TAXOL¤
TAXOL¤ Alternative Supply
Semisynthesis
Renewable
Biomass
(European and
Himalayan Yews)
Extraction
Purification
10 DAB
TAXOL¤
Formulation
Vialing
Sidechain
Coupling
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Plant cell culture is a more environmentally benign process and produces
product faster than cultivation of biomass. It is a controlled, reliable source
of high-quality material and production levels can be matched to commercial
demand. The cell culture conditions are more easily controlled to assure the
fermentation of the product of choice and its high quality. Downstream pro-
cessing for isolation and purification of the desired product often can be simpli-
fied. This may translate into lower costs, but that has not yet been established.
Cell culture provides the opportunity for additional novel metabolites to be
identified that may have a broader spectrum of activity or an increased potency.
These interesting possibilities have been recognized by major pharmaceutical
companies other than BMS. For example, Merck and Pfizer are using cell
culture for discovery of new or improved medicinal compounds, and new
companies, such as Phytera, are being formed specifically for this purpose.
Today, in Arensburgh, Germany, Phyton operates the world’s largest dedicated
plant cell culture facility. There are cascades of fermentors from 75 to 75,000
liters, and the facility is currently being modified to comply with Good Manu-
facturing Process regulations required for production of human pharmaceu-
ticals. BMS and Phyton continue to collaborate on scaling up the fermentation
of new Taxus sp. cell lines and to develop an optimized isolation and recovery
process.
Today, TAXOL® is approved for use in the therapy of both breast and ovarian
cancer. New, improved treatment schedules have been developed and approved
for use. The semisynthetic method for manufacturing the drug is approved and
TAXOL® is currently in use in more than 50 countries worldwide. Another
major market, Japan, should clear the product for marketing in 1997.
Advantages of Plant Cell Culture
¥ Environmentally benign
¥ Faster growth compared to plants
¥ Controlled, reliable supply of high quality bulk
¥ Quick response to variability in demand
¥ Culture conditions controlled easily
¥ Simplified downstream processing
¥ Novel metabolites
BMS expects the need to increase somewhat as the clinical research program
defines new uses for the drug. The company is confident, however, in its ability
to meet all patent and market demand for TAXOL®. New efficiencies will be
implemented in the semisynthetic process, as well as full development and
commercialization of plant cell culture within a few years.
TAXOL® is an exciting product, which in addition to offering clinical benefit
to hundreds of thousands of patients, has been the sole justification for com-
mercial development of an important technology that was little more than a
laboratory curiosity for decades.
TAXOL¤ Bristol-Myers Squibb
Regulatory Status
¥ U.S. FDA approvals
12/92 ovarian cancer
4/94 breast cancer
6/94 improved dosage regimen
10/94 semisynthetic manufacturing process
¥ Approved in over 50 countries worldwide
I have been referred to as the father and even grandfather of modern-day indus-
trial uses of agricultural materials. In January 1985, in Columbia, Mo., Roger
Mitchell and I had the first “big” debate/discussion on the industrial uses of
agricultural products. This was in the period following the agricultural crisis of
the late 1970’s and early 1980’s. The question was “Can we do something with
agricultural products other than eat them or feed them to livestock and then
eat them?” We needed additional non-food and non-feed uses for our excess
production of agricultural crops. We had to find some new uses for this “stuff.”
At a reception in Washington D.C. at about that same time, I ran into Secre-
tary of Agriculture John Block. He asked what I would do if I were secretary
and I responded that I would appoint a group to look at agriculture with a
new perspective — what can we do with the stuff we grow other than use it
for food and feed? We had several million excess acres at that time with which
we needed to do something. Secretary Block appointed a task force called the
Secretary’s Challenge Forum, which led to the New Farm and Forest Products
Task Force. That task force met throughout a two and a half year period. I was
privileged to be a member of the group. We made a series of recommendations
that ended up on Capitol Hill. I was fortunate to work with Cooper Evans, who
was on President George Bush’s staff for agricultural policy. The staff was sup-
portive, and the 1990 farm bill included legislation for the establishment of the
Alternative Agriculture Research and Commercialization Center (AARC) to
invest in commercialization of non-food and non-feed uses of agricultural and
forestry materials. In the 1996 farm bill, the AARC Center became the AARC
Corporation. The AARC has made investments in more than 60, mostly small,
entrepreneurial companies that use agricultural and forestry materials to make
The Environmental and Energy Sector and
Agricultural Biotechnology
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value-added industrial products. Those products include construction and
building materials, oils, lubricants and fuels, paper, landscaping, composting
and plant protection materials, environmental remediation products, shipping
and packaging materials, household and personal care products, and human
oral health products. The list is diverse and represents categories from niche to
huge markets like fuels. I will provide more details to document the reality of
this industrial products opportunity. Biotechnology is not yet playing a major
role in this area, but is expected to do so.
An intense education effort has been necessary to promote this industrial
products opportunity for agriculture. This has involved the Congress, govern-
mental agencies, and environmental groups. The promising story of industrial
uses, including the whole area of biotechnology, has been told. It involves the
participation and opportunity for growers to benefit or profit beyond traditional
mass-produced raw material kinds of markets; the full use of our arable land;
the replacement of imported materials such as petroleum with domestically
produced plant materials; the creation of new jobs in rural areas and associated
rural development; and the environmental benefits of using plants rather than
petroleum. The AARC’s mission and strategic plan addresses this area in greater
detail.
Let me put a historical perspective on industrial use of agricultural materials.
These efforts were initiated in the 1920s, 1930s, and 1940s by Henry Ford,
Thomas Edison, and Billy Hale, who married Mr. Dow’s daughter (of Dow
Chemical), and Wheeler McMillan, who was the well known publisher of the
Farm Journal, a prolific writer, and overall interesting guy. McMillan, who was
98-years-old, spoke at a meeting in Washington in the late 1980’s. He gave one
of the most dynamic presentations that I have ever heard. In 1933, that group
representing the Chemergy Council, came to Washington and tried to establish
some permanent farm legislation to give an industrial agricultural approach to
farm programs. They tried to mandate 10 percent use of ethanol — does that
sound familiar? The American Petroleum Institute was formed about that same
time. We have gone in the direction of teaching and emphasizing petroleum in
our universities and have almost eliminated any emphasis on the use of plant
or bio-based carbon. Our national energy policy needs to refocus from almost
exclusively coal, petroleum, and gas to a reemphasis on bio-based materials.
The reemphasis has started. We’re finding a lot of information on the shelves
of laboratories like the USDA Regional Laboratory in Peoria, Ill., in companies,
and various other places. Some of it is being developed, but it is not known
because of the confidentiality concerns. It is exciting to see that finally we’re
getting underway. I believe we’re beginning to find ways to put rural America
and agriculture back to work in a meaningful rural economic development
program. I want to give you a few specific examples.
We have formed a group called the North American Industrial Hemp Coun-
cil, and we have made very serious efforts to keep the “recreational” users out
of it. It is a significant example of a rare opportunity for agriculture. Industrial
hemp is not used as a source of marijuana. Marijuana comes from a different
hemp plant, not the one grown during WWII for industrial use. Industrial
hemp produces a fiber that can be used to make paper and clothing. Because
of the unfortunate association of marijuana with hemp, there are legal restric-
tions that prohibit its growth but allow its sale in the United States, and allow
its growth, but not its sale, in Canada.
We need to take a serious look at those issues. If New Jersey wants to do
something, let me talk to you about generating a bill for your legislature. We
have done four of them this year — Colorado and Missouri did not make it, but
Vermont and Hawaii passed bills. Essentially those bills permit test plot produc-
tion to provide material for evaluation of uses, how to handle it, and how to
market it — all the questions that need to be answered for a new crop and mar-
keting of its products. The Drug Enforcement Agency (DEA) says that you can-
not grow it unless you have a cyclone fence and guard towers and searchlights.
Let me tell you about the opportunity for a crop like hemp. I’m working on
behalf of the AARC Board with a former U.S. senator who represents a company
that manufactures the interiors of vans and automobiles, like side panels and
dashboards. They use a wood fiber from Spain and they don’t like it. It’s not the
quality they want plus it doesn’t meet Detroit standards for a “green” car by
2002. Ford Motor Company says we want ours by 1999. This company is the
sole supplier of those parts for Ford, General Motors, Chrysler, Honda, and
Toyota. They are looking at kenaf, which is a tropical crop; hemp also meets
their needs. Paper may be another opportunity for hemp. It’s increasingly
unpopular to cut down trees to make paper, and we’re using more and more
paper. The demand is up and rising in the paper industry. International Paper
has a member on the Board of Directors of the North American Industrial Hemp
Council; they are very concerned about alternative sources of paper. They need
a good, renewable, annual, large volume supply of a quality long fiber, which
hemp provides. Hemp can be grown anywhere. It’s also extremely resistant to
disease and insects. It does require high levels of fertilization, but it anchors the
soil with its great root system. It reduces the need for pest control and it’s one
of the most resistant plants in the world. Norman Borllaug, Nobel Peace Prize
winner, told me in St. Louis recently that he would do anything he could to
help make this plant available to grow industrially because it’s a fantastic plant.
It’s the oldest known commercially grown plant in the world. It has lots of
things going for it. Does biotechnology have a role to play in hemp?
In the AARC we are seeing the commercialization of agriculture products that
appear to have significant positive environmental impacts, as well as agricul-
tural and economic development impacts. One example is a product called
Citrasolve being marketed by a company in Connecticut. Citrasolve is a hand
cleanser made from citrus. The product may have other uses, such as control of
difficult-to-control fire ants, and a university is examining that possibility.
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Maybe this product could be a biodegradable kind of soap that you could spray
on tomato, bean, or other plants to control pests. What are the applications of
some of these products? We really don’t know. What we are finding is that the
more you look, the more you find.
We are also finding that marketing, not technology, is the major challenge
for bio-based agriculture and forestry products. There are many opportunities
and it is difficult to decide where to focus. Marketing is the biggest challenge
in conducting due dilligence of projects for possible funding by the AARC. We
have lots of good ideas, but it is hard to get them into the market. We usually
don’t have the marketing intelligence that we need.
In the energy area, liquid fuels is a major market that is currently dominated
by gasoline from petroleum, more than 50 percent of which is imported. Etha-
nol from corn has grown to one to two percent of the gasoline market, where a
mixture of ethanol and gasoline is sold as gasohol. In the long-term, a combina-
tion of waste paper, straw, residues, and a crop such as switch grass grown for
biomass may provide ethanol that is cost competitive with liquid fuels from
petroleum. The pollution laws in certain states make it necessary to find ways
to use/get-rid-of straw because it cannot be burned and there is too much to
plow under. Ethanol production from those kinds of waste streams makes a lot
of sense and will help clean up the environment. AARC has made investments
for commercialization of ethanol from biomass and biodiesel. Some biobased
industrial products need technical advances to be economic, as does ethanol,
while others are economic and need production and marketing input.
In the 1980s I thought that economics would be the biggest problem. I don’t
think so anymore. Lubricants from plants are an environmentally favorable
example. Crankcase oil for engines and oil for chain saws, outboard motors,
and hydraulic fluid lines are being made from plant oils. Because the plant-
based ones are more biodegradable than petroleum based ones, we are going
to be required by law, like in Europe, to use them. Some biobased industrial
products are going to be driven by environmental requirements and others
are going to be driven by the pure economics of the marketplace. We need to
project what those opportunities/needs will be so that agriculture and forestry
material use can be maximized.
My grandparents and parents composted everything and they had fewer pest
problems. We are relearning the benefits of composting. AARC has funded
Earthgro to commercialize a compost that has disease suppressive ability and
reduces need for chemical fungicide sprays. This product has added economic
value and is favorable to the environment.
Of the about 30,000 plants that are known, agriculture has only domesticated
and used about 30. Soybeans is a new crop to the U.S. that has become very
important, and canola is a genetically modified crop that has become important
in Canada. Why don’t we have more crop alternatives? There is a lot of oppor-
tunity out there for new crops and products from them. The more I look, the
more I’m convinced of this opportunity. AARC has made some investments in
new crops such as Syrica (milkweed) and kenaf, also for their fiber.
The Defense Department is a driver because of national security and because
of its increasing emphasis on the environment. It is essential to make linkages
to those interests outside of agriculture. Those linkages are essential to market-
ing. The size of the United States, in contrast to Japan, will enable us to develop
approaches to things here that are not possible for countries like Japan. The
United States has the acreage to support biobased liquid fuels while countries
like Japan do not. But we must establish linkages with major groups outside of
agriculture to meet the challenges.
Let me close with a factual statement about plants. I will use corn as a plant
example. You can make anything out of a bushel of corn that you can make out
of a barrel of crude petroleum oil. The former is renewable, the latter is not.
The processes for corn are different than those for petroleum. Petroleum now
dominates energy and chemicals. We need to refocus use of plants such as corn
for those products. The plant route will be more favorable to the environment
and to rural growth and economic development. Biotechnology has a significant
role to play in this redirection.
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When I speak to managers of environmental agencies or chemical companies,
they are often looking for a risk communication magic wand. The hope is that
I will provide a few risk communication abracadabras that will make their
audiences see risk as the managers do. In short, managers are hoping for a risk
communication incantation so audiences, which are overreacting to a risk (in
the eyes of the experts), will magically calm down. And, they assume I can also
provide another incantation to wake up audiences that are overly complacent
about other risks. I have been studying communication about toxic chemicals
for many years and have yet to find any magic wands. While much of the
research on toxins has applicability to agricultural biotechnology, I can safely
say that you are even less likely to get magic wands today. Instead, I plan to
discuss five questions that I feel have relevance to the communication issues
facing agricultural biotechnology: 1. What the role of information? 2. How
does support differ for specific products? 3. Who supports agricultural bio-
technology? 4. How can trust be increased? and 5. Can our institutions handle
the rapidity of technological change? My examples come from research dealing
with chemicals and radiation, but I think you will find them applicable to
agricultural biotechnology.
WHAT IS THE ROLE OF INFORMATION
I’ll begin by challenging your notion about the power of information. I think
many of us have in our heads a model that says if you provide people with
information you will change their attitudes and, in turn, their behavior. This
model (see Figure 1) is a bit simplistic. Yet, this is the model that drives the
biotech industry to “educate” the public in hopes that the public will then
support field trials of biotech plants, will buy biotech products, and will favor
the biotech industry.
FIGURE 1:
Overly Simplistic Model of Human Response
Information
Þ
Attitude
Þ
Behavior
Let’s look at some research on the role of information. The data indicate that
people are far more complex than the linear model that suggests an injection
of information will transform how people respond to agricultural biotech-
nology. If people were as simple as the model in Figure 1, no one would smoke,
we would all use our seat belts, and I certainly wouldn’t jump horses on the
weekends. We have all experienced this at some level. If you have tried to
“educate” your spouse or your children, you have found that information
doesn’t necessarily transform the family’s behavior. Information is not sufficient
to make people rational. A social scientist (Rayner, 1992 ) has pointed out that
the concept of “rational” is subjective: where you sit in society determines
where you stand on what you consider rational.
Because I am an academic, I am going to provide you the results of several
empirical studies about the relationship between information and behavior.
The nuclear industry, concerned about the public’s “irrational” concerns about
nuclear power, has funded a variety of studies to determine if well-informed
people support nuclear issues. Most studies focused on what the people knew
about radiation. Questions asked were of the following type: What is the
process that generates energy in nuclear power plants? What is the fuel that
is used in nuclear fission plants? The researchers then looked at the relation-
ship between knowledge of radiation and pro-nuclear attitudes.
About half of the studies indicated that the people who knew the answers
to such questions supported nuclear power (Johnson, 1993). The other studies
either found no difference in knowledge between pro- and anti-nuclear sup-
porters or found that the people who knew more were more anti-nuclear.
Johnson (1993) also reviewed studies dealing with other issues such as irra-
diated food and hazardous waste. He found, once again, that some studies
indicated that knowledgeable people supported the technology and, in other
studies, the relationship between knowledge and support was just the opposite:
the more knowledge, the more opposition to the particular technology.
The research on the relationship between support of agricultural biotech-
nology and knowledge seems to show the same signs of inconsistency. An early
survey by the Office of Technology Assessment (OTA) (1987) found approxi-
mately the same percentage of support for agricultural biotechnology among
those who were college graduates and those with less than a high school
education. However, a more recent survey of New Jersey residents (Hallman
and Metcalfe, 1993) found that support for genetic engineering was approxi-
mately 80 percent among the college educated or those with some college,
while less than 60 percent support was found among those with a high school
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diploma or less than a high school education. And both the OTA survey and the
more recent New Jersey one found significantly more support among those who
said they had heard a lot about genetic engineering than those who heard little.
Conversely, an analysis of attitudes of citizens of different European countries
towards biotechnology, found that countries with the highest level of education
and information, Denmark, Germany, and the Netherlands, had the least sup-
port for biotechnology (Almas and Nygard, 1995). In short, the link between
knowledge, attitude, and behavior is unclear, at best.
Am I suggesting that you can forget about providing information? No. But
I am suggesting that experts of all types tend to overestimate the transformative
power of information.
WHAT CONSTITUTES USEFUL INFORMATION?
Let’s look at what is considered useful information. I wonder if the studies
found tenuous links between knowledge of radiation, attitudes, and behavior,
in part, because the radiation experts’ notions of important information are a
bit skewed. If you need to make informed decisions about nuclear power, how
important is your knowledge of the energy process and the fuel? Similarly, the
Centers for Disease Control was very upset that a survey they conducted early
in the AIDS epidemic suggested that people didn’t know AIDS is caused by a
virus. But Baruch Fischhoff, one of the country’s most eminent scholars con-
cerning risk communication, pointed out that changing people’s behavior is not
going to depend on whether they know transmission is caused by a virus rather
than bacteria.
One of the questions for the biotechnology industry is: What should stake-
holders know about agricultural biotechnology to make informed decisions?
This is the question you need to consider carefully. In fact, you should conduct
research on what people want to know about agricultural biotechnology. I have
read many studies about people’s perception of biotechnology in general, and
agricultural biotechnology in particular. None of them asked people what they
wanted to know about agricultural biotechnology. While questions were asked
about their attitudes towards products, no one was asked if there was any
information that they needed. And yet, there are a variety of materials written
for the public about agricultural biotechnology. Did anyone ever test those
materials to see if readers cared about, let alone understood, the information?
SHOULD INDUSTRY RETHINK LABELING?
For the most part, the agricultural biotechnology industry has vehemently
opposed labeling of its products. But results of surveys of the public suggest
the opposite. Even supporters of agricultural biotechnology feel strongly about
the desirability of labeling (e.g., Hallman and Metcalfe, 1993). Arguably, the
question of labeling needs to be considered as a way to address concerns about
biotechnology. If you want me to know more about the technology, the prod-
ucts might come with a label, like that on my yogurt container that tells me
about acidophilus. In fact, there is a large body of research that suggests people
see risks as riskier if the risks are unfamiliar (e.g. Slovic, 1987). This explains
why people are usually more fearful of chemical plants than automobiles —
despite the mortality statistics that indicate chemical plants cause far fewer
deaths per year than automobiles. The evidence suggests that familiarity with
new technology does not breed contempt, but rather greater familiarity and
comfort.
People learn when they have a reason to seek information. For example,
we are motivated to learn because we need to make a decision or we are emo-
tionally involved in some way. You can hold all the conferences you want, but
you will not get most people to attend because they do not yet care enough
about the issue to devote the time. So how will you reach consumers? Yes,
marketing is important. But you might want to look at labeling to help create
both familiarity and information-seeking behavior. Questions to consider about
the role of information: Are you over relying on information as the way to
change behavior? What information do people want? Can labeling help?
HOW DOES SUPPORT DIFFER FOR SPECIFIC PRODUCTS?
The research on agricultural biotechnology indicates that people view different
products differently. They don’t view biotechnology animal products, for
example, the same way they do vegetables developed through biotechnology
(Lacy et al, 1991) Research is beginning to look at the specifics. See Table 1.
TABLE 1. SUPPORT FOR AGRICULTURAL BIOTECHNOLOGY PRODUCTS
Percentage of respondents that strongly or mildly approves of the product
New grass that doesn’t need to be mowed so often 78 percent
Fruits and vegetables that are less expensive 73 percent
Better tasting fruits and vegetables 67 percent
Fruits and vegetables that last longer on the supermarket shelf 57 percent
Hormones that enable cows to produce beef with less cholesterol 57 percent
Hormones that allow cows to give more beef 39 percent
Hormones that allow cows to give more milk 40 percent
(Data from Hallman and Metcalfe, 1993)
Opinion varies by the type of product, and the perceived benefits of that
product may impact the formation of that opinion. Respondents felt no short-
age of beef (at least not sufficient to overcome their objections to genetic
manipulation of animals) but did care about whether they could eat hamburg-
ers with less cholesterol. Less expensive vegetables are supported more than
vegetables with longer shelf life. Those responses make sense when you think
about what matters to consumers.
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Other products raise questions about how the risks and benefits might be
distributed through the population. Grass that needs less mowing appealed to
most people (at least in May when the survey was conducted). From another
perspective, New Jersey residents spend a great deal of money on lawn mowing
services that employ workers that might otherwise be unemployed. Also, the
services are run by people who count on the spring and summer to provide the
bulk of their income for the year. The extent of support for various products
raises a critical question: Who benefits from new use agriculture and who bears
the risk? (Lacy et al, 1991).
WHO SUPPORTS AGRICULTURAL BIOTECHNOLOGY?
I have been exploring the differences between people who support the concept
of agricultural biotechnology products and those who don’t. The New Jersey
data in Table 1 suggests that some people were supporters of products that didn’t
exist at the time of the survey. What is the difference between those early sup-
porters and those who say “no thank you” to a product that does not yet exist?
Multivariate analysis of the data using discriminate analysis suggests that
the issue of morality is one of the strongest discriminators between those who
oppose a product and those who support it. In addition, for men, one of the key
variables that distinguished those who supported agricultural biotechnology
products was their conviction that they had already eaten biotechnology prod-
ucts when that was not yet possible in 1992. These data reinforce the notion
of familiarity reducing fear. The men obviously did not know much about the
agricultural biotechnology market, but they thought they did. They may have
been uninformed, but they were reassured by their own perceptions of reality.
Thus, another question to explore: What makes people supporters of agricul-
tural biotechnology? This recurring issue of familiarity raises once again the
question of labeling.
HOW CAN TRUST BE INCREASED?
The perception of trust in the agricultural biotechnology industry is important:
What makes people feel trusting. One of the founders of the field of risk per-
ception has studied this issue — using nuclear power as the basis (Slovic,
1993). He asked people to respond to statements about a hypothetical nuclear
power plant in their community. He gave two versions of the same statement —
one phrased in a way to decrease trust and another dealing positively with
the same issue. Figure 2 illustrates how these two questions were framed. The
statement: “the county medical examiner reports that the health of people
living near the plant is better than average” had a minimal impact on trust.
But the trust-decreasing statement had a very powerful impact.
Figure 2. Judged Impact of a Trust-Increasing Event and a Similar Trust-Decreasing Eventa
Impact on trust
Very Very
small powerful
1 2 3 4 5 6 7
Trust-increasing event
The county medical examiner reports
that the health of people living near
the plant is better than average 21.5 14.0 10.8 18.3 17.2 16.1 2.2
Trust-decreasing event
The county medical examiner reports
that the health of people living near
the plant is worse than average 3.0 8.0 2.0 16.0 21.0 26.0 24.0
aCell entries indicate the percentage of respondents in each impact rating category.
In Table 2, Slovic
presents data that
show what we
always have known:
Trust is very easy to
lose and very hard to
build. Trust-
decreasing events
have a significant
negative impact on
participants’ trust,
and the trust-
increasing events
minimally increased
trust.
Table 2. Differential impact of trust-increasing and trust-decreasing event.
Note: Only percentages of Category 7 ratings (very powerful impact) are
shown here.
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Equally significant is the one statement that increased trust more than mini-
mally: A local board has the power to shut down the plant if it is not per-
forming up to expectations. In essence, the statement conferred power to the
community to make the hypothetical plant live up to public expectations.
How should you involve people in making decisions so you increase trust?
Peter Day and Laura Meagher developed a community advisory panel in
southern New Jersey before the field trial of genetically-engineered eggplants.
The involvement of stakeholders in decision-making was successful in increas-
ing trust by incorporating their suggestions.
The key questions are: What power will consumers have? What power will
the government have? And to be even more provocative, might you be better
off if you said: Go ahead. Regulate us. We know we can do it. Would this type
of willingness to yield power inspire greater trust? Essentially, this was the
route taken voluntarily by the manufacturers of the Flavr-Savr™ tomato to
increase consumer confidence. Research should be done to determine if more
such actions will increase trust in the agricultural biotechnology industry.
RAPIDITY OF TECHNOLOGICAL CHANGE
Last night I was both exhilarated and terrified by information about the
rapidity of the development of agricultural biotechnology products. The
speaker expressed frustration with the slow rate of government responses to
these advances. Yet, consider that we have essentially the same government
infrastructure we had 25 years ago, and we have universities operating for the
most part as they did years ago. Our decision-making capabilities as a society
have not evolved significantly, as the difficulty of developing environmental
policy illustrates. In short, our societal institutions are not even beginning to
keep pace with our technology. We need to pay more attention to bridging the
gaps between technological innovation and institutional capacity. I recommend
to you one small step towards bridging the gap: a 1996 report by the National
Academy of Sciences — Understanding Risk: Informing Decisions in a Democratic
Society. You might examine this report for suggestions on how to bridge the
social and technological issues confronting agricultural biotechnology and
responses to some of the questions I have raised. Dealing with the social
issues of agricultural biotechnology deserves at least as much attention as
technological issues.
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MacGillis
At the outset, it is important for me to describe myself as a layperson in this
gathering. My background is in art. I have no formal education in science
or agriculture. But I am here with a point of view completely opposed to
biotechnology in general and to its place within agriculture in particular.
I say this out of my own experience. I left teaching art in the early 1970’s,
having been deeply moved by the specter of world hunger as it was looming
on the global horizon. After the oil embargo of the same period, and in order
to meet its balance of payments, the United States quadrupled the price of its
export agricultural commodities. It was a response to the lawlessness of the
global market system, whereby unilateral decisions on oil and food commodi-
ties wreaked havoc on the desperate economies of the non-industrial world.
I remember the vivid realization of learning that the cattle of the feedlots of the
United States were daily consuming grain adequate to feed the hungry peoples
of the world. That fact determined the direction of my life, and I have been
involved with the analysis of hunger and agriculture ever since.
In 1977, I heard a paper delivered by Thomas Berry. The context he outlined
also set a direction in my life that has helped me to probe ever deeper the root
causes of the kind of dysfunction that plays itself out in the global crises of our
times.
Thomas Berry is a renowned historian of world cultures and in his two
seminal books, The Dream of the Earth and The Universe Story , which he
co-authored with Brian Swimme, he suggests that the root of our crises is
contained with the cosmology that has shaped the total context of western
thought. I suggest in this presentation that this cosmology also underpins the
world of biotechnology and that it is both flawed and dangerous. I also suggest
that a contemporary scientific understanding of the origin, nature, and func-
tions of the cosmos would indicate that biotechnology is itself an extension
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of the same inadequate worldview and that it is taking us in a direction that
is counter to the natural progression of the universe, the earth, and life.
The following chart is my simple attempt to model some of the assumptions
that are inherent in our traditional western cosmology. Our origin story, rising
several thousand years ago out of the Mediterranean world, provided a context
of meaning that attempted to answer the ultimate question of the mystery of
existence. In short, it provided a coherent set of meanings upon which the
various structures of culture were formed. Some of them are:
• That the divine is totally transcendent to the universe, hence perfect
and unchanging.
• The human has a transcendent destiny to be brought into union with
the divine, but this union depends on the human transcending the
cosmos.
• The cosmos itself does not have this spiritual transcendent destiny.
It is a physical, material plane of existence and possesses no inherent
spiritual substance.
• The human is free to explore the physical world, analyze its physical
energies, and redesign them to bring about some of its original
perfection lost after the fall.
Hence, this world view might be described by this simple model:
In this worldview, the ordinary conditions of life are perceived as temporary
and abnormal. Thomas Berry suggests that this perception sets the stage for
a growing pathological rage within the western psyche. This rage is directed
towards the conditions in which life is actually granted to us. Historically, it
has made it nearly impossible to develop the inner capacity to live creatively
or graciously within the whole fabric of life. Instead, we have resisted all
limitations imposed on us as abnormal, as a punishment from which we will
one day be liberated. Our inner capacities have been stunted and our total
intrusion into the fabric of life, as it has brilliantly evolved, is nearly total.
So it is the scientific story of evolution itself that suggests that our obsession
with genetic engineering may well bring about a total undermining of the very
life we commit to re-designing. I would like to suggest that as we review the
process of evolution, seen now as a total evolution of the inner as well as outer
dimensions of the universe, that this context provides an essential correction
to the direction that agri-biotechnology is pursuing.
GARDEN BLISS HISTORY BLISS MILLENNIAL AGE
The following overview of the evolution of DNA was prepared by Dr.
Lawrence Edwards, PhD, of Genesis Farm.
EVOLUTION OF DNA
About 15 billion years ago
The universe flared into existence. At first all was symmetric. Within much less
than a millionth of a second the symmetry is broken as the primal four forces
emerge. All subsequent relationships will be governed by these four. In par-
ticular, the nature of the electromagnetic force is now set. Even though there
were no molecules in existence, the laws of chemistry are now in place. So
even though no DNA was present, limits were in place on the strength of the
hydrogen bonding and therefore on the diameter of the helix.
A billion years later
The universe coalesces into galaxies and stars. The stars live by consuming
primal hydrogen and helium and fusing them into new entities — lithium,
beryllium, oxygen — all the chemical elements up to iron in weight. The
larger stars exhaust their supplies of hydrogen and helium and can no longer
sustain their existence as stars. They become supernova and, in that cataclysmic
process, fuse to become the heavier chemical elements. Their bodies, rich in
chemical elements, are strewn throughout the cosmos.
For billions of years after
Subsequent generations of stars form by gathering the chemically enriched
gaseous clouds of hydrogen into themselves, fusing, become supernova, and
again distributing more elements into the cosmos.
About 4.6 billion years ago
A large star in our galactic neighborhood became a supernova.
About one hundred million years later
Our sun and solar system formed from the body of this supernova. For several
hundred years the planets grew in size by accruing smaller asteroids in often
violent collisions. The earth was often molten during this period. During this
process the chemical elements born in the star and supernova combine to form
simple molecules (e.g., water) and minerals (rocks, stones, etc.).
About 4.1 billion years ago
The great bombardment was over. The solar system reached its present con-
figuration of nine planets. The earth now cooled for the last time, eventually
enough so that steam could condense. It rained violently for eons creating
the oceans.
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About 4 billion years ago
Probably during one or many of those thunderstorms, the first complex mole-
cules were synthesized from the simple molecules and minerals. (No one
knows; there are many theories.) Once created, those molecules self-organized
themselves and others into creative possibilities. At least one of those possi-
bilities worked. Over the eons those organizational capabilities resulted in the
first living organisms. Probably the first genetic capability was through RNA
(ribonucleic acid). Later, apparently, DNA (deoxy-ribonucleic acid) proved to
be more effective and RNA was then used not for the storage of the genetic
information, but only as a “messenger” between DNA and the enzyme pro-
duction capability. (Again no one is certain of the process in those early years.)
DNA is a chain of four specific nucleic acids. A “word” in the language of
DNA consists of a particular sequence of three of these acids. Thus, there are
4x4x4 or 64 possible words in the DNA language. Each word “speaks” of a
particular amino acid. So a sentence of words specifies a sequence of amino
acids, which is a protein (enzymes are proteins). In all life forms, the same cor-
respondence exists between the DNA words and the particular amino acid. (In
many cases there is more than one word possibility for a specific amino acid.)
This was all worked out 4 billion years ago!
Some hundred million years later
Simple bacteria emerge. A bacterium consists of a cell wall surrounding and
containing protoplasm, a complex mixture of organic molecules including
naked strands of DNA directing the maintenance of the bacterium. The
protoplasm connects with the outside environment through the cell wall.
Occasionally, the cell clones itself, a process directed by its DNA. Thus, DNA
not only remembers how to create a new cell and how to maintain its existence,
but also directs the processes.
About 2 billion years ago
In response to the menace of oxygen, a new form emerges, the eukaryote cell,
the cell with a nucleus. (Of course, the bacteria live on and prosper without a
nucleus.) The cellular DNA is collected and stored in the nucleus as a double
helix. This helix unzips during the reproduction process and then each strand
duplicates itself in the daughter cells. During this unzipping the DNA is very
susceptible to damage. Mutations occur primarily during this time. Apparently
this susceptibility to damage is just right: more would result in higher death
rates of the daughter cells, less would result in less ability to adapt. (Later,
cells developed molecules to “walk” along the DNA helix strand to find and
correct errors.)
For the last 2 billion years
DNA has learned, memorized, and directed the processes of life. Changes
in the DNA of a particular species have been slow, in earth time. There have
been periods of accelerated change, but these periods have still been long —
hundreds or thousands of years when compared to human time. All changes
were rigorously tested for compatibility with the organism’s ecosystem.
15,000 years ago
Humans started consciously changing the DNA of other organisms through
horticulture and domestication of animals. Those changes were made much
more quickly than normal evolution, but still over many generations. There
was not such rigorous testing of the changed organisms and this led to prob-
lems in some cases, e.g., exotics taking over an ecosystem. Often the changed
organisms are not even independently viable and must be supported by human
activities. But, overall, the changes were not large. For example, there was
never the mixing of genes between species.
Today
Humans have learned many words and sentences in the DNA language, the
means to change sequences within a gene, and the ability to move sequences
from one organism to another organism of a different species. Now the time
scale of radical evolutionary changes is instantaneous. There is not the time
nor the incentive to thoroughly test the new organisms.
There is not even the knowledge of how to test such unknown creatures.
While the goal of many of these manipulations is laudable, e.g., the curing of
various inherited, debilitating diseases, most are driven by commercial goals.
One can imagine taking a certain risk in order to improve the health of a
certain segment of the population. We have done this before, e.g., fluoridation
of drinking water and vaccinations. But often there have been unforeseen
disadvantages to such activities. In any case, much of the genetic manipulation
today is for profit. There are few, if any, redeeming qualities except a more
efficient product, e.g., a longer lasting tomato.
We do not understand the consequences of genetic manipulations. We are
launching yet another massive experiment on ourselves with little under-
standing of the long-term consequences.
In conclusion
I would suggest that our refusal to live within the limitations of the unity of
the whole, which has enabled the elegant miracles of life to unfold, is a dark
extension of our mythology. Biotechnology is a commitment to myth. By
refusing to acknowledge the superstition implied in our blind adherence to
our vision of a world of bliss, we move deeper into a chaos from which life
itself may be unable to recover.
MacGillis
That a university would commit itself to direct its young research capacities
and its young scientists to such a distorted view of reality is a tragedy, made less
understandable with the evidence that science itself holds forth.
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A revolution in the basic science related to plants has occurred over the last
fifteen years as techniques for genetic engineering have been developed. It is
now possible to introduce foreign genes into almost all major crops, resulting
in stable genetic transformants that pass the new trait on to their progeny
following the principles of Mendelian genetics. Those protocols have led to
detailed understanding of the mechanisms by which gene expression is regu-
lated in the different tissues, and at different times, in the plant life cycle. From
an applied standpoint, this understanding can be used to cause foreign genes to
be expressed only in selected tissues — such as fruits or grains. Plant biotech-
nology has yielded commercial products in the field of agriculture as plants
resistant to insects, viruses, fungi, and herbicides have been created. In addition,
foods with modified ripening characteristics are now commercially available.
Beginning in the last few years, various research laboratories have experi-
mented with the use of plants for “biomanufacturing” of specialty products.
These approaches utilize transgenic plants created to accumulate high value
proteins/enzymes. Some of those studies have explored the production of
proteins of potential pharmaceutical value. It has been shown that plants will
produce molecules as diverse as human serum albumin (which requires exten-
sive conformation folding) and both serum and secretory antibodies (which
require assembly of multiple peptide subunits to produce a functional antibody).
Crop Biotechnology in the Service of Medical
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EXPRESSION OF ANTIGENIC PROTEINS IN TRANSGENIC PLANTS
It has been well documented that molecular biology has had enormous impact
on the fields of immunology and vaccine development. Tools to identify and
clone the genes encoding antigenic determinants of infectious agents have
been developed and are in wide use. The introduction of the gene encoding
the surface antigen of the hepatitis B virus (HBV) in recombinant yeast was the
first commercial example of a recombinant subunit vaccine. The HBV vaccine
produced by recombinant DNA techniques is extremely safe and effective;
however, its high cost has led the Institute of Medicine to list the development
of a lower-cost recombinant DNA vaccine as a top priority. It can be readily
anticipated that numerous other recombinant subunit vaccines will also become
available in the next decade as our understanding of immune recognition of
individual proteins grows. While these offer exciting opportunities for disease
prevention, dependence upon fermentation technology and protein purification
will influence both cost and availability of the new vaccines to the developing
world. This led us to explore the use of transgenic plants as a subunit vaccine
expression system.
HEPATITIS B SURFACE ANTIGEN EXPRESSION IN PLANTS
We began our studies of candidate vaccine expression in transgenic plants using
the gene encoding hepatitis B surface antigen (HBsAg). This protein was chosen
because the commercially available vaccine and the associated human immune
response have been very well characterized, because the structure of the immu-
nogenic form of that protein was known, and because the availability of a cost-
effective recombinant HBV vaccine for the developing world is a high priority.
In our initial studies, the gene for HBsAg was introduced into cells of tobacco
plants and individual transgenic plants were regenerated. We chose tobacco
for the experiments because of its ease of genetic manipulation and abundant
literature on controls for gene expression in this facile “model laboratory
plant.” When transgenic leaf material was extracted, virus-like particles could
be recovered. These were characterized and were found to be very similar in
structural properties to the recombinant HBsAg, which is formulated in the
commercial vaccine produced in yeast cells.
When plant-derived HBsAg was used for parenteral immunization of mice,
anti-HBsAg antibodies were recovered that reacted with authentic HBsAg from
human serum. This was our first indication that antigenic properties of the
protein were maintained in recombinant plants. Subsequently, T-cells were
isolated from mice immunized with tobacco-derived HBsAg. When grown in
culture, these T-cells could be activated using the commercial vaccine, as well
as a synthetic peptide that mimics the “a” epitope determinant of HBsAg. In
total, the immunology studies conducted to date show that the recombinant
HBsAg recovered from plant cells retains both B- and T-cell epitopes. These
studies have demonstrated that plant cells have the capacity to not only synthe-
size this protein but to allow it to assemble in an immunologically active form.
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VACCINES AGAINST BACTERIAL DIARRHEAL DISEASE
Diarrheal disease is the major cause of infant mortality on a worldwide basis.
Vaccines to prevent diarrheal disease caused by bacteria or viruses could have a
significant impact on human health in the developing world. As my colleagues
and I had an interest in testing the oral immunogenicity of recombinant anti-
gens produced in plants, we made an early choice to focus on enteric diseases.
The binding subunit of the heat-labile enterotoxin of E. coli (LT-B) was an
obvious candidate for evaluation in plant expression systems since it has been
extensively characterized in structural and immunological studies. Because it
is very similar in structure and immunological properties to the B-subunit of
cholera toxin (CT-B), immunization with CT-B leads to cross protection against
enterotoxigenic E. coli (ETEC). Early field studies of cholera vaccines in
Bangladesh showed that CT-B immunization was useful in preventing cholera,
although protection was relatively short lived and protective immunity would
require frequent boosting.
Our initial studies utilized an expression vector that caused the production
of recombinant LT-B in transgenic plants using the native bacterial gene.
Characterization of this protein was hampered by the low amount of protein
that accumulated in the plants. Subsequently, the bacterial gene was modified
to encode a fusion protein, which has a six amino-acid microsomal retention
signal at the C-terminus of LT-B. We reasoned that retention of the newly
synthesized LT-B in microsomal vesicles of plant cells would allow an increase
in the relative concentration of the protein, leading to assembly of the active
pentameric form of LT-B. We found that higher amounts of LT-B accumulated,
and it could be isolated for characterization. Based on its physical properties
and its ability to bind GM1 gangliosides, we determined that the LT-B fusion
protein assembled into the active oligomeric structure within plant cells. When
this protein was partially purified from transgenic plants and given by oral
gavage to mice, both serum and secretory antibodies that were specific for LT-B
could be recovered from the treated animals. These antibodies were effective
in inactivating the E. coli toxin when tested using in vitro assays as an indicator
of protective immunity.
My colleagues and I are continuing our efforts to create transgenic plants that
accumulate abundant amounts of recombinant LT-B in edible tissues. We have
been guided by the earlier CT-B vaccine field trials that used one milligram of
protein per oral dose. By creating a synthetic gene that encodes an LT-B protein
of the authentic amino acid sequence, but uses codons which are preferred by
plants, we have recently been successful in creating plants that accumulate
one milligram of LT-B in a potato that could be consumed raw by a human
volunteer. We are cooperating with John Clements of the Tulane Medical
School, as well as Michael Levine and Carol Tackett of the Center for Vaccine
Development at the University of Maryland, to evaluate this material in human
clinical trials for feasibility of use as an oral vaccine.
VACCINES AGAINST VIRAL DIARRHEAL DISEASE
Multiple viruses cause diarrheal disease. Rotavirus may be the principal agent,
especially in infants. As we began studies of the potential value of transgenic
plants to produce recombinant subunit vaccines, I consulted with Dr. Mary
Estes of the Baylor College of Medicine about the potential for a plant-based
vaccine for rotavirus. From the data she provided, we concluded that coor-
dinate expression of at least two (and possibly more) rotavirus coat proteins
might be needed to cause the assembly of an immunogenic virus-like particle.
Since we had not yet evaluated the capacity of transgenic plants to produce
immunogenic proteins and because coordinate expression of multiple foreign
proteins in plants had not been characterized, we concluded that a simpler
system was needed that would provide “proof of principle.” For this system we
turned to the characterization of a candidate vaccine against Norwalk virus.
Norwalk virus (NV) is a member of the Caliciviridae family. It is a causal
agent of severe epidemic outbreaks of viral diarrhea. When the gene encoding
the single capsid protein of Norwalk virus was expressed in insect cells, virus-
like particles (VLPs) could be isolated. These particles were also found to be
effective in causing oral immunization of mice, resulting in production of
both serum and antibody specific for the capsid protein. Unfortunately, there
is no animal model to demonstrate protective immunity of vaccines against
the Norwalk virus; those determinations will require human clinical trials.
Extracts of plants expressing the NV capsid protein were found to contain
VLPs that mimicked the structural properties of VLPs recovered from insect
cells. When these were partially purified and given to mice by gavage, both
serum and secretory antibodies to the NV capsid protein were produced.
ORAL IMMUNIZATION USING EDIBLE PLANT TISSUES
Although our initial subunit vaccine experiments used tobacco as a test system,
our goal was to produce candidate vaccines in edible plant tissue to evaluate
the potential for immunization simply by eating the tissue. Because the oral
immunogenicity of plant-derived antigens had been demonstrated by the oral
gavage studies, we developed protocols for genetic transformation of potato
using genetic regulatory elements that cause the accumulation of the desired
recombinant protein in the potato tuber tissues. We chose potatoes for two
reasons. First, we could recover transgenic plants and grow them to maturity in
greenhouses in a relatively short period (about three to four months). Secondly,
mice will readily eat raw potatoes.
Transgenic plant material has been generated that contains both recombinant
LT-B and the recombinant Norwalk virus capsid protein. The proteins assem-
bled into the appropriate structures (LT-B pentamers that bound GM1 ganglio-
sides, or VLPs for the NV capsid protein). Potatoes were peeled, and five gram
samples were fed to mice on a schedule that was analogous to the previous
experiments using gavage for oral immunization. In both cases, the mice
produced serum and secretory antibodies against the recombinant protein in
the potato eaten by the mice as food. These studies provide “proof of concept”
for edible vaccines.
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Figure 1. A schematic diagram showing the steps involved in creating transgenic plants expressing
immunogenic proteins. A. Based upon earlier immunology studies, a candidate antigen with
known or potential value as a subunit vaccine is identified. B. The structural gene encoding the
antigen of interest is obtained or isolated. C. The gene is ligated into a plant transformation vector
which contains plant-specific promoter and terminator sequences to regulate gene expression.
D. The natural gene transfer system of Agrobacterium tumefaciens is usually utilized to mobilize the
genetic construct into the chromosomes of plant cells. E. Plants are regenerated from transformed
cells that contain a stably integrated gene encoding the desired antigen. F. and G. Immunogenicity
of the plant-expressed antigen is determined by either extracting the foreign protein and delivering
it by parenteral or oral routes, or simply by feeding a plant sample as food.
VACCINES FOR ANIMAL DISEASES
Oral vaccines can provide efficient and humane strategies for disease prevention
in production and companion animals, as well as feral populations. The above-
mentioned “proof of concept” for edible vaccines suggests that the design of
subunit vaccines in feed crops is a viable strategy. Seed-specific genetic regu-
latory elements are known for crops such as corn and soybeans, and stability
of foreign proteins in dried seeds has been demonstrated.
Recently, transgenic plants have been generated that expressed the gene
encoding the glycoprotein (G-protein), which coats the outer surface of the
rabies virus. Although the immunogenicity of these materials has yet to be
reported, it is encouraging to note that bait containing some G-protein pro-
duced in a more traditional in-vitro system was effective in orally immunizing
raccoons, providing protection against “street virus” challenge.
REMAINING QUESTIONS/OPPORTUNITIES FOR EDIBLE VACCINES IN
TRANSGENIC PLANTS
The research conducted to date has demonstrated that transgenic plants have
the capacity to synthesize and accumulate subunit antigenic proteins that retain
immunological properties of their native counterparts. In the case of the HBsAg
and the NV-capsid protein, virus-like particles accumulate; this may be very
significant because the particulate form of the proteins is likely to be important
in determining immunogenic properties. It is likely that particulate structures
will have greater oral immunogenicity than soluble proteins.
Studies not yet conducted will involve the evaluation of dosage requirements
for plant-delivered vaccines. Successful experiments conducted thus far have
used proteins from two enteric organisms. It will be necessary to determine if
other proteins, which may not be normally transmitted via the oral route, will
be as effective in inducing an oral immune response. We are optimistic, how-
ever, because plant cells represent a natural bioencapsulation system with
surrounding layers of cell wall, cell membrane, and (in some cases) internal
membrane compartments to encapsulate and thereby protect the desired
subunit protein from digestive degradation. It remains to be determined if
the release of the desired protein in the gut acts as a “slow release” as the plant
cells are degraded in the normal digestive process. If so, dosage levels may have
to be adjusted accordingly.
A potential major advantage of recombinant plants for vaccine production is
the possibility that multi-subunit vaccines, including an oral adjuvant such as
CT or LT (or derivatives thereof) could all be produced in a single plant. There
is no theoretical limit to the number of different genes that could be introduced
into a single plant species. Plant tissue could, therefore, contain multiple anti-
gens in one delivery system. In addition, this could circumvent the need for a
cold chain in vaccine delivery when produced and utilized in developing countries.
It is well recognized that most food proteins do not trigger an immune
response; in general this is due to the induction of a state of immune tolerance.
It will be necessary to determine if food-based vaccines will also induce oral
tolerance to the desired antigen. If so, controlled use and dosage will be a
requirement for “edible vaccines.” This should not be an insurmountable
obstacle, however, as only a small amount of plant material would need to be
propagated for wide-scale vaccine delivery and its distribution could become
a component of public health care systems.
The type of plant material that would best serve as an “edible vaccine” is yet
to be determined. For human vaccines, our own research team has focused on
the use of bananas. This crop has three major attributes: it is grown in almost
all tropical or sub-tropical developing countries throughout the world; the food
is eaten uncooked (which would avoid denaturation of subunit proteins); and
bananas are a food that is widely consumed by infants and children. At the
present time, we have developed a methodology for the genetic transformation
of bananas and are cloning fruit-specific genetic regulatory elements, which
we believe will cause the tissue-specific production of the desired candidate
vaccine in the developing fruit. The primary disadvantage of bananas is one of
technical limitations during feasibility stages of research. This is due to the fact
that the time from genetic transformation until harvest and evaluation of the
fruit is relatively long. We anticipate that the time period will be at least two
years. Our first transgenic banana plants containing genes encoding candidate
vaccines are still in the seedling stage.
For animal vaccines, a variety of grain crops (such as soybeans or corn) rep-
resent excellent possibilities for vaccine delivery. Transformation techniques
for those crops are known, as are strategies for causing seed-specific gene
expression.
In summary, the expression of vaccines in plants may be the first large-scale
example of production of high-value pharmaceuticals in transgenic crops.
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As I will describe later, we have sophisticated technology to handle agricultural
applications with sludge. With this technology you would expect government
regulators to be supporting our efforts. Not so. Our biggest enemy and clearly
our most serious obstacle, whether in wildlife preservation or quality beneficial
bioremediation, is the very government reportedly there to protect us. The
Federal government’s weakening of regulatory processes at the state level has
created a time bomb — an environmental disaster just waiting to happen or be
reported. I do not want to be a continuing part of an industry “in retreat” from
prudent regulation. My only forum for available protest is to retreat from that
management practice until prudence returns.
What a wondrous time we live in. At no time have the twin spears of tech-
nology and communications had such impact and influence on people’s lives.
Over the years, I have traveled a great deal and have seen much of what the
world has to offer. On my travels, one observation stands out above the rest.
From New York to Tokyo, from Cartegenia to Boise, from Tel Aviv to Ciudad
Obregon, from Mexico City to Kansas City — no matter how small the card-
board hut or how exquisite the mansion, no matter how beautiful the home or
how small the apartment, most all have televisions. Whether in the streets of
Mexico City or the ghettos of Los Angeles, the most affluent neighborhood in
Scottsdale or the middle class suburbs of Atlanta, being able to see the news
and the latest fashions instantly has produced a silent but powerful revolution
in thinking throughout the world. Under all of the extremes of social and
economic class differences, designer sneakers and jeans are there . . . and there
in abundance. Kids may not have enough to eat but they know what’s “in” and
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they wear it. They see political and economic and social conditions elsewhere
and they want the best of what they see. This worldwide communication
explosion has brought images of Robin Leach’s “Lifestyles of the Rich and
Famous” into people’s homes, dreams into their eyes, hope into their hearts,
and an insatiable hunger to their belly. The bringing of news and current affairs
and entertainment into the homes and lives of earth’s inhabitants will one day
be recognized as the most significant political, social, and educational event in
recorded history. Televisions were the powerful fans that produced the winds of
change around the globe. But television will be to the telecommunication, tele-
information and tele-management tools of the 21st century what slide rules
were to computers.
I will now describe the advanced technology used for sludge application at
my farm.
In the early morning dawn, as the spine-tingling scream of the 903 diesel
engine grew close, it became apparent to the college visitors that the machine
was using all of its power to pull the seven tine, deep chisel plow. But it wasn’t
the display of raw power that caught their attention. Nor was it the precision
driving that had kept the tractor on target within six inches across a half mile
field — 2,600 feet. Neither was it the high-tech instrumentation that had
regulated the application rate to within 0.03 percent of the target rate of 48,450
gallons per acre. It wasn’t the cab’s air conditioned, stereo tape deck, CD ROM
dust-free environment or its computer instrumentation. What impressed the
visitors to this 12,000-acre southwestern family farm was their discovery, as the
tractor turned, that there was no driver. The 300 horsepower sludge injection
tractor was controlled remotely by a portable computer sitting on the seat of
my Chevy pickup.
The use of biosolids, as better quality sludge is now called, has been a
scientifically based management tool on our ranch for the past 18 years now,
but that will likely come to an end as a result of government abandonment
of reasonable standards for the industry. When was the last time you heard a
farmer say he wanted more government regulation? More on that later. Over
the years, we have carefully applied and tracked over 3,000,000 metric tons of
municipal biosolids. We have actually raised the elevation of our 22 square mile
ranch over three inches.
What in the world do biosolids have to do with biotechnology? Well, as
Peter Day, Director of the AgBiotech Center at Rutgers University, told this
group in 1994, one of the most underdeveloped opportunities for agricultural
biotechnology is in the area of bioremediation. For those who have visited our
farm, however, this is not the typical sludge dump-and-run operation you see
all across America. In addition to the high-tech application equipment, which
my family has pioneered, we have also developed high-tech, biotechnology
methodologies to monitor and track nutrients, pathogens, and heavy metals.
As an example, we have pioneered the use of DNA/PCR gene probe testing to
provide us with analyses of Escherichia coli pathogen levels in the biosolids
prior to application. To give you a scoping perspective, we have run more
than 22,000 pathogen tests this year. Additionally, we use a Strontium 90 CPN
Neutron Probe to give us instant measures of heavy metal concentrations in the
biosolids so we can track those as well. In the last six months we have diverted
nearly 1,200 truckloads of biosolids to a landfill because it did not meet our
quality standards. Additionally, our reporting is done electronically using an
instantaneous and accurate reporting protocol.
Today, I have been asked to focus on regulatory and social changes affecting
Agricultural Biotechnology in the Environmental and Energy Sector. Specifi-
cally, where we are, where we’re going and how we’re going to get there. The
biotechnology sector is about where the budding computer industry was in
1976. We are facing enormous changes in the agricultural sector over the next
few decades. Let’s discuss a few of the changes that will most affect us.
1. Farmers of the future will produce more food and fiber, and more than just
food and fiber.
Agricultural biotechnology will affect every single farmer and rancher. As
the emphasis shifts from yield per acre to yield per unit of resource expended
delivering products to the end-consumer, biotechnology will play an increas-
ingly important role. Additionally, crops that will be engineered specifically to
yield feedstocks for the pharmaceutical, energy, and industrial sector will dot
21st century farms. Growing fuel and cosmetics will become as important as
growing feed and cotton.
2. Production of industrial and chemical feedstocks will be a major source of
revenue, not a novelty.
As the percent of GDI spent on food and clothing continues to decline along
with the demise of government subsidies, a new generation of farmers will
emerge. The appropriate infrastructure must be embraced in order for this to
occur globally.
3. Tomorrow’s farmers will be as comfortable on the internet as yesterday’s
were on a tractor, and as comfortable using a computer as their dad was
using a shovel.
The internet has evolved from an information gold mine to an information
glut, to a management and marketing tool. This evolution, as discussed earlier,
will touch every aspect of our lives. Smart computers, tied to worldwide infor-
mation and data, will allow individual producers to make better decisions. We
must develop an infrastructure that allows open and free movement of informa-
tion between private business and government, between the regulated and the
regulator. We must give up old crutches and embrace new concepts of com-
munity welfare, individual accountability, and shared responsibility for the
public and environmental well-being of this space ship we call Earth.
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4. Conservation will become an established philosophy religiously practiced
— not a mandated farm practice.
The worldwide environmental movement and community sensitivity about
environmental and wildlife protection, coupled with global access to what we
do, or don’t do, on our farms, will force farmers and ranchers to modify their
farming philosophy to take into account public attitudes about the impact of
farm practices on the environment.
5. A new alliance will emerge between land grant universities and commer-
cial researchers and farmers, end-users, and true environmentalists that
will carry us well into the next century.
The next decade will produce a blurring of the traditional structural lines in
business and society. Responsibility for the administration of social goals will
continue to evolve away from government and toward a shared public-private
partnership. From education to medical care, from basic research to child care,
from prisons to the airwaves, a blurring between private enterprise and govern-
ment regulation will occur at an ever escalating pace. Even the lines between
labor and management will become hard to distinguish. Banking, insurance,
and marketing will blur until they cease to exist as discernible institutions and
focus instead on function and vision. To succeed, we must identify, develop,
and cultivate those new alliances that share our common vision. We must also
tell our story. We must spend more of our resources educating the public and
ourselves. The public’s right-to-know and their access to huge amounts of
information regarding every aspect of business and the environment will force
us to be more open and forthright in business practices and government
operation. We must address phobias, fears, and suspicion by the public and
within our own industry. We must be willing to change.
6. Farmers who succeed will need to expand into providing for other societal
needs such as recreation, wildlife management, environmental management, etc.
The most recent USDA report revealed that the 1.5 million small-and medium-
size American farmers received nine-tenths of their disposable income from
off-farm sources, with even the largest producers receiving more than half of
their disposable income from off-farm sources, as well. As a further indication
of this trend, three State Farm Bureau Presidents make more money on wildlife
and recreation than on the cattle or crops on their ranches. American farmers
in the 21st Century will have to learn to farm for the maximum benefit of the
entire ecosystem we call Planet Earth versus mining the land or farming direc-
ted by government programs. Providing recycling for such waste products as
biosolids and the beneficial reuse of our dwindling resources will become more
widespread. Biotechnology will play a critical part in accomplishing this goal.
7. We must do a better job of telling our story.
We have accepted and embraced proven, as well as emerging, technology. The
public does not understand what we are doing or why. In response to Caron
Chess, yes there is a segment in society that has a higher latent trust factor than
the “white-coated scientist.” They are the family farmers. There is a difference
between having information versus having understanding. To prevent special
interest groups of political activists and environmental extremists from mis-
using their access to massive amounts of data to create mass hysteria, we must
empower the average citizen with access to and understanding of this ocean
of information. We have heard much about the shortcomings of the nuclear
industry or the chemical industry or the plastics industry. Perhaps the greatest
weakness and most damning deficiency of modern society is our illiteracy when
it comes to understanding risk. As a people, we expect the government to give
us freedom from all risks, even those we can’t define. While one-third of the
world is hungry, we demand: convenience without cost, pleasure without pain,
thrills without danger, recreation without work, service without sacrifice,
freedom without price, glory without honor, products without waste, energy
without pollution — any at all. We expect to have toys that do not break, cars
that don’t wreck, trains and planes that don’t crash — ever! We want to gamble
and win, but do not accept the risk of losing. We even want tans without
sunshine and health with out prudence. We fantasize about nature being in
balance and then bankrupt ourselves and squander our children’s future trying
to restore a balance to nature . . . a balance that never was nor ever, ever will be.
To survive we must educate an entire generation about the concept and cost of
risk avoidance. Risk cannot be eliminated. Risk can be reduced — at a cost.
Cost benefit analysis must be a core part of education.
These changes are occurring, with all of their attendant challenges and
opportunities. I, like you, have a hard time visualizing what the 21st Century
farm community will look like. But this much I do know. Telecommunication
assisted, real time, graphically enhanced technology will put substantial regu-
latory and public pressure on every aspect of business and education including
the development and commercialization of biotechnology. In spite of that,
biotechnology will play a significant role in the future of farming.
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We have heard many bad things about the U.S. government and government
regulation; people have argued that there is either too little or too much
regulation in U.S. agriculture. I am going to say a few good things about the
U.S. biotechnology regulatory regime.
As you all know, regulation serves a role in safeguarding the environment
and assuring food safety in the agricultural industry, and product safety,
efficacy, and the consistency of the manufacturing process in the pharma-
ceutical industry. In both the food and pharmaceutical industries, regulation
and government approval raise consumer confidence and provide com-
panies with a powerful marketing tool — the label that says “USDA” or
“FDA approved.” The industry wants regulation. One only has to recall the
case when Richard Godown from the Biotechnology Industry Organization
and Rebecca Goldburg from the Environmental Defense Fund went jointly
to the Council on Competitiveness asking the council to please not
deregulate too much.
On the other hand, there is legitimate concern about regulation stifling
innovation, the economic implications of regulation, and questions of
international competitiveness in comparison to Europe and Japan. Over
the years, the EPA has been criticized for not issuing its policy guidelines
on time; the USDA for over-regulating or deregulating the wrong crops; the
FDA for its long review times and requirements that were supposedly
greater and more burdensome than their European counterparts.
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Hence, the desire for regulation and the fear of regulation are hostages of
each other. To have the seal of approval on your product, you need
regulation. And regulation is always slower than no regulation.
In the case of biotechnology, the relationship between regulation and eco-
nomic development has been at the center of all regulatory debates, I be-
lieve more so than in any other industry. There are three reasons for this
phenomenon. First, the technology is thought to hold enormous economic
promise and social benefit. Second, the industry is composed of many small
start-up companies with limited resources to devote to regulatory affairs.
Third, we are dealing with a sophisticated industry whose players have
been, from its origin, very involved in regulatory matters. It was the
scientists who came to Asilomar in the 1970s, many of whom subsequently
became the founders of biotechnology start-up companies and the industry
as a whole.
Many years later, the major question is: Has regulation negatively or
positively affected the development of the U.S. biotechnology industry? I will
speak to this subject in comparison to Europe. I will primarily address the
regulation of plant biotechnology, but will also mention the regulation of
the medical biotechnology industry because the pharmaceutical industry is
prominent on this year’s program. I will begin with my conclusions.
CONCLUSIONS
• The U.S. plant biotechnology industry has been positively affected by
domestic regulation and finds itself at a competitive regulatory
advantage to its European counterpart.
• The industry has, however, been negatively affected by European
regulation, in that companies hesitate to develop export crops for the
European market or make investments in Europe because of perceived
regulatory uncertainty.
• The U.S. medical biotechnology industry is domestically subject to
very burdensome and stringent regulatory requirements. The industry
is, however, not more disadvantaged than its European counterpart,
because both regulatory regimes are costly and provide few incentives
for the regulator not to err on the side of caution.
Those conclusions, as well as the subsequent arguments, are based on
studies of companies with similar operations in Europe and the United
States, of which I will give you an example. I call it: A Tale of Two
Companies.
A TALE OF TWO COMPANIES
This is the example of a U.S. and a German based company, both of which
developed a virus resistant crop, a squash, and a sugarbeet. Each crop raised
very similar regulatory concerns in each country, i.e. questions of gene trans-
fer and cross-compatibility with wild relatives. In order to gain a permit for
field testing the crop, the U.S. based company faced a one-step regulatory
process involving primarily the USDA-APHIS. The German based company
instead faced a three-step regulatory process. The company first needed to
submit its application to the national authority. The national authority in-
turn sent a summary of the company’s dossier to the European Commission,
that, in-turn, sent the summary dossier to all member states of the European
Union.
As far as the applications are concerned, the U.S. application consisted
of 21 pages: seven pages on host and recipient organisms, vectors, and
the genetically modified crop; four pages on the purpose of the field test,
methods of data collection and harvest procedures; and one paragraph on
the location and supervisory personnel. The remaining pages were graphs to
support the above. The German application consisted of 100 pages: 60 pages
on host and recipient organisms, vectors, and the genetically modified crop;
30 pages on the purpose of the field test and environmental risk; and 10
pages on company personnel and the supervision of the test.
Monitoring requirements in the U.S. call for only an annual field trial
report, while the German company must issue a mid-trial and final envi-
ronmental assessment report. In a 1995 article in Bio/Technology, Margaret
Mellon and Jane Rissler showed that the U.S. monitoring requirements are
inconsistently implemented by the USDA, while in Germany the imple-
mentation is consistent.
The initial review time for the U.S. application was 118 days. This number
was reduced as the agency gained experience with the company’s product
and subsequent field trials were approved much more rapidly. In Germany,
the approval took 175 days, followed by an appeal to court that added 32
days to the overall approval time.
The overall cost was greater in Europe than in the U.S. The estimated cost
of company regulatory affairs time in the U.S. was $5,000, while in Germany
it was approximately $100,000. An application fee does not exist in the U.S.
but is in the range of $7,500 to $45,000 in Germany, dependent on the time
and effort it takes the agency to review the application. A legal cost that
is not an issue in the U.S. was estimated by the German company to be
approximately $100,000.
This company comparison illustrates what I call the American regulatory
advantage in plant biotechnology. The American regulatory advantage in
plant biotechnology is two-fold. It consists of the regulatory regime per se,
and companies’ regulatory proficiency.
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THE REGULATORY REGIME
Regulatory Structure: The U.S. regulatory regime is much more centralized
than its European counterpart and presents fewer regulatory hurdles to the
company.
Regulatory Requirements: The U.S. regulatory requirements are far less
burdensome than their European counterpart where more data regarding the
environmental safety of the field test, the specifications of release conditions,
and the monitoring and control of test sites are required.
Stringency: U.S. regulatory requirements are less stringent than their
European counterpart.
Regulatory Style: The U.S. regulatory agencies are less legalistic than their
European counterparts, clearer in their requirements, more cooperative, and
less adversarial.
Review Times: Review times are consistently faster in the U.S. This is more
so since the introduction of the notification process for well-characterized
crops.
Regulatory Certainty: In comparison to Europe, the U.S. issued its guidelines
for field-testing genetically modified crops and the commercialization of trans-
genic foods much earlier.
Statutory Flexibility: In the U.S., a single agency can adapt to technical
progress given requirements and policies. In Europe instead such decision has
to be taken by the European Commission and in part with the agreement of
the European Parliament.
Other speakers may discuss whether these U.S. regulatory advantages come
at a cost of increased environmental risk and reduced safety. I believe that
one can have an efficient regulatory regime that safeguards the environment.
The second important part of the American regulatory advantage is the
companies’ regulatory proficiency or their capacity to respond to regulatory
challenges.
COMPANY REGULATORY PROFICIENCY
Company Organization: U.S. biotechnology companies are staffed with a
director for regulatory affairs who is actively involved in product development.
In Europe it is often the lead scientist who interacts with the regulator.
Company Experience: U.S. biotechnology companies are often experienced
in dealing with environmental regulation, as often they are managed and/or
staffed by former employees of the chemical industry (e.g. Mycogen’s CEO
formerly worked at Monsanto) or former employees of the EPA. Many
European companies have never been regulated on environmental grounds.
European regulators rarely move into the private sector.
Status of Regulation: Many U.S. companies consider regulation an integral
part of product development. Many European companies consider regulation
after they have developed their product.
Company Ingenuity: Some of the U.S. biotechnology companies established
relatively early proved to be extremely innovative and imaginative in their
response to regulatory challenges. European companies have not shown such
ingenuity.
Following the above, it is tempting to conclude that the success of the U.S.
agricultural biotechnology industry, in comparison to its European counterpart,
is in major part the result of the regulatory proficiency of both the industry
and government.
I conclude, however, that this is not entirely so. Regulation is only one factor
in a complex innovation system. While regulation is critical at certain stages
of product development, it rarely determines whether a company is founded,
an entrepreneur realizes his or her plans, a product gets developed, or a tech-
nology is adopted. Hence, it does not have a direct impact on innovation per se,
but is always reactive. Only in situations where there is extreme regulatory un-
certainty can regulation seriously affect the development of an entire industry.
Why have the same set of techniques generated so much more industrial
activity in the U.S. than in Europe (measured in terms of the number of field
tests)? I suggest the difference goes beyond regulation to the industrial orga-
nization in place at the time of the introduction of the technology.
INDUSTRIAL ORGANIZATION
When biotechnology was introduced, there was an established European chemi-
cal industry (e.g. Hoechst, Bayer, BASF) that was dominated by chemists who
were reluctant to enter biotechnology and had historically never been in the
seed business. On the other hand, the European seed industry consisted of
small- and medium-sized companies that were mostly family-owned and very
traditional in nature. They were slow to innovate, reluctant to go high-tech, and
had limited resources.
In contrast, the United States biotechnology industry consisted of start-up
companies and established chemical companies. The start-up companies were
very innovative and open to risk-taking, specialized in biotechnology tech-
niques, and were staffed by university researchers and molecular biologists with
close ties to the research community and the land grant institutions. Those
companies were highly dependent on product approval because of the need to
demonstrate to the venture capital community that they were worthy of fund-
ing. In most cases, the established chemical companies (Monsanto, Dow etc.)
were active in crop protection and, in some cases, the seed business. In the
1970s, many U.S. chemical and petro-chemical companies had bought into
seeds. The large chemical corporations also benefitted from the close proximity
of innovative start-ups. Finally, the U.S. industry consisted of the world’s largest
seed company (Pioneer) with large resources. This U.S. industrial organization
favored it over its European counterparts.
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In conclusion, I wish to emphasize the following points:
• Regulation plays an important role in assuring consumer confidence. This
is particularly so in a new industry such as biotechnology.
• A good regulatory framework, such as the U.S. framework for the regula-
tion of plant biotechnology, provides a support structure to industrial
development but is not critical to innovation.
• The largest responsibility for innovation, industrial development, and the
success of the regulatory process lies with individual companies, their
organization, and the industry as a whole.
This is one way to frame the discussion, but we must recognize that the
title itself — food industry — is a cultural expression. It is a way of seeing
the world. It also implies a monoculture: there is one correct way to view the
world, including food and agriculture. This is the way the wealthy industrial-
ized societies of the North view the world out of their historically and culturally
distinct experience. But what about other perspectives and experiences? A
woman’s perspective, or that of a laid off worker? Or the perspective of a lesser
developed country’s subsistence farmer? Or an aboriginal in Costa Rica, or in
the southwest or north of this continent?
Are we even aware of the biases and assumptions that we take on when we
use the cultural expression “food industry” and do we, or are we willing, to
take account of how others might view these issues?
I am not castigating the NABC, because when I raise these alternatives, I
must say that the NABC looks like the most thoughtful and sincere discussion
on biotechnology going. Look, for comparison, at the hype surrounding the
1996 “Agbiotech International Conference” being held in Saskatoon. “New
Technologies! New Marketing Partners! New Opportunities!” is the conference
slogan. Complete with exclamation marks. In keeping with their slogan, I can
find no indication in their program that there will be any critical discussion of
anything. (Not that this surprises me, given who has organized the event.)
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The Food Industry Workshop: “Evaluate the pathways to
be taken by new agricultural biotechnology food products;
issues of communication, regulation, and concern over
something so ‘personal’ as food; and ways in which the
production of new food crops might impact the structure
of the agricultural industry and the food industry itself.”
Or look at the program for Bio ’96 in Philadelphia. As far as I can see from
the program, there is one workshop, out of about 80, that deals with ethics,
titled “Characterizing & Addressing Ethical Issues.” The information package
states “The Bioethics Committee and industry representatives will discuss case
studies where research and product development yield ethical implications, and
will participate in analysis of ethical implications of case studies.”
The language boggles my mind: what is meant by “yield ethical implications”?
At first I thought there had been a mistake when I saw that I was down to
speak in the Economic and Structural Issues session, rather than yesterday’s
session on Social Issues, Regulations and Ethics. But as I pondered it, I realized
that this is indeed the right slot for me. When I studied theology, ethics was my
major interest. The subject was referred to as Christian ethics or social ethics,
and the focus was largely political and social, not individual and personal. Since
then, I have found myself increasingly focused on economics and its institu-
tions and structures — as well as the values and assumptions on which they are
based. Meanwhile, it seems to me that ‘ethics’ has been increasingly defined in
individualistic terms as issues of personal choice. The rising field of medical
ethics and bioethics is a good illustration of this, where individual choice reigns
supreme and social good does not seem to be even a recognizable category,
much less an ethical framework.
A good example of the application of this individualized ethics is the V-Chip,
described by New Scientist magazine as a way “to banish TV sex and violence
from American homes.” This bit of technology seems to be based on the
assumption that there is no way, or desire, to get rid of TV sex and violence,
along with an acknowledgment of negative effects on children. An obvious
social problem of rather substantial ethical significance is reduced to a matter
of individual parental option.
And while it may strike you as stretching the point, it seems to me that the
labeling of genetically engineered foods is being approached in much the same
way. There appear to be no questions raised either about the production of
violence on TV or about the production of genetically engineered food. In the
case of food, the biotechnology industry promotes the position that it would
be absurd, unworkable, and costly to label genetically engineered food. In a
1993 interview, an FDA spokesperson said: “It would not be merely a matter of
putting a sticker on a tomato or a banana. Producers would have to segregate
the genetically engineered foods from other varieties. Does the label have to
follow the food processing chain? It would increase the cost of these foods to
consumers and would disrupt our complex food distribution system.”1
1 James Maryanski, biotechnology coordinator, Center for Food Safety and Applied Nutrition, FDA,
in a 1993 interview by FDA consumer writer Mary Alice Sudduth.
Monsanto’s 1995 kit for the American Dietetic Association2 takes the same
line: “Some consumers believe that foods derived from new plant varieties
[notice the slick linguistic trick of referring to “new plant varieties”] should be
labeled as such. These individuals [only “individuals,” of course] base their
position on the consumer’s ‘right to know’ the food’s method of production.
Practical considerations make such a position difficult to implement . . . and
would result in increased costs to consumers with no benefits.” Except, of
course, their ability to reject Monsanto’s biotechnological products.
But if there is a problem of informing the public about what they are
expected to purchase and eat, then maybe the production of these foods in
the first place is the real problem, and not labeling at all.
Since this session is on the subject of economic and structural issues, I must
ask why it is that our culture is so loath to examine the structures of business.
For myself, I find it necessary to focus on structures and institutions in order to
properly frame the ethical and social issues, and I seldom use the language I
was once trained to use. In fact, I was a little appalled when I pulled some old
textbooks off my shelf and looked at them from my current perspective. They
were terribly inadequate in the way they framed the questions and in their
cultural bias — typical, I am afraid, of the chauvinism and imperialism of
American culture at the time. But is it any different today?
The processes and products of agricultural biotechnology, as well as their
human counterparts, are expressions of a particular historic culture: the culture
of Enlightenment, Industrial Revolution and Reductionism Science. Biotechnol-
ogy is an artifact of this culture. It is no more a universal outcome of evolution
than our notion of science itself.
In fact, we might describe biotechnology as an apocalyptic remnant of the
19th and 20th century idea of Progress and Development — sustainable or not.
Just recall the language you see in virtually every piece of literature on biotech-
nology: “improved” seeds, “superior” genes, “best” traits, and so on. Mean-
while, fewer and fewer people believe in the myth of progress — and those who
still do are generally of the white northern business class — a rather small elite
of the global population whose own children appear to be rejecting the idea.
Stripped of its emotive language, biotechnology would look like Swiss
cheese — or the brain of a cow suffering from BSE!
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Company in cooperation with The American Dietetic Association, 1995.
On the basis of its belief in a deterministic understanding of evolutionary
progress, it is not surprising that our culture has taught us that there is only
one valid epistemology, only one way to know about life and the world. We
might well apply the term ‘monoculture’ both to the knowledge system of our
rationalist, industrial culture, and to its practices, for example agriculture.
Our notion of science and technology is, in fact, based on an epistemological
monoculture. One might well add that sexism, racism, and nationalism are also
expressions of monoculture. As in a field of hybrid corn, variation and differen-
tiation are not welcome! They interfere both with the images we have come to
accept as normative and with the production process. The model is still the
production line. (You should see the difference in my garden and my daughter’s
— I have a hard time not planting in tidy rows, while hers is helter-skelter —
herbs, flowers, and vegetables in glorious confusion.)
Lest you think I am being extreme, let me remind you that not very long
ago the term “junk DNA” was used to describe what could not be explained:
because it could not be explained, it was junk. Prions did not exist very long
ago either, much less mutant prions that seem to cross species barriers on their
own. And an article on the genetic blueprinting of yeast in the April 27, 1996
issue of New Scientist made the interesting comment that, “Sequencing the yeast
genome has revealed a vast terra incognita. Biologists have no clue as to the
function of 40 percent of the genes they have identified. Half of these enigmatic
genes have DNA sequences similar to other, equally puzzling genes in fruit flies,
mice, or other organisms, but half have never been seen before. Researchers
have dubbed these genes ‘orphans’ because no one knows which gene families
they belong to.”
I suppose the common response is that we will soon fill in those blanks and
complete our knowledge. But will this be the case, or only the case as we wish
it to be? Unfortunately, we are all too likely to simply ignore (or eliminate or
“disappear”) what does not fit, or, for that matter, other ways of knowing.
I do not say this with malice. I, like most of you, grew up in an era and a
culture of imperialism — only we called it “development”. In this culture it
has been assumed that everyone wants to, and could, become like us. And, of
course, it has been assumed that we know how to make this happen. Agri-
cultural biotechnology, as a reincarnation of the Green Revolution, and based
on the same neo-Malthusian assumptions, is simply the latest artifact to be
devised in pursuit of this goal. Monoculture is a perfectly reasonable phenome-
non in this context. There is one goal, and one way to achieve this goal. Cer-
tainly the propaganda of industrial biotechnology expresses this monoculture.
But I have been taught by others, as well as by my own experience, which I
refuse to invalidate, that there are always more ways than one to know anything
and to do anything. It all depends on perspective, experience, culture.
Now we are faced with a profound contradiction in modern industrial
biotechnology: the claims made for it are that it will enhance life, improve
nutrition, increase biodiversity, and save the environment. Yet it seeks to
achieve this through the violent manipulation of the very foundations of life.
If we look at the medical field, we see the application of biotechnology in
the form of esoteric and heroic measures to defy death, almost exclusively on
an individual basis. It is not vaccines for malaria or treatments for pneumonia
or cholera that get the research — it’s the transgenic animal organs for xeno-
transplantation.
The director of the World Health Organization recently commented that
“The optimism of a relatively few years ago that these [infectious] diseases
could be brought under control has led to a fatal complacency.” The report that
he introduced points out that diseases known for centuries are now popping up
in incurable strains, many of them increasingly resistant to drugs as a result of
“the uncontrolled and inappropriate use of antibiotics.” Making matters worse,
the report points out, are modern methods of food production, such as the
use of antibiotics in meat production to promote growth, but not in sufficient
amounts to kill microbes, with the result that drug-resistant bacteria are then
passed through the food chain to the consumer. “In the contest for supremacy”,
reports the World Health Organization, “the microbes are sprinting ahead.”3
The advocates of biotechnology are quick to claim that what they are doing
is simply more of what we have been doing for millennia — making bread
and wine and cheese. In a sense they are correct. Biotechnology is just another
expression of the drive to control not only the world around us (nature, or
Creation), but also other people. It is fully in keeping with the attitude of
Francis Bacon who, more than 300 years ago, as Sandra Harding points out
so lucidly, used the sexual imagery of rape and torture to describe the proper
scientific attitude toward nature.4
Technology, or technique, is a culturally embedded approach to acting on the
world. It is a set of tools, particular tools that express cultural attitudes and
values, such as speed, or taking things apart to see how they work. In the case
of western industrial society, it is also a technology of domination and control,
over nature, people, and life itself. Biotechnology is specifically the application
of technology to life forms.
If we look candidly at the practice of biotechnology, we see violent interven-
tion in the structures of life in order to reshape it according to our goals and
purposes. In this respect, it can be said that biotechnology is engaged in a form
of structural adjustment, but directed by Ciba-Geigy and Monsanto rather than
by the World Bank and International Monetary Fund (IMF).
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Applied to biology, however, structural adjustment is social engineering,
and this should remind us of eugenics, that is, the deliberate selection of
“superior” genes, organisms, people. What else can the constant talk about
“improved” seeds and crops mean? Structural adjustment, whether in the lab
of Plant Genetics System (PGS) or the board room of the IMF, is about selecting
preferred structural characteristics and effectively disposing of those not con-
sidered desirable.
The purpose of structural adjustment is, after all, control. And in a market
economy society this control is translated into profit and the accumulation
of wealth.
In biotechnology and genetic engineering, then, we have simply taken what
may be the final step in a logical process. We are now engaged in the redesign
of life itself, with wealth and eternal life as the goals. (We might also describe
this as an expression of the fear of death.5) We cannot, however, honestly say
that we are trying “to enhance life” in general. It is only those with the money
to buy hopes of immortality that are of interest to the market.
Look at current developments in genetic testing for cancer. While many
social, ethical, and medical questions remain unanswered, including questions
about the efficacy and interpretation of testing itself, companies are gearing up
for large-scale testing for BRCA-1 and the more recently discovered BRCA-2,
genes that “cause” or predispose to cancer. “Profits are expected to be huge.
The cost of Myriad’s new test for BRCA-1 is going to be near $1000 a patient,
and this doesn’t include the cost of the doctor’s examination and counseling
after the results come in,” according to an executive at Myriad Genetics. Myriad
is itself gearing up to test 100,000 women per year.6
Speed kills. This has been a popular slogan to reduce automobile accidents.
As in the case of the V-chip or the labeling of genetically engineered food, the
slogan blames the victim, as it were, rather than putting the blame where it
belongs in the first place, on the automobile manufacturers who build auto-
mobiles to go fast and sell them on the basis of performance, performance
defined as acceleration and speed, or on the investors in the production of
violence for TV.
Isn’t it exactly the same with biotechnology? One of the industry’s favorite
justifications for biotechnology is the speed with which changes can be made
and results achieved — on the assumption, of course, that this is inherently
good. Speed is, after all, what comes with progress: faster aircraft, faster cars,
5 “Having directed so many life trends in North America for the past couple of decades, baby boomers
are looking to dictate new terms for death, including its elimination. With their late first marriages,
late parenthood, second careers, fitness fixations and pharmacological inroads on aging, many of
them — and the social institutions that cater to them — seek to defy and deny the outrage of finite
existence.” (Toronto Globe & Mail, 5/18/96).
6 Toronto Globe & Mail, 7/5/96.
faster trains, faster communications of all sorts — and I just love e-mail! (Let’s
just ignore, for now, the contradiction between speeding fruit by jet from Chile
to Canada while it has also been designed for longer shelf-life.)
Currently the biotech industry is making a great push to have its notion
of the benefit of speed applied to the regulatory system. Quick approval has
somehow become a desirable goal, a ‘good thing’. ‘You can’t stand in the way
of progress’, we are told.
The Canadian Government’s proposed revisions to the Environmental Pro-
tection Act are a good illustration of this. In its position paper the government
stresses that it is “the new paradigm of global competitiveness” and “the ability
to innovate and respond to new technologies [that] determines corporate suc-
cess,” and says that it “wants to ensure that we have a regulatory regime in
place which . . . places Canadians at a competitive advantage.”7 What little it
says about social or ecological health is strictly an addendum to
competitiveness.
I do not think that a cynical response is out of order. If the regulation of bio-
technology is subject to such mindless criteria, we will indeed be able to say
that ‘speed kills’ — but it will be too late. The point of a regulatory process is
not speeding new products to market in the name of global competitiveness. It
is sanity and health — not the health of the market or the corporation, but the
health of the society and all life.
Unfortunately, industry seems to see itself as above and beyond society, and
its corporate health as achievable without public benefit or control. As a result,
we see industry engaged in blackmail, in Germany and other jurisdictions
around the world, saying that if the regulatory process is not liberalized and
speeded up, it will take its business elsewhere. So now we are in a game of
competing globally to see who can get away with the lowest standards. It is
genuinely frightening!
The second characteristic of biotechnology is supposedly the precision of its
processes. The industry makes much of this precision, although many prac-
titioners deny it exists. Even if the precision is real, we must still question its
value; after all, it is precisely the lack of precision that makes it possible for
organisms to evolve and survive.
What is more interesting, however, in terms of the structural issues we
should be addressing, is the fact that both speed and precision are character-
istics of process, not product. So we are faced with this contradiction: the
industry claims it is the process which makes the products of genetic engineer-
ing superior to traditional plant breeding, then turns around and says that as
far as regulation and labeling are concerned, it is only the product that counts.
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Let’s look more closely at this process-product issue, because it is present
at every level, from Codex Alimentarius to the City of Toronto’s Food Policy
Council.
I think the biotechnology industry is right to resist the labeling of foods as
products of biotechnology. They know the public concern, and they know that
the public does not make the process/product distinction that the industry
would like them to. Why should the public make this distinction? In Ontario,
for example, kosher dairy products have been on the market for quite a while,
labeled as such. And halal is also recognized. Yet when a very substantial group
of organic diary farmers wanted to market certified organic dairy products, the
Ontario Milk Marketing Board fought them all the way, saying they could not
make an exception to the rule of monoculture. The OMMB lost, and organic
milk is now on the Ontario market and doing very well. The underlying
concern here was well expressed by the exasperated comment of a western beef
rancher: “What am I, inorganic?” It is assumed that the organic label indicates a
superior product. This is acceptable when the group for whom the product is
superior is small or marginal (Jews, Muslims, people allergic to peanuts), but it
becomes terrifying when the assumed superiority has a more general appeal as a
more wholesome, less high-tech or manipulated food.
The recent meeting of the labeling working group of Codex Alimentarius in
Ottawa had to wrestle with this process/product issue: on its agenda was the
labeling of halal, kosher, organic, and biotechnology foods. All are process
issues, but not much headway was made on the biotech issue because there was
no agreement to proceed on the basis of the U.S. position that how a food is
created, grown or processed is irrelevant — at least in the case of biotech foods.
In the FDA interview cited earlier, in response to the question, “What values
will these genetically engineered plants have — more nutrients, better taste?”
the FDA spokesperson had an honest response: “Right now, it’s more a matter
of giving fruits and vegetables better shelf-life and shipping properties.” In food
production, genetic engineering is being applied primarily to the industrial
commodity crops: tomatoes, corn, oilseeds, soybeans, potatoes and cotton.
These are not crops that are in short supply or that need, as the industry calls
it, improving. And what has been done to them is to make them more amenable
to monoculture industrial production — regardless of what the companies
might say about nutrition and the environment. These crops are being adjusted
structurally in order to provide greater sales and profits for a very limited
number of very large transnational corporations — corporations that are getting
fewer in number and larger every day. (The merger of Ciba-Geigy and Sandoz
into Novartis is just the latest and largest. Monsanto, meanwhile, is busy with
another kind of expansion, having taken control of Gargiulo and Calgene in
recent months.)
Even the World Bank is getting concerned. An agricultural specialist with
the bank recently warned a Saskatoon audience that biotechnology might start
avoiding research of public value, but little private profit. “Who is going to
make the public good investments in fundamental research to agriculture?”
Alex McAlla asked.8
At the same time, there is another sort of structural adjustment going on.
One begins to realize that ‘jobless recovery’ and ‘downsizing’ and a whole lot
of other euphemisms are really telling us that the corporation is no longer
interested in production. It is not sales that count, as a look at the way Forbes’
magazine rates companies reveals. What counts is equity and return on equity,
dividends, and increases in share value. These are all expressions of what is
now being heralded as “shareholder value”. Another expression of this is the
preoccupation of business with the financial markets, that is, those markets
where the trading is not done in real commodities, things that people can
actually eat or use to keep warm, but in invisible or imaginary commodities,
such as derivatives that are based on the movement of stock indices or currency
exchange rates.
If we are honest about it, we must conclude that, as presently practiced,
biotechnology is going to offer nothing to the subsistence farmer anywhere —
except perhaps lower prices for what little surplus he or she may try to sell.
What it promises is greater ‘shareholder value’ for wealthy northern investors,
much of this to be derived from the value-added activities of everyone from the
biotechnologist to the further-processor. But this shareholder value is simply an
extraction or transfer of wealth that has nothing to do with social benefit,
personal well-being, or even nutrition.9
In the case of food, value-added is used to describe anything that might
provide an opportunity to increase the selling price of a product, from simply
washing potatoes instead of selling them covered with mud to turning them
into pre-cooked frozen french fries, or what’s worse, reprocessed, cooked, and
canned “Pringles” (now P&G’s biggest export product). And in practice, value-
added largely means nutrition-subtracted.
Kneen
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9 “Imperial Oil aims to boost shareholder value” was a recent newspaper headline: “Imperial Oil is
considering a number of moves to boost shareholder value, including buying back a large chunk of
stock or paying a special dividend... Investors believe the company’s managers will take bold steps
to enhance the value of its stock. A large buyout would have that effect, as it would dramatically
increase demand for the stock. At March 31, Imperial, Canada’s largest integrated oil company, had
$2 billion in cash and marketable securities, with $1.8 billion in debt. In 1995 it earned $514 million
on revenue of $9.4 billion.” (Globe and Mail: 5/14/96) .
When I butchered the lambs we had raised, I did not consider that I was
adding value. I was, first of all, taking a life. Second, I was putting that animal
in a more attractive and convenient form for human consumption. I was not
adding value to the meat of that lamb as a delicious and nutritious food.
Another example from my experience as a sheep farmer. We found it
necessary, for our survival, to organize a cooperative. It was a non-share capital,
farmer owned and operated co-op that took charge of marketing lambs for the
sheep farmers of Nova Scotia on a voluntary basis. That is, there was no legal
compulsion or authority in what we were doing. What we did, in fact, was gain
control of lamb marketing — from the farmer through delivery to the super-
markets. We had to concentrate power and control in order to gain a reasonable
return on our labor. Not to make a profit, not to make a return on our capital,
and not to increase shareholder value for the co-op, but to hopefully make a
living wage.
The application of biotechnology to food is often described as ‘adding value’.
I can see the added cost aspect of it, particularly given the new emphasis on
intellectual property rights, though the speed of new product development is
outrunning the patent process. However, I have yet to see any indication of the
added nutritional value that the industry uses as a selling point, particularly
with gullible health professionals and their organizations, such as the American
Dietetics Association (ADA) and Canadian Dietetics Association (CDA).
So when we look at agriculture, and at that application of biotechnology to
agriculture, we readily see that it is not about feeding the hungry of the world,
or even the growing population of the world, in fact. Nor is it even, really,
about feeding the growing appetites of the growing global middle class. What
it is about is making more money for corporations out of what is already being
produced. We are, in fact, in the midst of a massive structural adjustment for
the simple purpose of increasing shareholder value.
We are fond of referring to this new economy as an information economy,
and noting that DNA is merely a form of information, which can be manipu-
lated for profit just like other forms of information. Considering the global
economic structural adjustment I have been describing, I think it may be more
accurate to describe this as a post-production economy. I leave you with that
thought.
The agricultural industry is experiencing a period of dramatic change as new
developments in biotechnology provide different methods for making products.
How the industry responds to the new challenges will, to a large extent, be
governed by the attitudes of the consumer. One of the major effects of biotech-
nology will be the altering of consumers’ attitudes towards farm crops. Future
farms will produce food more efficiently, perhaps in environments where
originally it was considered too difficult. In addition, farms will produce many
different raw materials for industrial processes, a variety of pharmaceutical
proteins for human and animal use, and serve as a source of vaccines for many
of the developing nations.
One of the technologies that will contribute to this expansion in new prod-
ucts is the generation of transgenic species, both plant and animal. The purpose
of this paper is to introduce transgenic animal technology by describing what
it is, how it is performed, and why it has such potential. A few examples of
possible products will be discussed, and the concept of livestock “stem cells”
will be introduced.
WHAT IS TRANSGENIC TECHNOLOGY?
A transgenic animal has been defined as an animal that is altered by the
introduction of recombinant DNA through human intervention. The first
transgenic mice were produced in the early 1980s, but it is only within the
past seven years that transgenic livestock have been produced on a routine
basis (Wall, R. J. 1996).
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PPL Therapeutics is the world’s leading producer of transgenic animals. We
are based on three continents (Roslin, Scotland; Blacksburg, USA; Whakaru,
New Zealand) and have the ability to produce transgenic mice, rabbits, sheep,
pigs, and cows. The different species allow PPL to tailor the production route
to the product’s market volume and the customer’s requirements for speed to
market (see Table 1).
TABLE 1: CHARACTERISTICS OF DIFFERENT SPECIES
Milestones Cow Sheep/Goat Pig Rabbit
G0 birth (1) 9 5 4 1
Induced milk (1) 16 9-10 – 4
Volume of induced ~1- >100 ~1-50 – 0.01-1e
milk (2)
G0 adult (1) 21 13 11 6
G1 birth (1) 31 18 15 7
(natural milk)
Milk Volume (3) >10 000 250-700  >100 ~1
per lactation.
(1) all times are in months and relate to the starting point of microinjection
(2) all volumes are in liters and can vary considerably between individual animals
(3) all volumes are in liters
e estimate
Each species has its own quirks and difficulties, but essentially, the process is
the same. A DNA construct is designed and built to express the desired protein
in the animal. The site of expression is determined by the regulatory sequences
used in the construct to control the coding sequence. This construct must then
be introduced into a single cell embryo to allow incorporation of the transgene
into the animal’s genome. There are several methods available for this purpose,
including retroviral transmission, stem cell transfection, and microinjection
into the pronucleus or cytoplasm. The most popular and most successful
method involves microinjecting the DNA solution into the pronucleus of the
embryo using a very fine glass needle. The injected zygote is then transferred
into a hormonally prepared recipient and brought to term. Finally, positive
transgenic animals are matured and the level of expression of the transgene
is determined (Palmiter et al., 1982).
DNA CONSTRUCT PREPARATION
The DNA (a gene) that codes for a suitable therapeutic protein is cloned and
sequenced. Every complete gene that codes for a protein has a control element
(a promoter) attached to it. These direct the expression of the gene to specific
sites in the body, at specific levels and times, depending on the function of the
protein. PPL attaches a milk gene promoter (ovine b-lactoglobulin) to the
therapeutic protein coding region to direct expression of the gene specifically
to the mammary gland of the animal. In this way, the transgenic protein is
produced in the milk of the animal and can be harvested and purified with no
adverse effects on the animal. An added advantage is that the protein can be
purified using regular dairy techniques, as well as high technology chromato-
graphic procedures.
TRANSGENIC PRODUCTION
After introduction of the construct DNA into the one cell embryo, the construct
DNA is incorporated into the DNA of the cell by an, as yet, unknown mecha-
nism, and only in a few cases are transgenic animals produced. The rate of
transgenesis can be 5-25 percent of live births; it is generally believed that the
larger the animal the lower the rate, although in recent experiments with cows
PPL has achieved high rates of transgenesis.
The embryos are cultured in vitro for various lengths of time before being
transferred back into a hormonally prepared recipient female. The pregnant
animals are brought to term, the offspring are tested for transgenesis, and the
positive ones are bred for milk production. This whole process of injection to
milking takes 13 weeks in mice, 44 weeks in sheep, and 135 weeks in cows,
although with the development of hormonally induced premature lactation,
information on the transgenic protein’s expression level and quality can be
obtained within 70 weeks for the cow. Because the quantity of induced milk
produced by a cow can be far greater than a natural lactation from sheep or
goats (see Table 1), a lot of the purification and pre-clinical studies may be
performed without having to wait for the cow’s natural lactation to begin.
WHY USE TRANSGENIC TECHNOLOGY?
There are various methods of protein production available commercially,
including bacterial, insect, fungal, and mammalian cell culture systems. How-
ever, they each suffer, to varying degrees, from two major limitations. First,
many therapeutic proteins have specific configurations that are necessary for
activity. In addition, they frequently require quite complex post-translational
modifications (PTM).
Some proteins require glycosylation (the addition of certain sugar residues)
for activity or to ensure that they are not cleared from the circulation too
quickly (Jenkins et al., 1996). Bacterial expression systems cannot perform
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most of these modifications and can subtly alter the folding of the protein.
Yeasts and higher plants can make many of the simpler additions, but are
limited in their ability to perform complex modifications.
One form of PTM found only in mammalian cells is gamma carboxylation,
which is essential for the vitamin K dependent proteins, such as Factor IX, used
to treat hemophilia B, and protein C, an anti-coagulant. Although these proteins
can be produced in mammalian tissue culture systems, the levels of expression
are very low and attempts to increase it have not been successful. Another
source is fractionation from human blood plasma, but the quantities available
cannot satisfy the market, and possible contamination with human viruses
(HIV, or hepatitis B and C) is a significant risk.
Large complex proteins, such as fibrinogen, cannot be produced at com-
mercial levels in any culture system available today. Fibrinogen is an hexameric
molecule consisting of two sets of three polypeptides encoded by different
genes, and held together by 29 disulphide bridges. For proteins such as this,
transgenic animals probably represent the only possible method of production.
The second limitation is that the cost of building and running modern
production facilities for cell culture is extremely high. The initial capital
investment in a very expensive production facility for a product that has not
been through clinical trials, and which may fail, is hard to justify. This gives
two compelling reasons for the development of transgenic technology:
Production of complex proteins: The mammary gland is able to perform most
PTMs that are needed for therapeutic proteins. Even a protein as large and as
complex as fibrinogen can be produced in the mammary gland in gram/liter
quantities.
Cost of manufacture: The initial capital investment to produce transgenic
animals is one to two orders of magnitude lower than for large production
facilities. Operational costs are also considerably lower.
Alpha-1-Antitrypsin
One of the most advanced transgenic products is alpha-1-antitrypsin (AAT),
a serine protease inhibitor. The protein is being developed by PPL for the treat-
ment of lung disorders, including cystic fibrosis.
The transgenic sheep line that was chosen for this product has been studied
in great detail. Expression levels and transgene copy numbers have been fol-
lowed over five generations of sheep, over four complete lactations in indi-
vidual sheep, and between more than seven siblings, all without showing
any significant change. All of the production animals are New Zealand sheep,
especially flown to Scotland to avoid any possible problems with scrapie, a
spongiform encephalopathy of sheep that is not found in New Zealand.
There are now nearly 150 milking ewes in the production flock, producing
AAT in the new pilot production facility, the first of its kind in the world.
This facility has been designed and built by PPL to combine a high-tech dairy,
operating within Good Agricultural Practice (GAP), with a state-of-the-art
protein purification plant operating in accordance with Good Manufacturing
Practice (GMP) requirements.
REGULATORY ISSUES
A very important part of any new technology is developing procedures and
practices to ensure that regulatory concerns are addressed. PPL has been in
contact with the regulatory authorities in Europe and the United States for
several years to help to establish the highest levels of safety possible. The Food
and Drug Administration’s (FDA) Points to Consider (Aug. 22, 1995) and the
European Community’s CPMP Draft Guidelines (July 4,1995) on production
of therapeutics in transgenic animals were generally well received by the
industry. Using those documents and our own expertise, PPL has developed
a regulatory strategy for transgenic animals in the production plant. That
strategy begins with checking the sequence of the transgene to ensure there
are no known oncogenic sequences present, and continues after the birth
of transgenic animals with:
Check Insert: An analysis of copy number, transgene integrity, number of
insertional sites, and stability of the insert is carried out.
Seed stock: Semen of low generation male from the same line. This could be
compared to the working cell bank of a tissue culture system.
Production flock: As the seed stock comes from low generation males, the
production flock will consist of several groups of half sisters with the same
integration site.
Highest possible quality animals: PPL’s sheep are imported from New Zealand
specifically because the health status of these animals is the best in the world.
Quarantine animals: The sheep on our farms are kept in strict quarantine from
other animals to minimize the risk of infection.
Control of feed stock: There is strict control over the feed stock and only
approved suppliers are used.
Regular health screening: The animals are regularly checked by qualified
veterinary surgeons. Animals showing any signs of disease are immediately
removed from the milking flock.
Dual site production: In the future there will be several sites of production.
This is a precaution in the unlikely event of a flock or herd infection at one site.
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POTENTIAL PRODUCTS
Protein C
Protein C is an anti-coagulant that plays an important role in the blood clotting
cascade. To be active, the polypeptide must be cleaved into light and heavy
chains, N-glycosylated, correctly folded and linked with disulphide bridges, and
have nine gamma-carboxyl groups attached. Clearly this is a complex protein.
PPL has produced fully active transgenic protein C at levels of 0.3g/l in sheep.
In addition, in blood plasma it can be seen that not all of the polypeptide is
cleaved into two chains. Some single chain material remains that cannot be
activated. In collaboration with Zymogenetics of Seattle, Wash., we have altered
the cleavage site to increase the efficiency of cleavage to 100 percent (Foster et
al., 1990). Therefore, all of the transgenic material can potentially be processed
to make active protein C.
Fibrinogen
Fibrinogen is a complex plasma glycoprotein required for the final phase of
blood coagulation. It is produced in liver parenchymal cells where the six
chains are assembled and linked by 29 inter-chain and intra-chain disulphide
bonds. Complete molecules are then secreted into the blood stream. Fibrinogen
is going to be useful as a therapeutic protein and is one of the main components
of surgical tissue sealants. These are being developed as a treatment for wounds
as well as surgical procedures. PPL has demonstrated the production of g/l
quantities of mature hexameric fibrinogen, which was functional in clotting
reactions in the milk of transgenic mice (Prunkard et al., 1996), and also in
induced milk from prepubertal sheep.
Neutraceuticals
In the past year, PPL established the technology to produce transgenic cattle,
with nine transgenic animals born so far. Another 130 pregnant cows carrying
potential transgenics have been generated. Those embryos were injected with
a gene to produce a therapeutic food.
THE FUTURE OF TRANSGENICS
The present method of producing transgenic livestock animals, random inte-
gration of injected DNA into the genome, has two major disadvantages. First,
it is inefficient and relatively more expensive than it could be. Second, currently
it is only possible to add genes to an animal with no control over the site of
integration. Livestock “stem cells” would address both these problems.
Embryonic stem (ES) cells are cells derived from the inner cell mass of blas-
tocysts, which have been adapted to grow in in vitro conditions in the labora-
tory. The cells maintain their totipotency and when they are reintroduced into
another blastocyst they contribute to the animal, and in some cases, to the germ
line. Therefore, any changes introduced into the ES cells in culture can become
part of a new line of animals. Because the cells can be propagated in vitro, it
allows various techniques to be employed to alter the genome of the animals
into which those cells will ultimately develop. For example, homologous
recombination and targeting are very powerful techniques used in genetic
manipulation, which have allowed researchers to mutate, delete, and/or add
genes in mice (Fässler et al., 1995).
At present, totipotent ES cells can only be isolated using standard approaches
from specific mice strains. It has previously been suggested by others that it
may never be possible to use this type of cell for other species. However, alter-
nate techniques are currently being investigated and we have recently achieved
the derivation of totipotent ES cells from strains of mice previously shown to
be intransigent to classical techniques (McWhir et al., 1996). The application of
this technique to different species may allow the future derivation of totipotent
ES cells from livestock. That and other approaches are directed towards allow-
ing the transfer of genetic manipulations performed on cell lines into live
animals. In some cases, these scientific approaches involve the generation of
cells that could not be considered in the classic sense as totipotent ES cells.
However, they may allow genetic manipulation of the genome in vitro and the
subsequent transfer of modifications to the genome of a live animal. Therefore,
when people talk of livestock “stem cells,” they are usually referring to a
method of production, rather than the actual cells used in the process.
Recently, Campbell et al. (1996) demonstrated that a sheep could be pro-
duced by nuclear transfer from a cell grown in tissue culture. This is the first
time a route from in vitro cultured cells to live animals has been demonstrated
in a livestock species, and offers the same opportunities for analysis and
modification of gene function as are available in the mouse using ES cells.
In practical terms, it will enable transgenics to move on to the next phase in
its development; giving precise control over many more useful genetic altera-
tions in livestock animals and increasing the efficiency of production. Clearly,
this new approach to transgenic production will raise ethical issues that will
need to be addressed in the next few years. One of the most controversial will
probably be the use of this technology for the production of transgenic animals
for xenografts (Jones 1996). This is the proposed replacement of diseased
human organs with those from a transgenic animal, preferably a pig. Several
companies are working towards this end already, however, the application of
homologous recombination and targeting would undoubtedly improve their
ability to realize their goals.
It is important that this debate is conducted in public, not just in academic
circles, in a rational and sensible manner, so that the ultimate consumers can
have properly balanced information upon which to base their decisions.
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Phytoremediation is a new application of biotechnology — an exploitation of
specific plants to clean up the environment. Plants are used to treat or remove
environmental contaminants from soil and other solids like dredge spoils,
water, other liquids, and air.
Plants may be viewed as the original polluters. Our earth was hospitable to
methanogenic bacteria before the evolution of photosynthesis by plants, pro-
ducing oxygen that now is 20 percent of our atmosphere. Oxygen forced the
methanogens into anaerobic regions of the world. Now we plan to use plants
to help us clean up toxic soils. Scientists at the Ag Biotech Center at Rutgers
University, such as Ilya Raskin, have explored methods of using plants to treat
organic and inorganic contaminants in soils, and have discovered that plants
provide very effective biological processes for cleaning up and removing
contaminants from the environment.
I will focus on the use of plants to remove and concentrate heavy metals.
Heavy metal contaminants in the soil and water in all developed countries are
a large and important worldwide problem caused by manufacturing processes
and other activities of commerce dating back to the 1700s. One may view a
plant as a solar driven concentrator of chemicals like metals that took 360
million years to build, test, and optimize. The scientists at the Ag Biotech
Center enhanced that process so it is more rapid and useful for clean up at
contaminated sites.
What is the appeal of phytoremediation? First, it is an elegant method of
treating contaminated sites relative to conventional treatment methods in which
contaminated soil is transferred to a landfill (which means simply moving it
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somewhere else), presumably for permanent storage, and then transferring
uncontaminated soil to the original site. Plants leave the soil in place while
removing the contamination. Phytoremediation is cost effective, while transfer
of contaminated soils to a licensed hazardous waste site is expensive.
Even after 25 years of cleanup efforts and growing awareness of the dangers
posed to the environment by contaminated sites, America still has a huge
number of contaminated sites. The main reason for the slowness of the cleanup
is the large expense of using conventional technology to clean up these sites.
We must find more cost effective methods. The use of plants helps address
the economic issue. This use offers owners a new method of remediating con-
taminated property at less cost, which presumably will accelerate the pace of
remediation.
Phytoremediation is compatible with public concerns about technology.
People have been concerned about biotechnology. They are frightened particu-
larly about genetically engineered bacteria. They always will be. It is easy to
frighten people about bacteria. For example, when you tell people how many
bacteria there are in yogurt, it doesn’t make them think better of the bacteria,
it makes them quit eating yogurt. Plants are something that everyone can see;
they are familiar and therefore comfortable with plants. Using plants to clean
up a contaminated site is more acceptable to community members than the use
of bacteria.
At the time of the Exxon Valdez oil spill, the state of Alaska decreed that no
non-Alaskan micro-organisms could be used. This was the first microbial-
immigration policy and it was useless. Bacteria travel on the wind, and in many
other ways, and they didn’t seek Alaskan regulators’ permission before they
entered Alaskan waters to eat the oil on the beach.
Phytoremediation is sophisticated scientifically. Technology must be devel-
oped so it can be safe, effective, and reliable.
Over the next five years the United States will spend $43 million to treat only
sites contaminated with heavy metals and heavy metals mixed with organics.
That’s not what would be needed to clean up all the sites. We need low-cost
approaches so that we can accelerate the pace of remediation.
Phytoextraction is the subset of phytoremediation in which plants remove
contaminating toxic or radioactive metals from a site by root uptake and
accumulation in the plant shoots.
I will describe the use of a plant — Indian Mustard — to remove lead from a
toxic site. The plants are watered with agricultural chemicals that make the lead
water soluble. The water containing lead is taken up by the roots and moved
into the stems and leaves where it evaporates, leaving the concentrated lead in
the plant. The harvested plants may be sent to a smelter where the metal is
recycled — a hazardous waste is removed from the environment and recycled to
commerce. This technology, developed by the Ag Biotech Center, is the subject
of a technology transfer agreement between Rutgers University and Phytotech.
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Brassica juncea (Indian Mustard) has the special property of metal accumula-
tion that was discovered at the AgBiotech Center by screening plants for their
metal uptake abilities. This metal uptake property is being expanded and en-
hanced by research including genetic engineering, mutagenesis, and selection at
the Ag Biotech Center and at Phytotech. Most plants do not accumulate heavy
metals in the stems or leaves and are not useful for phytoextraction. For most
plants, some metal is taken up by the roots, but not much is transfered to
the shoots and stems. Indian Mustard and Amaranthis accumulate cadmium,
nickel, zinc, copper, lead, and chrome6, a widespread pollutant in New Jersey
and a carcinogen.
To increase availability of lead, a biodegradable, short-lived chemical is added
to the soil to cause the plants to take up the lead. An example is the metal che-
lator EDTA added to contaminated soil. There is a direct correlation between
the amount of EDTA added and the metal uptake. We are also doing environ-
mental impact rates and effect studies to evaluate the environmental impact,
good and bad, of removing metal from the soil by growing the plants on site
and adding chemicals to induce uptake and clean the site.
We are in the process of modeling, analyzing, and monitoring the impact
of this approach to remediating contaminated sites. What do you do with the
harvested plants following phytoextraction? We dry the plants, may incinerate
them, may compost them, or may compact them by pressing followed by acid
leaching and disposal, or recycling, of the heavy metal. The volume or mass of
the plants that contain the extracted heavy metals is only about two percent of
the volume or mass of contaminated soil. This is a 50-fold concentration.
Indian Mustard has many attractive characteristics for cleaning up toxic
metal sites. It is inexpensive to grow and grows very rapidly to about five feet
in about two months, producing 2-10 tons/hectare of dry weight with fairly
rapid clean up of the site. We believe there are a significant number of con-
taminated heavy metal sites in the U.S. that could be remediated in about three
years or less so that the Environmental Protection Agency or the state environ-
mental agency would conclude that that site was safe for use. We have great
hope that we will be able to use phytoremediation as an effective technology.
We have treated a site in the middle of an urban environment, Magic Marker,
in Trenton, N.J. It was originally contaminated by a battery manufacturing and
recycling facility located there since about 1950.
Other sites that we have examined in Trenton and other New Jersey towns
were contaminated in the 1700s and 1800s by practices such as pottery making.
Trenton was a big pottery making center at one time. Pottery glazes contained
lead or cadmium and there is a large number of lead and cadmium contami-
nated sites in the city of Trenton.
The Magic Market site was blocked out, samples were taken to establish lead
content, the site was plowed, and fertilizer was added. The soil on the site is
dark, not because of humus, but due to the asphalt in the soil. The site was
once a parking lot. An irrigation system was installed and Indian Mustard was
hydroseeded to evenly distribute the seeds without disturbing the soil.
We collaborated with the local residents. There was a Phytoremediation Day
in Trenton. Through an organization called Isles Inc., we attended community
meetings, told everybody that lived in the area (there are houses all around this
site) what we were doing, and invited everyone to attend the first planting. The
costs of those trials were paid by Phytotech, which had raised $6 million of
venture capital and has 16 employees.
As indicated in my presentation, we are enthusiastic about the role of
phytoremediation in the cleanup of toxic sites.
I am particularly pleased and somewhat surprised to be a speaker today, given
that I am neither a scientist nor an expert in biotechnology. Frankly, I have
only a limited understanding of biotechnology. I’m just a plain ordinary family
farmer from a long line of plain ordinary family farmers. However, this humble
status has never prevented me from striving to make as much money as pos-
sible and I see exciting opportunities ahead to do just that: rapid improvements
in the quality of crops, livestock, and livestock products; huge reductions in
input usage and costs of production; and the creation of new consumer prod-
ucts. In fact, I expect that my family farming operation will be fundamentally
changed over the next few years because of the things most of you are doing.
However, in the push to advance the field of agricultural biotechnology,
farmers are often the last to be considered or consulted. Does the research
always meet our production needs? Does the regulatory system provide for
timely approvals of new technologies? Are farmers sought out to participate
in forums like this?
At NABC 7, held in May, 1995, I met very few farmers, though I found our
input in workshops much appreciated. This year, I doubt I’d see many hands
raised if I asked how many people rely on farming for their income. Yet farmers
are your critical link in the biotechnology path to market. We utilize the re-
search and produce the product which then must be marketed and find public
acceptance. And all this in a world where the anti-technology crowd is way out
in front in shaping public opinion.
Most farmers are cautiously optimistic about agricultural biotechnology,
but they need someone to take leadership in managing this controversial issue
on their behalf.
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Because the theme of this conference proposes partnerships, I would like
to describe chronologically the slow and often tortuous journey of my own
general farm organization in its attempt to foster new partnerships to manage
the agricultural biotechnology issue.
First let me tell you about the Ontario Federation of Agriculture (OFA).
The OFA has a membership comprising 40,000 Ontario farm families and 28
organizations, mostly commodity specific. Its mission is to improve the eco-
nomic and social well-being of farmers. The responsibility of fulfilling that
mission rests with a seven-person executive committee that is governed by
a board of 100 elected directors. I am one of those directors. So who would be
better placed to attempt to draw together the broad range of stakeholder groups
necessary to manage the agricultural biotechnology issue? It should have been
easy, right? Not quite!
1993
In June 1993, the OFA hosted a workshop on the Impact of Biotechnology
on Agricultural Production and invited agricultural leaders from across the
province to attend. It attracted a disappointingly low 30 participants, but was
the first attempt by the OFA to address agricultural biotechnology issues and,
I believe, was the first attempt to do so by any Ontario farm organization.
That initial workshop had only two objectives. The first was to have speakers
provide updates on biotechnology as a production tool in both plant and animal
agriculture, regulatory aspects of biotechnology, and ethical questions asso-
ciated with biotechnology and agriculture (not a subject any of us wished to
tackle).
The second objective was to have workshop participants discuss their views
on the impact of biotechnology on agricultural production, on our ability to
compete globally, and our responsibility to feed a hungry world. Break-out
groups were asked to consider three questions: 1. What did you hear today
that concerns you?, 2. How should the agricultural industry respond to these
concerns?, and 3. What is the next step?
The concern most often expressed was about the lack of information on
agricultural biotechnology. It was observed that both producers and consumers
need to be better educated with regard to this technology. One participant sug-
gested that there was a huge gap between reality and perception that needed
to be filled. Another individual questioned whether or not the production tools
resulting from agricultural biotechnology would be universally available to
farmers — all farmers, whether large or small in scale. It was felt that more
workshops were needed, but a broader range of stakeholders should be invited.
For the first time, the notion of forming a coalition of organizations having
an interest in agricultural biotechnology was raised. We had taken our first
tentative steps into deep and controversial waters.
1994
In May 1994, the Chair of the OFA’s Environmental Committee, who also
served as an OFA Vice President, attended NABC 6 at Michigan State University
along with an Ontario contingent of farmers, professors from the University of
Guelph, and farm organization staff. The objective was to become familiar with
the conference theme, Agricultural Biotechnology and the Public Good, and
draw on the material to develop an agricultural biotechnology position for
Ontario’s agricultural industry.
Then things became slightly complicated. A position paper planned for
distribution at the OFA’s annual meeting was never written. Even worse, the
OFA Vice President, who had taken the most interest in addressing agricultural
biotechnology issues, was not re-elected. Consequently, by December 1994, the
OFA found itself in the unfortunate position of not having moved forward on
the direction provided by the June 1993 workshop. We were in danger of losing
our momentum just when farmers were experiencing frustration and contro-
versy over the BST battle, and Bt corn and potatoes were quickly coming to
market.
1995
The OFA had a much more productive year in 1995. In January, our Environ-
ment Committee, of which I am a member, nominated Paul Verkley, a registrant
here at NABC 8, as chairman and took the initiative to identify agricultural
biotechnology as one of our primary areas of emphasis.
In May 1995, four members of the OFA Environment Committee and one
OFA staff member traveled to NABC 7 in Columbia, Missouri. The Committee
made a conscious decision to utilize resources in this area, given their com-
mitment to keeping abreast of agricultural biotechnology issues. While at the
conference, it became apparent that the OFA was the only farm organization
in North America that gave agricultural biotechnology this level of priority.
However, I would be less than honest if I did not report to you that some
members of the OFA Executive Committee strongly disagreed with the Envi-
ronment Committee’s decision to send a significant delegation to NABC 7.
Ostensibly, their objection was because of the cost, but I think it really demon-
strates the subtle conflict within the farm community on biotechnology, and
the real difficulty in developing a unified position.
Then in the fall of 1995, farm groups began to make progress. The OFA
arranged a meeting where representatives from farm organizations, agricultural
input suppliers, food processors and retailers, consumer associations, govern-
ment (provincial and federal), and the University of Guelph conversed on the
subject of agricultural biotechnology. The OFA was delighted that 50 people
attended this meeting, remembering that there were only 30 people in atten-
dance at our meeting in June 1993.
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Part of the agenda was to ask all registrants to briefly outline the position on
agricultural biotechnology held by their organization, agency, or institution.
While that exercise clearly demonstrated the wide variance of opinion both
between and within groups, it led to an agreement that some coordination was
needed. From that meeting came a proposal for an Ontario Agricultural Bio-
technology Committee that should have three distinct roles: communication,
advocacy, and consensus building.
While there was some discussion as to who should take the lead role on this
committee, it was quickly decided that the OFA, as a general farm organization
with no particular vested interest, was best suited. By the time the meeting
adjourned we had a long list of stakeholder organizations to be contacted and
invited to participate in the inaugural meeting. These included some groups
seldom asked to directly partner with farm groups, such as agricultural input
suppliers, grocery distributors, consumer advocates, academics, and govern-
ment bureaucrats.
1996
As of June 1996, the Ontario Agricultural Biotechnology Committee has met
four times and, in my view, has been enormously successful in bringing to the
same table a number of disparate players in the agri-food industry to discuss
an extremely controversial topic. In the short time the committee has been
together, it has established a mission statement, a set of goals, and a subcom-
mittee structure that breaks issues into three categories: communication,
research, and regulation.
The committee’s mission is to foster the growth and development of agri-
cultural biotechnology for the maximum benefit of the Ontario agri-food sector
and the community-at-large.
The stated goals are:
1. Instill a higher level of knowledge and understanding of agricultural
biotechnology within the agricultural industry.
2. Effectively communicate within the agricultural community, and
between the agricultural community and society-at-large.
3. Influence future biotechnology research and commercialization.
4. Encourage a timely, science-based assessment of biotechnology products
for potential use in the Ontario marketplace.
Establishing this committee was certainly an accomplishment, but not with-
out some difficulties. For example, some within the farm community question
whether we should be focusing our communications efforts on educating
farmers about agricultural biotechnology. In their view the emphasis should
be directed only to consumer education. There have also been questions
regarding the role of the OFA, or more specifically, the appropriateness of
having the OFA’s Environment Committee take the lead in managing
agricultural biotechnology issues. And within the OFA itself, there is still
considerable debate as to where agricultural biotechnology fits into their
existing committee structure. But I ask, where would the issue fit any better
than in the Environment Committee? Despite these minor irritants, I can
tell you that the Ontario Agricultural Biotechnology Steering Committee is
generally supported and acknowledged as the best vehicle for developing
unified agri-food sector positions on issues relating to agricultural bio-
technology. And as a farmer, I want to see that happen soon.
From the perspective of farmers, having unified positions on agricultural
biotechnology issues is absolutely critical. It is ironic that the rate of scientific
discovery in the field of agricultural biotechnology is advancing far more
rapidly than is our ability to address the issues which are raised as a result of
these discoveries. It has taken the OFA a considerable length of time to get to
the point where we have now assembled a committee capable of initiating a
process whereby agricultural biotechnology issues can be managed to the
satisfaction of the agri-food sector. I, for one, look forward to the committee
accomplishing its mission of fostering the growth and development of bio-
technology for the maximum benefit of the Ontario agri-food sector and the
community-at-large. As a farmer, I can’t afford to have it fail.
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